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Abstract 
 
Background 
The surgical treatment of endometriosis has developed in recent decades 
alongside the development of laparoscopic surgery and has been directed 
towards understanding and improving the outcomes related to fertility and pain. 
Little is known about the techniques and instruments actually used by 
gynaecological laparoscopic surgeons in relation to the evidence available. 
Furthermore, it is still not clear whether vaporisation or ablation of lesions is as 
efficacious as excision.   
 
Objectives 
Firstly, to internationally survey the views of gynaecologists to find out how they 
surgically treat endometriosis. Secondly, to determine whether excision or 
vaporisation is the optimal surgical technique for minimal to moderate 
endometriosis. 
 
Methods 
A 34 question web-based survey was constructed, piloted and sent out by email 
to the members of the BSGE, ESGE and AAGL to get a snapshot of current 
practice. A randomised blinded trial of harmonic scalpel excision versus carbon 
dioxide laser vaporisation for the treatment of minimal to moderate 
endometriosis in women with pelvic pain was carried out, using as a primary 
outcome measure EHP-30 Core pain domain, and secondary outcomes for VAS 
scores for dysmenorrhoea, dyspareunia, chronic pelvic pain and dyschezia, 
EHP-30 HRQoL measures, and HADS.    
 
Results 
From the survey, the predominant view is that endometriomas should be 
excised and that bowel resection should be avoided if possible in recto-vaginal 
disease. For minimal to moderate disease, superficial disease can be treated 
with a combination of excision or vaporisation depending on the case, but that 
deep disease should be excised.  
The trial results show that both excision and vaporisation result in an equally 
significant proportion of patients showing some level of pain improvement at 12 
months (85.4 v 72.9%). However, excision results in a significantly greater 
extent of improvement for both superficial and deep disease than vaporisation 
(p=0.008). In addition, for deep disease, the extent of improvement in pain with 
vaporisation is not significant (p=0.262). Overall 20% of patients stay the same 
or get worse. 
 
Conclusions 
Excision results in greater pain and quality of life improvement than vaporisation 
for minimal to moderate disease, and is the optimal technique for the surgical 
treatment of all types of endometriosis. However it must be taken into account 
that the range of improvement is wide and a proportion of patients will continue 
to deteriorate. 
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 1 
Chapter 1 - Introduction 
 
 
In the surgical treatment of endometriosis there are two views that favour either 
vaporisation or excision as the optimal means of treatment. There exist various 
instruments to carry out these treatments. The “excisers” tend to use 
electrosurgical or ultrasound instruments to cut around the lesion and remove it 
along with the underlying fibrotic tissue. The “vaporisers” tend to use lasers, 
electro-surgery or modified electro-surgical techniques to vaporise the lesion 
and underlying fibrosis. 
 
The “excisers” claim that the vaporisation of endometriosis is too superficial and 
does not go deep enough to remove infiltrating tissue. The risk of inadequate 
treatment or recurrence of symptoms may be greater. The “vaporisers” claim 
their technique is faster and more efficient for the removal of widespread 
disease and just as effective. It is unclear why surgeons use one approach or 
the other and how many are using each approach.      
 
There is only one randomised trial comparing the two approaches. This 
compares the treatment of rASRM (revised American Society for Reproductive 
Medicine) (1979) stage 1-2 minimal and mild endometriosis by excision or 
vaporisation. This trial shows no difference in the two modalities in terms of pain 
outcome (Wright et al., 2005), although it did not include stage 3 moderate 
disease. The “excisers“ claim that the more advanced the disease, and the 
more infiltrating and nodular it becomes, the more important excision becomes. 
This disease “progression” culminates in the most extreme form of pelvic 
 2 
endometriosis: the recto-vaginal nodule. This is probably treated by excision, 
with or without bowel resection, by all endometriosis surgeons. The 
vaporisation/excision debate is not an issue here. 
 
In our unit we use both vaporisation and excision to treat rASRM stage 1-3 
endometriosis. By vaporisation, we mean complete destruction or vaporisation 
of endometriosis and fibrotic tissue down to underlying normal tissue, not just a 
superficial treatment as often seen with ablation. At the end of treatment the 
macroscopic appearance is identical for both excision and vaporisation. With 
the correct surgical approach, both techniques can be used around sensitive 
structures including ureters, bladder and vessels. We use CO2 laser for 
vaporisation and the harmonic scalpel for excision.  
 
The CO2 laser can be used both as a vaporisation and excision tool. At 
Guildford, Professor Chris Sutton carried out the first randomised double blind 
controlled trial of ablative surgery using a CO2 laser (Sutton et al., 1994). 
Harmonic (ultrasound generated) energy has been around for more than a 
decade as a cutting tool (Feil, 2005). In comparison to electrical energy, it 
removes the risk of electrical injury and results in less thermal spread to 
adjacent tissues.  
 
A review of the endometriosis literature in chapter 2 reveals gaps in our 
knowledge and capabilities in many areas. I have attempted to present a 
rationale for surgical therapy as the current optimal treatment for endometriosis 
in most cases. 82% of cases of endometriosis fall into stages 1-3 (Redwine, 
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1990b). It therefore seems most logical to mainly concentrate on this group in 
my thesis. 
In particular I wish to focus on the fundamental question of whether or not there 
is a difference between the excision or vaporisation of minimal to moderate 
endometriosis in terms of improvement in pain scores. To achieve this I aim to 
critically review the literature for the surgical treatment of endometriosis to see if 
there is any evidence in favour of one technique over another. I then aim to 
compare this with the actual use of techniques and instruments used by 
gynaecological laparoscopists. This will be determined by a web-based survey. 
My thesis therefore divides into the three areas that are listed below: 
 
1. A literature review of the diagnosis, management and treatment of 
endometriosis with particular reference to surgical management (an earlier 
version of this review was published in a peer reviewed journal and is at 
Appendix A) (Barton-Smith et al., 2006). 
 
2. An international survey of techniques and instruments used in the treatment 
of endometriosis: who is using what and why? 
 
3. A randomised blinded trial of carbon dioxide laser vaporisation versus 
harmonic scalpel excision of rASRM stage 1-3 endometriosis in women with 
pelvic pain. 
   
 
 
 
 4 
Chapter 2 - Literature Review 
 
A general review 
 
Endometriosis is a common condition of unknown aetiology that can cause pain 
and infertility in women. It is defined as the presence of endometrial glands and 
stroma present outside of the uterus (Olive and Schwartz, 1993). It is most 
commonly found in pre-menopausal women but rarely can also occur in 
postmenopausal women or pre-menarchal girls.  
 
Prevalence 
The prevalence of endometriosis has probably increased over the last one 
hundred years or so for several reasons. Modern women have many more 
menses than their predecessors as they spend less of their reproductive lives in 
a state of pregnancy. Women now have an estimated 450 menses in their 
lifetime compared to the 100 that their Victorian forebears had. Consequently 
the frequency of dysmenorrhoea has increased. The introduction of 
laparoscopy over the last three decades has allowed us to diagnose 
endometriosis more easily, and nowadays most gynaecologists are able to 
perform a diagnostic laparoscopy at least. The current prevalence is estimated 
to be up to 10% (Vessey et al., 1993, Kjerulff K. H., 1996, Vigano, 2004). 
Vercellini stated in his address to the World Congress on Endometriosis in 
Maastricht in 2005 that the incidence has not increased in the last thirty years 
and remains at 2.37-2.49 per 1000 women per year, equating to an 
approximate prevalence of 6-8% (Hummelshoj, 2006, Leibson et al., 2004). A 
national epidemiological study of endometriosis within a community based 
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sample, revealed that the prevalence of diagnosed endometriosis in women 
aged 18-50 is 1.5% (Ballard et al., 2009). This lower prevalence can be 
explained by the sample being drawn from women attending primary rather than 
secondary care. 
 
Localisation and Appearance 
Endometriosis is most commonly found in the pelvis (Jenkins et al., 1986). More 
rarely it is found in remote sites like the lungs and brain (Di Palo et al., 1989, 
Thibodeau et al., 1987). It has even been found in men (Oliker and Harris, 
1971). In the pelvis, it is more frequently left sided (Vercellini et al., 2004). The 
reason for this left sided dominance is unclear, although the direction of flow of 
peritoneal fluid been proposed as a possible cause (Chapron et al., 2003). 
  
Endometriotic lesions can infiltrate any structure in the pelvis. They are seen 
more commonly on the pelvic peritoneum, utero-sacral ligaments, bladder, 
sigmoid colon and rectum, the most severe presentation being the recto-vaginal 
nodule. On the ovaries, endometriotic cysts can form that contain a thick 
“chocolate-like” substance formed from old blood. These cysts are often 
adherent to the pelvic side-wall. Rarely, the ureter can be infiltrated with 
endometriosis itself, though stenosis is more commonly due to fibrotic 
impingement by a proximal uterosacral nodule (Lucero et al., 1988). 
 
Endometriotic deposits can appear in a range of colours and textures from 
transparent vesicles and white fibrotic plaques to red haemorrhagic flares and 
blue/black nodular lesions, first systematically described by Martin et al in 1987 
(Martin and Vander Zwagg, 1987). These may be superficial or described as 
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deep if they extend more than 5mm beneath the peritoneal surface. This wide 
variety of appearance is not always recognised by the general gynaecologist 
and the diagnosis may be easily missed. Overall appearance may vary from the 
barely visible through to the “frozen pelvis”.  
 
Epidemiology 
There are several large epidemiological studies detailed below that give us an 
insight into the disease (Hummelshoj, 2006, Treloar, 2005b). The results reveal 
the depth of the problem for women, their families and society in general, as 
well as highlighting the current inadequacy in management. 
 
The All Party Parliamentary Group in the UK has so far collected 
epidemiological data via its on-line questionnaire from 7025 women from 52 
countries. It estimates that two million women in the UK suffer from 
endometriosis. The results of this survey to date show a delay in diagnosis in 
this cohort averaging 8.3 years. 65% of women complained of being wrongly 
diagnosed initially. Only a third believed their treatment to be effective. A 
startling 78% took an average of 5.3 days off work per month and 72% reported 
relationship problems (Hummelshoj, 2006). These results are similar to those 
found in a recent Australian genetic epidemiological study of 3895 women 
diagnosed with endometriosis where the average age of onset of endometriosis 
symptoms was 20.1 6.8 years (Treloar, 2005b). The youngest diagnosed 
participant in this study was 13 years old. The disease or its antecedent has 
been diagnosed in females as young as eight years old (Marsh and Laufer, 
2005).  
 
 7 
Endometriosis is less common in black African women compared with 
Caucasians and more common in East Asians, but is found in all ethnic groups 
(Sangi-Haghpeykar and Poindexter, 1995, Hasson, 1976). 
 
Endometriosis is found in 40-60% of women with pelvic pain and in 20-30% of 
women suffering from infertility (Mahmood and Templeton, 1991, Eskenazi and 
Warner, 1997, Ajossa et al., 1994). Women with more advanced disease have a 
higher rate of infertility (19.5% for rASRM stage 1 versus 28.7% for rASRM 
stage 2-4) (Plumb, 2005). 
 
Risk factors for endometriosis include early age of menarche, short menstrual 
cycles, long duration of menstrual flow, a family history of endometriosis, and 
there is an inverse relationship with parity (Vigano, 2004). 
 
Aetiology 
Many theories of the aetiology of endometriosis have been postulated since 
Rokitansky first described the disease in 1860 (Von Rokitansky). Meyer 
proposed the theory of coelomic metaplasia in 1909 and postulated that tissue, 
with the potential to develop into endometrial-like cells later in life, was laid 
down in the trans-embryonic coelom (Meyer, 1909). Halban proposed the 
possibility of haematological or lymphatic spread from the endometrium in 1924 
(Halban, 1924). Sampson proposed the theory of retrograde menstruation in 
1927 (Sampson, 1927) and this has become the “default” explanation.  
 
However, there remain several problems with Sampson’s theory. There is little 
doubt that reflux menstruation occurs. Bloody peritoneal fluid is found in 80-
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90% of menstruating women (Blumenkrantz et al., 1981, Halme et al., 1984) 
compared with only 15% of women with occluded fallopian tubes. However, 
most women do not develop endometriosis. Moreover, the cells found in 
endometriosis are not identical to normal endometrium (Redwine, 2002) and 
endometriosis does not generally recur if treated surgically as one might expect 
if retrograde menstruation was to continue (Abbott et al., 2003, Redwine, 1991). 
Also, it does not explain the small, but nevertheless relevant, occurrence in 
men, pre-menarchal girls and post-menopausal women.  
 
Consequently, all of the above theories remain in the frame to this day with no 
clear evidence having emerged for either one. Despite being the dominant 
theory, it seems likely that Sampson’s view was over simplistic.  
 
More recent advances in technology have permitted the emergence of new 
theories. Altered immune function has gained credibility with those seeking to 
find a basis for the discrepancy between the frequency of retrograde 
menstruation and the infrequency of endometriosis. This theory was first 
postulated in 1987 by Gleicher (Gleicher et al., 1987), who suggested that 
immune system alterations result in a failure to “mop up” ectopic endometrial 
cells and therefore allow them to infiltrate at the site of disease. Immune system 
alterations in endometriosis sufferers have been shown in natural killer (NK) 
and cytotoxic T cells, and aberrations have been found in immune mediators 
such as tumour necrosis factor-, Interferon- and polyclonal B-cell auto 
antibodies (Kitawaki et al., 2002).  
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Simpson first suggested a genetic basis for endometriosis in 1980 (Simpson et 
al., 1980). This is likely to be complex and polygenic in nature. Linkage study 
work has now shown a susceptibility locus on Chromosome 10q26 (Treloar, 
2005a). Work is also progressing in other areas including studies of expression 
profiling, tumour genetics and functional candidate genes (Barlow and 
Kennedy, 2005). 
 
There is evidence suggesting that endometriosis may increase the risk of 
cancer. Brinton’s work looking at cancer risk after a diagnosis of endometriosis 
shows a relative risk of 1.18 for developing cancer of any form, and a relative 
risk of 1.92 for developing ovarian cancer (Brinton et al., 1997). The K-ras 
oncogene and P-ten tumour suppressor gene appear to be involved in this 
process. Mice with either of these gene mutations developed endometriosis, 
and mice with both gene mutations simultaneously produced endometrioid 
ovarian adenocarcinoma (Dinulescu, 2005). Clinically, the endometrioma is of 
most concern as far as malignancy risk is concerned; a risk of 0.7% has been 
suggested (Nishida et al., 2000), and in one more recent report, 7% of 
endometriomas contained a neoplastic process (Bedaiwy et al., 2009). 
 
The theory of progesterone resistance is the most recent to emerge. In his 
review, Osteen has suggested that the impaired regulation of matrix 
metalloproteinases, that has already been shown to increase the implantation 
potential of the endometrial tissue (Bruner-Tran et al., 2002), may be due to a 
decreased responsiveness to progesterone (Osteen et al., 2005). 
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Other aetiological theories rely on environmental factors. Nutritionally, wheat 
has been implicated as a potential source of exacerbation in endometriosis. 
Manipulation of the diet in endometriosis sufferers resulted in an improvement 
in prospectively collected “measure yourself medical outcome profile scores” 
(MYMOP) that measure symptom improvement (Shepperson Mills, 2004). Other 
potential environmental agents include organochlorines (PCBs and dioxins). In 
rodents and primates these promote the development of endometriosis and 
have been found in higher concentrations in human sufferers (Heilier, 2004).  
 
Whilst endometriosis has been shown to be a predominantly oestrogen 
dependent disease, the underlying pathophysiology that creates the conditions 
for oestrogen to drive the development of endometriosis is likely to be multi-
factorial and include many of the above possibilities. 
 
Diagnosis 
The main clinical symptoms of endometriosis are infertility, dysmenorrhoea, 
dyspareunia, dyschezia, and chronic pelvic pain (defined as pain of greater than 
six months duration and not cyclical in nature) (Jantos, 2007). Other symptoms 
seen less commonly include haematuria and rectal bleeding. Making a 
diagnosis purely on presenting symptoms is difficult as there is considerable 
overlap with other conditions.  This often results in a delay in diagnosis of 
between five and ten years (Treloar, 2005b, Hadfield et al., 1996, Husby et al., 
2003, Arruda et al., 2003, Ballard et al., 2006).  This is an important finding 
when one considers that endometriosis is a progressive disease that worsens 
with time (Koninckx et al., 1991, Matsuzaki, 2004). The delay in diagnosis may 
also result in associated psychological morbidity (Jones et al., 2004b). 
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Clinical signs on examination can also be difficult to elicit. Endometriotic 
nodules on the utero-sacral ligaments or in the recto-vaginal septum may be 
palpable and are easier to feel on a combined vaginal-rectal examination. 
These are most reliably palpated if the examination is undertaken during 
menstruation (Koninckx et al., 1996). In some cases endometriosis invading 
through the vaginal mucosa may be visible on speculum examination. It 
remains to be seen whether symptom profile questionnaires alone, without 
invasive testing, will be able to improve diagnosis (Ballard et al., 2009). 
 
The gold standard for diagnosing endometriosis in the abdomen and pelvis is 
the visual identification of characteristic lesions at laparoscopy. In one study, 
this means of diagnosis was shown to be 97% sensitive and 77% specific 
(Buchweitz et al., 2003). Lesions may also be visually confirmed on vaginal 
speculum examination, in the bladder at cystoscopy or in the bowel mucosa at 
sigmoidoscopy. It is considered good clinical practice that the diagnosis is 
confirmed by histology of at least one lesion (Kennedy, 2004).  
 
However, negative histology does not exclude the diagnosis as explained by 
Clement who describes the potential alterations in glandular and stromal 
components of endometriosis, especially in small biopsy specimens resulting in 
false negative results (Clement, 2007, Shafik A, 2000). A correlation of 88% 
was found by Ballard between visual inspection and positive histology (Ballard 
et al., 2009). It should also be noted that visual inspection alone can produce 
false positive diagnoses as lesions may be mimicked by psammoma bodies 
caused by old haemorrhage or suture material from previous surgery for 
example (Martin and Vander Zwagg, 1987).  
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It is recommended that histology should be obtained for endometriomas of 
>3cm diameter and deep disease, to exclude rare cases of malignancy 
(Kennedy, 2004). Disease sites and depths should be mapped and recorded 
(Kennedy, 2004) to allow adequate reassessment of the disease subsequently. 
 
Many other tests have been employed to aid in diagnosis without resorting to 
surgery. CA125 is raised in some cases, but the test remains non-specific. Most 
endometriosis sufferers are pre-menopausal and there are many other causes, 
both pathological and physiological, for a raised CA125. Therefore it has been 
argued that, compared with laparoscopy, CA125 has no value as a diagnostic 
tool in endometriosis (Mol et al., 1998). Furthermore, if the level is raised in an 
endometriosis case and applied to a risk of malignancy index, then there 
remains the possibility of the woman being subjected to an unnecessary 
laparotomy for a high-risk score. If a laparoscopy is carried out first then a 
laparotomy may be avoided. 
 
New serum tests are being developed. One such test is based on the detection 
of autoantibodies against Thomsen-Friedenreich antigen bearing proteins found 
in endometriosis. Current sensitivity and specificity results are 80% and work to 
improve these is underway (Hummelshoj, 2006). Also, gene expression 
analysis is beginning to identify potential markers of endometriosis in peripheral 
blood samples as well as in endometriotic lesions (Hornung, 2005, Van 
Langendonckt, 2004). 
 
Ultrasound is commonly used as a diagnostic tool in most gynaecological 
departments. Trans-vaginaI ultrasound (TVS) is not a useful tool in the 
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diagnosis of peritoneal endometriosis although it is useful for diagnosing 
endometriomas, disease infiltrating the bladder (Moore et al., 2002, Bazot et al., 
2004b) and is becoming a more successful tool for the diagnosis of recto-
vaginal disease too (Hudelist and Keckstein, 2009). Also, trans-rectal 
ultrasound is a useful tool in diagnosing deep infiltrating disease in the recto-
vaginal septum (Chapron et al., 2004).  
 
Magnetic resonance imaging (MRI) has been shown to be of use in diagnosing 
the extent of deep nodular disease, particularly in the recto-vaginal septum 
(Bazot et al., 2005, Bazot et al., 2004a). Fat suppression MRI films and the use 
of phased array coils appear to offer even better images that can show the level 
of invasion into the bowel wall itself. In the future this may help tailor how radical 
the excision of recto-vaginal nodules should be prior to surgery. A recent report 
from Bazot suggests “MRI provides a more reliable map of DIE than physical 
examination, TVS or trans-rectal ultrasound” (Bazot et al., 2009).  
 
CT scans do not offer the required resolution to do this, although spiral CT may 
be better. Double contrast barium enema alone has been shown in two recent 
studies to have close to 90% sensitivity, and specificity ranging from 54 to 88% 
(Ribeiro et al., 2008, Faccioli et al., 2008). For suspected ureteric involvement, 
an intravenous urogram (IVU) or MRI may be used and a cystoscopy may be 
required to assess the bladder mucosa (Bazot et al., 2008). 
 
Staging the disease in a way that gives useful information about the extent of 
pain or fertility, its management and prognosis, has so far eluded us. With 
endometriosis, the extent or type of disease is not clearly correlated with pain 
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levels. Several systems have been attempted, often based upon the visual 
findings during laparoscopy, histological examination or a combination of the 
two (Acosta et al., 1973, Batt and Mitwally, 2003, Adamyan et al., 1993). The 
most commonly used one to date is the revised American Society for 
Reproductive Medicine (rASRM) originally produced in 1979 (1979) and revised 
in 1985 (1985) and 1997, which grades endometriosis as minimal (stage 1), 
mild (stage 2), moderate (stage 3) and severe (stage 4) (1997).  
 
Chapron argued that all of these systems fail to correlate well with symptoms of 
pain and fertility (Chapron et al., 2003, D'Hooghe et al., 2003) or aid in 
prognosis. He argued that including palpation to assess depth clinically was 
required. This concept of considering depth further was picked up in the Enzian 
system (Tuttlies et al., 2005). Further elucidation of the pathophysiology of the 
disease will hopefully facilitate the development of more useful scoring systems.  
 
We have begun to speak more about two types of disease, superficial and deep 
infiltrating endometriosis (DIE), as evidence emerges that these two forms of 
the disease may behave differently from each other (Garry, 2004). That 
superficial endometriosis is less severe in its symptoms and complexity of 
management, is one of the subjects to be considered in this thesis. In the light 
of all this evidence, future scoring or staging systems may be more 
appropriately aimed at predicting surgical morbidity or the appropriateness of 
radical surgery as Wright suggested in his unpublished thesis on surgical 
endometriosis. That being said, a new validated endometriosis fertility index 
(EFI) has been developed by Adamson (Adamson and Pasta, 2009). It is 
designed for patients who are attempting spontaneous conception and is an 
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intra-operatively derived score from visual assessment of the ovary, tube and 
fimbria, the patient’s age, years of infertility and previous pregnancies to give a 
graphical display of the chances of spontaneous conception over time. Its full 
evaluation in clinical practice is awaited.   
 
Medical treatment 
In most cases, women who reach the gynaecology clinic will already have been 
treated with non-steroidal anti-inflammatory drugs (NSAIDs) in primary care. 
Although there is some evidence that these drugs reduce endometriosis-related 
pain (Kauppila et al., 1979), the majority of women presenting to the 
gynaecologist in secondary care will report little benefit from this therapy.  
 
In the first half of the twentieth century the treatment and diagnosis of 
endometriosis had been surgical. In this era it became apparent to some 
observers, like Meigs, that there was a lower rate of pregnancy amongst 
endometriosis sufferers. He theorised that pregnancy itself was a prophylaxis or 
even treatment for endometriosis (Meigs, 1922). From this observation there 
grew attempts to hormonally create a “pseudo-pregnancy state” as a treatment 
(Kistner, 1958). This is the basis for the use of progestogens and combined oral 
contraceptives (COCP) in medical therapy.  
 
Similarly, it was noted that endometriosis is a disease of predominantly pre-
menopausal women. Therefore castration was recommended as a therapy to 
remove the oestrogen source driving the disease (Cattell R., 1936, Fallon, 
1946). From this developed the theory of creating a “pseudo-menopausal state” 
to treat endometriosis, and this forms the other cornerstone of current medical 
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therapy. Danazol and gonadotrophin-releasing hormone agonists (GnRH 
agonists) are employed along these lines (Audebert et al., 1977, Shaw, 1992). 
Cochrane reviews suggest that there is no benefit, in terms of pain relief, in 
favour of the pseudo-pregnancy over the pseudo-menopausal treatment 
strategy (Moore, 2004, Selak, 2004). All approaches appear equally efficacious 
and provide benefit for up to six months following the cessation of treatment. 
Consequently, the choice of drug will be driven more by the side effect profile 
and contraceptive requirements of the women. The levonorgestrel intrauterine 
system (LNG-IUS) also appears to be of equal benefit as well (Vercellini et al., 
1999a, Petta et al., 2005).  
 
The optimum duration of GnRH therapy is unclear. Extending GnRH therapy 
beyond three months up to six months does not seem to confer greater benefit 
in terms of sustained pain relief (Hornstein et al., 1995). However, extension of 
treatment up to two years appears to be safe, in terms of bone protection, if 
add-back hormone replacement therapy is used (Surrey et al., 2002). Also, 
GnRH analogues used as a post operative adjunct to surgical treatment delay 
the recurrence of pain compared with expectant management after surgery 
(Vercellini et al., 1999b). 
 
In terms of actual disease regression, medical therapies have been shown to 
reduce the extent of disease found at laparoscopy (Telimaa et al., 1987, Fedele 
et al., 1989, Cedars et al., 1990), but not to eradicate it entirely.  
 
The European Society of Human Reproduction and Embryology (ESHRE) 
guidelines for the management of endometriosis, suggest that it is good clinical 
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practice to use counselling, analgaesia and nutritional therapy combined with 
progestogens, the COCP or GnRH analogues, as an empirical treatment for 
pelvic pain presumed to be endometriosis (Kennedy, 2004). If a laparoscopy is 
carried out, ESHRE guidelines then logically recommend that, as the gold 
standard for diagnosis is laparoscopy, ideal clinical practice should be to 
surgically remove endometriosis at the same time. Surgery is the only means of 
ensuring complete removal of visible disease. 
 
Whilst a laparoscopy undoubtedly carries risks, endometriosis is a progressive 
disease and delaying surgical intervention might lead to a greater risk of 
compromised fertility as well as pain although there is no direct evidence of this. 
Most women have already tried analgaesia and hormonal intervention in 
primary care, so in such cases ideally an operative laparoscopy should be 
carried out as first line treatment if symptoms have been sufficient enough to 
warrant referral to a gynaecologist. 
 
As understanding of the pathophysiology behind endometriosis improves, novel 
medical therapies are emerging. These include GnRH antagonists (Kupker et 
al., 2002), mifepristone (RU486) (Kettel et al., 1996), TNF inhibitors (Falconer 
et al., 2006), angiogenesis inhibitors (Becker and D'Amato, 2007), matrix 
metalloproteinase inhibitors (Osteen et al., 2003), pentoxifylline (Creus et al., 
2008) and aromatase inhibitors (Nawathe et al., 2008). These agents are mostly 
in the experimental stage of use. 
 
Where pelvic clearance is performed, and hormone replacement therapy (HRT) 
required, then a theoretical benefit exists for including progesterone in the form 
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of combined HRT. Firstly, the addition of progesterone may prevent recurrence 
of endometriosis. Secondly, a lack of protective progesterone may result in 
endometrial carcinoma arising from endometriotic lesions after total abdominal 
hysterectomy and bilateral salpingo-oophorectomy (Ulrich, 2005). However, this 
has to be weighed against the possible increased risk of breast cancer in 
combined versus Oestrogen only HRT (Beral, 2003). 
 
Measuring outcome 
Second look laparoscopy to assess the state of the pelvis requires another 
surgical procedure that is most likely unnecessary, and does not give 
information on improvement in pain and quality of life issues. Therefore other 
measures are required to assess improvement peri-operatively. Visual analogue 
scores for pain, quality of life measures, mental state and sexual function 
questionnaires have been used. There is an endometriosis-specific validated 
questionnaire, called the Oxford EHP30 questionnaire (Jones et al., 2001), that 
assesses the impact of endometriosis on different aspects of life.  
 
Multidisciplinary approach 
Pelvic pain is not exclusive to endometriosis and there is a degree of crossover 
with other conditions like interstitial cystitis and irritable bowel syndrome. There 
is also a degree of psychological morbidity. Specific pelvic pain clinics that 
adopt a multidisciplinary approach encompassing a wider range of pathologies 
and treatments are more likely to offer improved support and relief to women 
(Metzger, 1997). They can also develop links with infertility clinics, colorectal 
surgeons, urologists, anaesthetist-run pain clinics, psychologists and patient 
support groups. Multidisciplinary pain clinics have been shown to be effective in 
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the management of other chronic conditions such as back pain (Guzman et al., 
2001). Endometriosis UK, the patient support group, now helps run a 
Department of Health sponsored Expert Patient Programme to teach women 
how to live with their symptoms (www.expertpatients.co.uk).   
 
A critical review of the surgical treatment for endometriosis 
 
There are no clinical trials directly comparing surgical and medical treatment for 
endometriosis. As no direct comparisons are available we must rely on other 
evidence to weigh up the pros and cons of each approach.  
 
Unlike medical therapy, surgery can diagnose and remove all macroscopic 
disease at the same procedure in the majority of cases. Even severe 
macroscopic disease can be entirely removed surgically. Remember also that 
surgery is the gold standard for diagnosis of most endometriosis. Surgical 
therapy compared to placebo can result in a continuing positive effect on pain at 
6 months after surgery (Sutton et al., 1994, Abbott et al., 2004). Both authors 
also have data suggestive of this effect lasting even longer (Sutton et al., 
1997b, Abbott et al., 2003). Treatment at laparoscopy seems to also improve 
rates of spontaneous conception for infertility associated with endometriosis 
(Marcoux et al., 1997). The evidence for this is analysed in greater detail below. 
 
The development of techniques to remove endometriosis surgically has been 
governed by the development of energy sources used in surgery. Most 
surgeons would regard complete excision or complete vaporisation as the 
preferred techniques for removing endometriosis surgically. These remove the 
 20 
active lesion and the underlying fibrosis, both of which are considered to have a 
causal link to pain. Only normal tissue remains. Superficial electro-coagulation 
with diathermy may destroy the active lesion but may also leave the treated 
tissue and the underlying fibrosis. Applying prolonged diathermy may also 
increase the risk of collateral damage.  
 
Cold scissors may be used to excise endometriosis. However, most surgeons 
prefer an energy source that gives them a degree of haemostasis as well as the 
precision of cold scissors. Electrical energy is most effectively used in its 
monopolar form to excise endometriosis. For example, 3mm monopolar 
scissors used at a high power of 90 Watts are a precise means of excision 
(Redwine, 1993). Electro-surgical energy essentially cuts and coagulates by 
applying high levels of heat to the target area. There is a potential of collateral 
damage by heat spread proximal to the target area, insulation failure, direct 
coupling or capacitive coupling. Bipolar energy is not a useful energy source for 
effective excision or vaporisation. 
 
Several modified electro-surgical devices have been developed to reduce the 
amount of electrical energy required to cut or coagulate. These devices include 
the argon beam coagulator (Daniell et al., 1994) and Helica Thermal Coagulator 
(Nardo et al., 2005). Both have been used for the coagulation of superficial 
deposits of endometriosis.     
 
Ultrasound generated energy is also a precise means of excision with 
simultaneous haemostasis. Ultrasound energy is converted to high-speed 
motion in an active blade. This cuts and causes haemostasis, by coaptation 
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more than coagulation, at a lower temperature than electrosurgical energy. 
Consequently there is a trend towards less heat damage to adjacent tissues in 
human and animal studies (Awadzi, 2005, Meltzer, 1994). Also, ultrasound 
energy devices are free from the risks of insulation failure, direct coupling and 
capacitive coupling as no electrical energy passes down the instruments. 
Haemostasis is good but not as effective as electro-surgery.  
 
Lasers can be used for either the excision or vaporisation of endometriosis 
(Bruhat et al., 1989, Sutton, 1989). The common lasers employ carbon dioxide 
(CO2 laser) or yttrium aluminium garnet modified with potassium tinanyl 
phosphate (KTP laser) to create a highly focused visible light beam that cuts 
tissue precisely by heat. Excision is precise and quick however haemostasis is 
not as good as electrical or ultrasound energy. Vaporisation is achieved by 
moving the beam around over the target area until only an underlying area of 
normal tissue remains. With the Swiftlase function on Sharplan CO2 lasers, the 
beam is automatically rotated around the aiming point, making vaporisation 
easier.       
 
The choice of energy source, instrument and technique is probably controlled 
by various factors, including what the surgeon is comfortable with, what they 
believe to be best, what they have available, whether the instruments are safe, 
and the cost. However, there exists no data on why surgeons use which 
technique or which instrument.  
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In addition to different techniques, there are three distinct areas of surgical 
treatment for endometriosis: minimal to moderate endometriosis, 
endometriomas, and lastly, recto-vaginal nodules. 
 
Surgical treatment of peritoneal endometriosis for Infertility 
As yet there has been no direct causal link established between sub-fertility and 
endometriosis (Vercellini et al., 2009). According to Hughes Cochrane review of 
the subject (Hughes et al., 2003) there is no evidence to suggest that medical 
therapy with hormonal drugs is beneficial for women with endometriosis-
associated infertility. Hughes, in a separate paper reviewing 5 cohort studies 
and a quasi-randomised study, suggests that laparoscopy is superior to 
Danazol by an odds ratio of 2.7 in terms of pregnancy incidence (Hughes et al., 
1993). Evidence does exist to suggest that surgical treatment may be of benefit 
in all stages of the disease including endometriomas (Jacobson et al., 2004b, 
Adamson et al., 1993, Guzick et al., 1997, Osuga et al., 2002).  
 
Jacobson’s Cochrane meta-analysis of minimal to mild endometriosis, 
“Laparoscopic surgery for sub-fertility associated with endometriosis” (Jacobson 
et al., 2004b) since updated in 2009 with no significant changes, includes the 
EndoCan trial of 341 patients (Marcoux et al., 1997), which shows a beneficial 
effect for laparoscopic treatment, and the Italian Group trial which shows no 
significant difference and a slight negative effect on live births 
(dell'Endometriosi, 1999). The meta-analysis of the two trials shows an 
improvement in fecundity with surgical therapy with an odds ratio 1.6 (95%CI 
1.05 to 2.57) of pregnancy progressing beyond 20 weeks gestation or live birth. 
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Jacobson has commented that this result should be treated with caution, as the 
two results are contradictory. 
 
On further analysing the two trials we find that both had strict eligibility criteria at 
the outset. Both had power calculations (although the Italian Group trial ended 
up being underpowered as it was attempting to show the 2.7 odds ratio 
suggested by Hughes above). The entry criteria for the Italian Group trial were 
two years of infertility, versus one year for the EndoCan trial. The Italian Group 
subjects probably reflect a group of patients with poorer prognosis at the outset 
as a result. There were also more stage 2 cases of disease in the Italian Group 
that may have disadvantaged it. The eligibility for the EndoCan trial restricted 
the visual diagnosis of endometriosis to blue or black lesions only and so 
missed a whole cohort of other appearances. Neither trial confirmed the 
presence of endometriosis with histology and so the possibility of false positive 
diagnoses exists. Surgical technique is not clearly explained in either trial and 
with the number of centres and surgeons involved there is a distinct possibility 
that the quality of treatment between the two trials was not consistent. Neither 
trial was blinded, so there were potential performance biases involved in that 
patient knowledge of which treatment had been received may have affected the 
sexual behaviour of participants subsequent to surgery. The two trials had 
different follow-up periods: 9 months for the EndoCan trial and 12 months for 
the Italian Group. However, about half of the Italian Group patients had 3 
months of adjuvant GnRH analogue treatment after surgery, meaning that there 
were also 9 months available to them to conceive in half of the cases. This 
addition of adjuvant therapy also created new subgroups of treatment though 
no significant differences were shown in any of them in the analysis. 
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On balance there appears to be some positive effect on fertility with 
laparoscopic surgery for treating endometriosis but it may be less substantial 
than originally suggested and recent reviews appear to be downplaying the 
positive benefits (Vercellini et al., 2009). In addition, the EndoCan group 
calculated from their data that one in eight women should benefit from 
laparoscopic treatment of endometriosis. In Jacobson’s meta-analysis 
(Jacobson et al., 2004b), the suggestion was that the number needed to treat 
for one additional ongoing pregnancy beyond 20 weeks lies somewhere 
between 3 and 100. Therefore, this evidence does not clearly indicate that all 
women suffering from infertility should undergo laparoscopy to purely look for 
endometriosis alone, as potentially only 1 in 8 of the 20% to 68% likely to have 
infertility associated with the presence of endometriosis are likely to benefit 
(1994, Koninckx et al., 1991, Mahmood and Templeton, 1991, Matorras et al., 
1995). However, in the absence of gamete problems, laparoscopic treatment of 
endometriosis can be recommended for endometriosis found at laparoscopy in 
association with infertility, especially if it can be removed at the same time as 
diagnosis. 
 
Endometriomas 
Medical treatment has shown a significant reduction in the size of 
endometriomas (Schenken, 1990, Batioglu et al., 1996) but there remains the 
risk of ovarian torsion, a small risk of malignancy, continued pain and the effect 
on fertility to consider. Surgery had already been touted as beneficial for fertility 
as far back as 1957 (Fredrikson, 1957). Furthermore, in modern times 
laparoscopy has not been shown to be disadvantageous compared with 
laparotomy, as shown by the many reports that considered this during the rise 
 25 
of laparoscopy in the 1990s (Daniell et al., 1991, Donnez et al., 1996, Adamson 
et al., 1992, Sutton et al., 1997a). Research then moved on to consider the 
technique that should be used to best treat endometriomas considering the 
outcomes in respect to pain, recurrence, reoperation, ovarian function and 
fecundity. It became clear that fenestration alone was inadequate (Vercellini et 
al., 1992) and so the front runners became either straight excision of the 
pseudo-cyst capsule or some combination of fenestration and coagulation 
involving varying energy sources and the possibility of staged procedures with 
adjuvant GnRH analogue therapy. Energy sources for ablation have included 
electro-cautery (Beretta et al., 1998, Alborzi et al., 2004b), CO2 laser (Donnez 
et al., 1996) and KTP laser (Sutton and Jones, 2002). The two-staged 
procedure allows for initial drainage, followed by down regulation for several 
months with GNRH analogue, to then permit definitive coagulation of the 
capsule and treatment of peritoneal lesions (Donnez et al., 1994).    
 
Randomised evidence appeared in three trials since 1998 (Beretta et al., 1998, 
Alborzi et al., 2004b, Alborzi et al., 2007b) that were considered together by 
Hart in his Cochrane review (Hart et al., 2008). On reading the methodologies 
for the 1998 and 2004 trials by two separate authors they appear to be very 
much based on each other, with some small variations. Fecundity seemed to be 
the primary outcome variable though this was not stated in either trial and 
neither was a power calculation done. Both trials appeared to have rigorous 
eligibility for infertility. It should also be noted that in neither trial were patients 
blinded from the treatment, and the investigators did not appear to be blinded 
from follow-up either. Pain outcomes were only judged by a single VAS for 
varying types of pain and were dichotomised into levels of severity. It is not 
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clear from either paper how recurrence of pain was derived and objective pain 
results are not described. In both trials fertility was judged by positive pregnancy 
on ultrasound, and not by pregnancy outcome. Recurrence of disease was 
judged by the recurrence of probable endometriomas greater than 3cm 
diameter on ultrasound.  Pain is a subjective measure, and the lack of blinding 
of patients is particularly concerning in this respect despite excision resulting in 
a significant reduction in recurrent pain. That being said, the evidence for fertility 
improvement and reduced recurrence with excision is strong in Hart’s meta-
analysis: the spontaneous conception rate was OR 5.21, 95%CI 2.04 to 13.29, 
and the reduced recurrence rate of OR 0.41, 95%CI 0.47 to 4.15. The 
combination of evidence was compelling in favour of excision when electro-
surgery is used for coagulation. With KTP laser there is a suggestion that 
pregnancy rates may be more comparable with excision (57% for KTP versus 
59% in Alborzi’s trial) (Jones and Sutton, 2002, Alborzi et al., 2004a). This has 
some logical credibility, though the evidence is not strong enough to draw firm 
conclusions, as the KTP laser penetrates well on the wet surface of an 
endometrioma, whereas CO2 laser penetration is stopped at a liquid interface, 
suggesting that the KTP may be more effective at destroying the pseudo-cyst. 
 
More recently research has shifted towards concern regarding damage caused 
by excision that might compromise ovarian blood supply, ovarian reserve and 
the potential success of assisted conception techniques. Consequently Canis 
has suggested a combination of excising the outer part, and ablating the deep 
inner part of the capsule proximal to the hilum (Canis et al., 2003), but there is 
no evidence yet for this approach and coagulating the hilar area may potentially 
cause more damage than excision of the capsule from this area. Current 
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research is beginning to be directed towards Anti-Mullerian Hormone as a 
marker for ovarian reserve and variations that may be found between excision 
and ablation (Lemos et al., 2008). All this being said, the Cochrane evidence 
still supports the evidence that higher spontaneous pregnancy rates result from 
excision, and even that the follicular response of ovaries to GnRH analogue 
after excision is higher for assisted conception (Alborzi et al., 2007a). However 
there is no evidence of improved outcomes of IVF following excision of 
endometriomas (Garcia-Velasco and Arici, 2004). There probably does remain 
a small risk of significant ovarian damage and potential ovarian failure from 
over-aggressive excision treatment with a rate of up to 2.6% in a retrospective 
review by Busacca (Busacca et al., 2006). 
 
Recto-vaginal nodules 
These cases present the ultimate surgical challenge for gynaecological 
laparoscopists in centres specialising in the treatment of endometriosis. The 
presence of a recto-vaginal nodule is not always obvious, either on recto-
vaginal examination or at laparoscopy. Deep infiltrating disease is under-
diagnosed as it may appear to be minimal disease if one only assesses its 
surface appearance (Koninckx et al., 1994). Usually there is obliteration of the 
Pouch of Douglas to a greater or lesser extent that can be easily missed by 
inexperienced eyes. 
 
Radical excision of recto-vaginal disease was known to carry a high morbidity 
and mortality and so was still regarded as less preferential to menstrual 
suppression in the mid part of the 20th century. However, evidence of bowel 
resection being used by some surgeons does exist coming into the 1970s 
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(McSwain et al., 1974, Gray, 1973, Cromer, 1967). Weed published his series 
of 163 cases of resection of bowel endometriosis at laparotomy in 1987, as 
laparoscopy began to develop (Weed and Ray, 1987). It is interesting that this 
series, and the 72 women undergoing bowel resection in Coronado’s series in 
1990 (Coronado et al., 1990), made no report of significant morbidity. 
Crosignani and Vercellini reviewed the relative benefits of laparoscopy and 
laparotomy in 1995 and found no difference between the two in terms of 
endometriosis outcome suggesting that technological advances in laparoscopy 
were already advanced enough to allow comparable results for even this 
complex area of surgery (Crosignani and Vercellini, 1995). Also, the benefits of 
laparoscopy over laparotomy in terms of recovery, pain and hospital stay were 
already becoming apparent (Luciano et al., 1992).  
 
The literature then continues in a procession of case series reports to the 
present day, here reviewed in a table constructed by Wright and presented at 
the ESGE Annual Meeting in Florence in 2009: 
 
 
 
 
 
 
 
 
 
Table 1. A summary of case series for the treatment of recto-vaginal endometriosis  
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Authors Date and Number of cases Reported Bowel 
fistulae/leaks n (%) 
95% confidence limits 
McSwain 1974/14 0 0-0.215 
Weed 1987/53 0 0-0.068 
Chen  1989/2 0 0-0.658 
Coronado 1990/76 0 0-0.048 
Redwine  1999/5 0 0-0.053 
Nezhatz 1986/22 0 0-0.068 
Bailey 1994/130 0 0-0.029 
Donnez 1995/231 0 0-0.016 
Koninckx 1994/285 1 (2.85) 0.001-0.02 
Jerby 1999/12 1 (8) 0.015-0.354 
Verspyck  1997/6 1 (16) 0.030-0.564 
English 2004/100 4 (2.5) 0.016-0.098 
Darai  2007/71 6 (8.5) 0.039-0.172 
Keckstein 2005/202 6 (2.9) 0.014-0.063 
Slack 2007/32 3 (9.3) 0.032-0.242 
Waters 60 5 (8.3) 0.036-0.181 
Possover 2000/34 0 0-0.102 
Total 1335 28 (0.21) 0.015-0.03 
 
(Bailey et al., 1994, Chen et al., 1989, Coronado et al., 1990, Darai et al., 2007, Donnez and 
Nisolle, 1995, Ford et al., 2004, Jerby et al., 1999, Keckstein and Wiesinger, 2005, Koninckx 
and Martin, 1994, McSwain et al., 1974, Nezhat et al., 1994, Possover et al., 2000, Redwine et 
al., 1996, Slack et al., 2007, Verspyck et al., 1997, Weed and Ray, 1987).  
 
This review by Wright considers a total of 948 cases of endometriosis 
undergoing surgical treatment for their disease. The overall complication rate 
was calculated to be 1.7% (95%CI 1 to 2.7). However, the more recent series in 
table 1 above seem to be showing up a higher frequency of bowel leaks and 
fistulas. This is an interesting finding that may reflect the fact that complication 
data was previously under-reported, or that the complexity of cases attempted 
has increased. Women presenting with recto-vaginal nodules need to be 
carefully counselled and prepared if surgery is being considered, as there now 
appears to be a genuine 4-10% risk of major complications associated with 
sigmoid and rectal surgery that is confirmed in the experience of general 
surgeons treating rectal cancer too (Canis, 2005, kenney, 2005). Acutely, these 
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include anastamotic leaks, fistulas and urinary system damage as well as the 
chronic bowel morbidity resulting from strictures and short bowel syndrome. It 
appears that these strictures may be more common in endometriosis patients 
than in those undergoing rectal resection for rectal cancer (Waters N, 20008) 
representing possibly the underlying fibrotic nature of endometriosis. Despite 
Dubernard reporting an improvement in all items of SF-36 for a series of 58 
colorectal resections of endometriosis, the major complication rate was 15.5% 
and tenesmus, constipation and bowel frequency were not improved in the long 
term (Dubernard et al., 2006).  
 
Surgically, a combined approach with a laparoscopic colorectal surgeon may be 
undertaken. The sigmoid colon and rectum are dissected away from the ureters, 
pelvic side-walls, uterus, cervix and vagina. Following this the endometriotic 
nodule or nodules are removed from the bowel. In the most conservative 
technique this is done by shaving the nodule off the bowel, thereby avoiding 
perforation of the bowel mucosa. However, if entering the bowel is necessary to 
remove the disease a disc resection may be performed that is subsequently 
closed by primary laparoscopic suturing. In cases where a nodule is deeply 
infiltrating over a larger area, and it is considered that disc resection could result 
in stricture, anterior or segmental resection may be carried out. Multiple sites of 
disease, that would otherwise require multiple disc resections, may also be 
treated by segmental resection. Recommending surgery as the main primary 
treatment is by no means the only option. With the risk of complications, 
patients may prefer to consider long-term medical therapy instead. Or, if 
pregnancy is the main requirement, then IVF may be preferential as a first line 
treatment.      
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We do not know which is the optimum technique to surgically remove recto-
vaginal disease. There are no RCTs and it would be very difficult to produce a 
robust trial to investigate this. Some surgeons advocate segmental resection in 
all cases as they believe that it is the only way to remove all disease, especially 
as there is evidence to suggest that up to 68% of patients have multiple lesions 
(Keckstein, 1999). Others believe that there is gene-profiling evidence emerging 
to suggest that the nodules are cervical in origin, and so surgery should be 
more radical on the cervico-vaginal side and less radical on the rectal one in 
order to decrease bowel complications and risk of recurrence (Van 
Langendonckt, 2004). Overall success rates of surgery for recto-vaginal 
nodules in terms of pain relief are in the region of 85-95% with recurrence rates 
of 5-15% (Canis, 2005) though the positive effects on fertility are less clear. 
Pain recurrence was estimated at 28% in Dubernard’s series despite colonic 
resection (Dubernard et al., 2006). In addition to this, Abbott showed in his 2-5 
year follow up of women undergoing laparoscopic excision for all stages of 
endometriosis that the risk of requiring subsequent surgery was 33%, estimated 
at 36% over 5 years, and that women with deep infiltrating stage 4 disease 
were significantly more likely to be in this group showing that their risk of re-
operation was even higher (Abbott et al., 2003). 
 
In summary, despite favourable improvement in pain symptoms after radical 
surgery, the acute complication risk, long-term bowel morbidity and the risk of 
recurrence tend to favour a more “conservative” radical approach, whereby as 
much endometriosis as possible is removed with the least risk of sustaining 
bowel complications. The level of pain improvement has not been shown to be 
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any worse for a more “conservative” approach. This seems particularly 
important in view of the fact that endometriosis is not lethal and has a 
substantial likelihood of recurrence despite how aggressive the resection is. In 
addition to this, the progress in robotic surgical techniques, allowing state-of-
the-art 3D vision and unparalleled precision, may allow for more accurate 
excision of recto-vaginal endometriosis with reduced bowel morbidity (Magrina, 
2007).    
 
Surgical treatment of minimal to moderate endometriosis for pelvic pain 
In the laparoscopic era of surgery for endometriosis, various techniques for 
operating on minimal to moderate endometriosis developed side by side, but 
can broadly be put into the categories of excision, vaporisation or 
ablation/coagulation. Excision is in a clear category of its own with no doubt 
over the technique of staying in normal tissue and excising around the 
suspected lesion. Ablation and coagulation are terms that have been used 
frequently to describe the application of heat energy to a lesion to result in its 
destruction. These terms reflect a wide range of resulting effects from just 
applying heat to the surface of a lesion leaving a charred area of tissue that 
probably represents sub optimal treatment, through to full destruction of tissue 
resulting is an appearance of normal tissue similar to excision. For that reason 
the use of the word “vaporisation” is perhaps more appropriate to describe the 
technique where energy is applied to a lesion where the outcome appears 
similar to excision. These varying approaches were reported in various case 
series throughout the 80s and 90s (Redwine, 1996, Candiani et al., 1986, 
Lomano, 1987, Martin and Vander Zwagg, 1987, Redwine, 1991). 
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Sutton then produced the first RCT looking at the surgical treatment of minimal 
to moderate endometriosis for relief of pelvic pain in 1994 with a series of 63 
patients (Sutton et al., 1994). Patients underwent laser vaporisation of all 
lesions with or without the addition of adhesiolysis and utero sacral nerve 
transection or had diagnostic laparoscopy alone. Patients completed VAS pain 
scores based on their worst symptom from dysmenorrhoea, dyspareunia and 
pelvic pain (which was dysmenorrhoea in all cases), at 0, 3 and 6 months. 
Scores were not significantly different at 3 months but became significant at 6 
months with 62.5% of the treatment group improving. There was no power 
calculation included in the report, no information on allocation concealment and 
no data on quality of life, yet this gave the first substantial evidence that surgical 
treatment was effective. However, it has subsequently been established that 
there is no evidence that laparoscopic uterine nerve ablation (LUNA) by itself or 
combined with surgical removal of endometriosis is of benefit for women with 
pelvic pain and endometriosis (Vercellini et al., 2003, Johnson et al., 2004, 
2003, Daniels, 2009). 
 
However, many gynaecologists continued with excision, presumably because 
they felt they were achieving the same effect, if not better, and were also saving 
the substantial cost of investing in a laser. More critical evidence for the effect of 
excision, including quality of life data, did not really arrive until Abbott’s paper of 
2003, prospectively looking at the outcome of patients for pain and quality of life 
at 2-5 years post laparoscopic surgical excision. This was a more substantial 
look at the evidence than their group’s previous report by Garry in 2000 (Garry 
et al., 2000). The findings showed that the most common symptom at 
presentation was non-menstrual pain (74%), 67% were improved (though a 
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disturbing 25% were worse), there was a significant risk of re-operation (33%), 
analgaesia was still required for 35%, and hormonal therapy in 26%. Median 
pain scores were significantly improved for all pain modalities and quality of life 
was significantly improved though not to normal population levels. 
Dysmenorrhoea remained the most common symptom at follow up. It must be 
noted that this sample of women appears to be skewed towards more 
advanced disease (41% had stage 4 disease) suggesting that these outcomes 
are those one may expect in a tertiary referral practice and not necessarily the 
general population of endometriosis sufferers.  
 
This prospective study was followed up with the first RCT for excision therapy 
by the same group published in 2004 (Abbott et al., 2004). This included 39 
women (just missing their power calculation of 40), again with all stages of 
disease that seems once more to be biased towards more complex disease 
compared with the general endometriosis population, with 17/39 (43.6%) of 
patients having stage 4 disease, in what was presumably a tertiary referral 
practice. Comparative data for excision versus control is available at 6 months, 
as in the Sutton trial, and showed that 80% (versus 32% in the control group) of 
patients in the immediate surgery group had some form of pain improvement, 
with a median improvement of 30 points on a 100-point VAS of overall pain 
improvement. Interestingly, for individual pain modalities of dysmenorrhoea, 
dyspareunia, non-menstrual pain and dyschezia, there was no significant 
difference in direct score comparison between excision and controls groups at 6 
months. However, within each group, excision significantly improved for all 4 
modalities and the controls for dysmenorrhoea and CPP only. The placebo 
effect noted by Sutton at 3 months appears to extend, to some extent, to 6 
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months in the Abbott trial. That the comparatively significant improvement in 
overall VAS for pain did not correlate with the individual pain modalities is 
disappointing and casts some doubt on the overall result at 6 months. The 
authors themselves call into question the potential limitations of VAS pain 
scores alone to interpret outcomes as they are probably subject to significant 
intra-observer error. Ideally, additional validated outcome measure instruments 
need to be used looking at HRQoL as was done in Abbot’s trial with EQ-5D and 
SF-12. This trial raised the question of whether 6 months follow up was really 
long enough to pick up a significant difference as suggested by Sutton’s trial. 
Sutton’s follow up report on his trial at 12 months also suggested that 90% of 
those who responded at 6 months had continued symptom relief, although the 
blinding was now broken (Sutton et al., 1997b). 12 months of direct comparative 
follow up was the logical next step.  
Jarrell et al attempted to look at 12 month follow up and simultaneously 
overcome the VAS problem above by taking repeated daily VAS pain scores for 
a month pre-operatively and at 3 monthly intervals up to one year (Jarrell et al., 
2005). Sadly only 16/29 women completed the rigorous follow up protocol, 
resulting in a significantly underpowered trial. The other two potential trials, by 
Tutunaru and Lachlandani, considered by Jacobson in his updated Cochrane 
review (Jacobson et al., 2009) were data presented from conferences, are 
unpublished in full form, and should be treated with caution. The meta-analysis 
of the advantage of laparoscopic treatment versus diagnostic laparoscopy alone 
at 6 months suggests an odds ratio of 5.72 (95%CI 3.09 to 10.60).         
These trials did not attempt to compare excision and vaporisation, the two 
leading forms of surgical treatment for minimal to moderate endometriosis. Only 
one published trial of 24 women exists from Wright, comparing excision and 
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ablation with monopolar electro-surgery for superficial minimal to mild 
endometriosis (Wright et al., 2005). A significant improvement was found for 
symptoms and signs in both groups but no significant difference between the 
two groups at 6 months. This trial was small and confined to only rASRM stage 
1 and 2 superficial disease, and perhaps the sensitivity of the 1 to 5 ordinal 
scale used is limited in being able to differentiate between treatments. 
 
There is currently insufficient evidence to differentiate between excision and 
vaporisation in the treatment of minimal to moderate endometriosis. It would 
seem logical to assume that, provided all endometriosis and fibrosis is removed 
leaving only normal tissue, then there should be no difference between the two. 
 
Conclusion 
Endometriosis is almost certainly under diagnosed and under treated and much 
more research is needed. The development of the World Endometriosis Society 
(WES), the availability of Internet information from quality websites like 
endometriosis.org, and the rapid development of patient-support groups are all 
helping to raise the profile of the disease. This in turn will hopefully lead to a 
better understanding of the aetiology and effectiveness of treatments. Ultimately 
however, it will be informed patients demanding high quality evidence-based 
treatment that will drive progress. The British Society of Gynaecological 
Endoscopy (BSGE) is also developing a national treatment database and 
network of accredited centres with the aim of improving standards of treatment 
and collecting data for research. Ten centres are currently accredited on the 
BSGE website (www.bsge.org.uk).  
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150 years after the disease was first described, we are still debating its 
aetiology. The rise of laparoscopic surgery has raised the profile of the disease 
over the past 30 years and this has led to a corresponding increase in our 
understanding of the underlying processes. As the evidence currently stands, 
laparoscopic surgery appears to be the most logical approach to treatment 
provided women accept the risks of surgery especially for complex disease. 
There is little evidence to support the use of one technique or instrument over 
another, and there are insufficient centres and surgeons capable of dealing with 
the problem. This thesis will hopefully be able to assess more clearly the 
currents trends in practice for all forms of the disease, and perhaps throw more 
light upon whether one technique or other is advantageous for minimal to 
moderate disease. 
 
 
 
 
 
 
 
 
 
 
Chapter 3 - Methodology 
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An International Survey of Surgical Techniques used in the 
Treatment of Endometriosis 
 
 
Introduction 
When the patient comes to the operating theatre there are many factors that 
have influenced the procedure that they will actually undergo. These include: 
  
1. Factors related to the surgeon themselves including their training, 
experience and character. 
2. Factors related to the evidence for the procedure including the 
medical literature and guidelines. 
3. Factors related to economics and availability of instrumentation 
pertaining to the hospital in which the surgery is being carried out. 
 
This complex inter-relationship is often not developed in a systematic way and 
instead is the result of a series of coincidences influenced in varying degrees by 
the factors listed above. Dealing with each of these factors in turn we can see 
more clearly the complexity of the issue. 
 
Part of why surgeons choose to use different instruments or techniques will be 
based upon their own character. Some may be more risk averse and more 
inclined to carry out less invasive and radical techniques than others who are 
more aggressive in nature. Some may be more driven by ambition and 
discovery and inclined to explore and develop their own new techniques that 
result in a change in widespread practice. The training that a surgeon has 
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received will vary considerably from a standard-type training path to a specialist 
Fellowship or postgraduate degree. Their theoretical and practical ability will 
vary widely as a result. The influence of the teacher in this process is likely to 
be significant in affecting the method that the surgeon ultimately applies on his 
or her own patient. Experienced surgeons are likely to be more confident and 
may be more likely to be more aggressive and innovative, or conversely may be 
stuck in their ways in outdated techniques. 
 
The medical literature for the surgical treatment has been outlined in detail in 
Chapter 2 but in summary suggests that the gold standard for the diagnosis of 
endometriosis is laparoscopy (Kennedy et al., 2005). This is not necessarily 
required if medical therapy controls pain symptoms, fertility is not an issue at 
that moment, and the woman is comfortable without a definitive diagnosis. This 
guideline was developed on the basis of RCT evidence summarized in the 
Cochrane database (Hart et al., 2008, Jacobson et al., 2009, Jacobson et al., 
2004b) as well as large numbers of non-randomised studies. There is no clear 
evidence that one technique or instrument is better than any other, and so 
factors 1 and 3 above play a larger part in influencing what happens to the 
patient on the operating table than they would if there was a definitive 
procedure with overwhelming evidence supporting it. 
 
Economical issues in health care play a large role in determining what is 
available to the surgeon. There are many instruments capable of carrying out 
excision, vaporisation or ablation of endometriosis with varying costs and 
characteristics. Less economically restricted hospitals, with visionary chief 
executives may be more likely to invest in the latest developments. Others will 
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wait until there is more evidence, or even till there is no choice once the 
evidence for a procedure is overwhelmingly in favour of it. 
 
This study looks at which instruments and techniques are currently being used 
and why. It is therefore an exploratory study to attempt to understand more 
about surgeons choices in instrument and technique in relation to the three 
factors listed above.          
 
Study design 
The survey was administered and designed to collect reliable, valid and 
unbiased data from a representative sample, in a timely manner and within the 
given resource constraints.  
 
In questionnaire design, certain methods have been identified that have been 
shown to help achieve this (Boynton, 2004, R Nakash, 2006). For administration 
these include: 
 
1. Saliency of the questionnaire to the responder 
2. Linguistic ability of the responders 
3. Efficient means to complete the questionnaire 
4. Will to complete the questionnaire 
5. Clear aim of survey conveyed to responders by covering letter 
6. Pre notification 
7. Reminders 
8. Use of incentives 
9. Available researcher to answer questions 
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10. Pilot study  
11. Efficient data entry and cleaning  
 
For design these include: 
1. Clear design and layout 
2. Visually appealing 
3. Short questionnaires 
4. Question wording 
5. Question ordering  
6. Question form 
 
Objectives 
Primary endpoints 
To discover the type of surgical techniques and instruments used in treating 
different types of endometriosis, including superficial minimal to moderate 
disease, deep minimal to moderate disease, endometriomas and recto-vaginal 
nodules, within the study population. 
 
Secondary endpoints 
1.The characteristics of the laparoscopic surgeons using these techniques and 
instruments defined by region, experience and training. 
2.The geographical distribution of the use of these techniques and instruments, 
and why the surgeons are choosing them. 
 
Population 
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The survey was sent to members of the British Society of Gynaecological 
Endoscopy (BSGE), European Society of Gynaecological Endoscopy (ESGE), 
and the American Association of Gynecologic Laparoscopists (AAGL). The 
Australian Gynaecological Endoscopy Society (AGES) was approached but 
declined to participate for data protection reasons. These societies had email 
addresses for 4878 medical members in total.  
 
Type of survey 
This was an international web-based self-completed survey with a large target 
population of nearly 5000. Clearly a self-administered questionnaire was 
preferable to an interviewer-administered approach for numerical and 
geographical reasons. An electronic web-based rather than postal distribution 
was chosen for several reasons: 
 
1. An electronic survey would be less expensive, saving on postal costs. 
2. Answering is controlled, by stopping responders from moving on until 
they have completed certain questions. 
3. Out of range answers are prevented from being entered in error. 
4. Response collation and transfer to a statistical database is electronic. 
5. A sampling frame existed, as each society maintained a member 
email address database. 
6. Electronic surveys are easy to distribute with less risk of postal failure 
provided that email addresses are accurate. 
7. Electronic surveys are efficient to complete in the presence of a good 
Internet connection. 
 43 
8. Responders, being doctors in mainly developed countries, were likely 
to have easy access to computer and Internet facilities. 
 
Survey Administration 
Covering letter and invitation to participate 
Each Society agreed to distribute the survey by an invitation covering letter, 
stating the clear aim of the survey, with an electronic link into the questionnaire. 
This confirmed the bona fide credentials of the survey, and was presented with 
headings and logos. It also guaranteed confidentiality. The BSGE and ESGE 
agreed to do this by an individual email invitation to each member on their 
databases. The AAGL would only agree to do this by including the invitation in 
the monthly newsletter. No other pre-notification technique was used. A copy of 
the invitation letter for the main survey is at appendix K. 
 
Use of incentives 
All responders email addresses were included into a post-survey raffle. The 
winner received an iPod Nano. This was stated clearly on the invitation email. 
 
Available researcher to answer questions 
On the bottom of each questionnaire page the researcher’s email address was 
included so that responders could ask questions. 
 
Pilot Study 
A pilot study was sent to a representative sample of 12 gynaecologists from the 
main study population. They were also sent a covering invitation email directly 
to their address, which allowed them to click on an electronic link into the pilot 
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questionnaire. The results of the pilot study were analysed to assess issues 
regarding layout and design, non-responses due to poor language or 
signposting, relevance, ambiguities and its ability to hold interest. An open free 
text box was included for responders to comment on the survey. A copy of the 
pilot invitation and pilot questionnaire are at appendices J and L.  
 
Data handling and record keeping 
All data responses were transferred to a secure central database operated by 
the commercial web survey system until the survey was closed. This was then 
transferred electronically into an Excel database. From there, the Excel 
database was copied manually into SPSS for further analysis. The SPSS 
database was held on a password protected laptop. No paper records of 
responders’ personal details were kept. All data was handled in accordance 
with data protection legislation.  
 
Reminders 
Both the BSGE and ESGE agreed to send out a reminder one month after the 
initial send out of the invitation email. The same invitation covering letter as 
before was emailed out to each individual member. The AAGL declined to send 
out a reminder, or to include the invitation in their next monthly newsletter.  
 
Questionnaire software 
The initial pilot study survey was set up using the Panorama online survey 
system that was developed at the School of Management, University of Surrey. 
The system was registered for copyright in 2004. It was compatible for PC and 
Apple Mac users and worked in common web browser systems including 
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Internet Explorer. For the pilot survey it was very successful, but unfortunately 
restrictions forced upon the IT Department at the University of Surrey in 2007 
resulted in this study needing to find a new distribution system. The survey was 
switched to the commercial system Zoomerang, which was recommended by 
the Sociology Department. It was simple, intuitive and straightforward to transfer 
the questionnaire from Panorama. Consequently, the main survey was sent 
out using Zoomerang. 
 
In Zoomerang, results are collated for each question and simple descriptive 
statistical outcomes are tabulated automatically. Responses are broken down 
by date and hour of the day allowing analysis of response patterns. Unlike 
Panorama, data was not broken down by the browser system that the 
responder uses, to rule out browser system bias. Also unavailable in 
Zoomerang were: 
 
1. Drop out analysis showing data on whether particular parts of the 
survey were repeatedly not completed to help identify problem areas. 
2. Duration analysis showing the time taken to complete the survey.  
3. Automatic coding for export into SPSS for further statistical analysis. 
 
Questionnaire development 
Initially a list of questions was generated from using the literature and the 
known instruments and techniques used for the surgical treatment of 
endometriosis in order to cover all of the areas for which information was 
required. Meetings were held with supervisors to ensure the validity of the 
coverage. The ideas and topics were then developed into open and closed 
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questions of varying types. Initially these were pre-piloted on members of the 
research group, and then formally piloted in electronic form as described above. 
They were then refined, and a questionnaire was created that took about 10 
minutes to complete and was subdivided into the following subsections: 
 
1. A profile of the respondent. 
2. The responders’ management of minimal to moderate endometriosis. 
3. The responders’ management of endometriomas. 
4. The responders’ management of recto-vaginal nodules. 
 
Clear design and layout and visual appeal 
The Zoomerang survey system produced a very clear, professional design and 
layout. It had varying designs that could be selected from, and had enough 
flexibility in question generation to be able to produce a simple, visually 
appealing result. An introductory welcome page gave clear instructions and a 
thank you statement was included at the end.  Any filter questions were clearly 
marked. Lower case letters were generally used to avoid the appearance of 
shouting. Numbering was clear, and response categories were never split over 
two pages. A paper copy of the main questionnaire is at appendix M (however it 
was not possible to print this out from the Internet with the page breaks in the 
correct place).   
 
Questionnaire length 
The questionnaire was kept a short as possible to get the required information, 
and was 34 questions long. No questions were added or removed after the pilot 
study and the main questionnaire remain the same length.  
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Question form 
The questionnaire mainly employed closed type questions with pre-coded 
scaled or dichotomous response choices. Some questions had small open 
response text boxes to account for response alternatives missed in the pre-
coded list. Closed type questions were used as they are simpler and quicker to 
administer and code, as well as being appropriate to the information required 
from the survey. However, it was appreciated that they can also give clues 
about the type of response expected, and this was minimised where possible.  
 
Response scales in Likert format (5 point scale, strongly agree to strongly 
disagree) were used for questions about why responders used the techniques 
they chose. They are commonly used, easily understood and analysed, and are 
more sensitive and precise than dichotomous responses. Creating categorical 
scales, by using words in the Likert scale, shows a similar responsiveness to 
visual analogue scales (Jaeschke, 1990) with less ceiling and floor effects than 
dichotomous responses. Neutral responses in the scale were felt to be 
important and so were included.   
 
Question ordering 
An advantage of electronic questionnaires is that responders are unable to read 
through them and assess questions in the light of ones further on in the 
questionnaire. A funnel approach was taken to question order, starting with 
broad questions in logical categories, filtering out responders who these 
questions were irrelevant to, and then progressing onto more detailed questions 
within that category.  Responders who were filtered out were automatically 
taken onto the next question that applied to them. 
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Question wording 
The wording, format and direction of response were varied where possible to 
make responders think about the question and avoid a “response set”. Wording 
was also aimed to be as non-confrontational as possible. Double-negatives and 
colloquialisms were avoided. Complex questions about the management of 
recto-vaginal nodules were broken up into a series of simpler questions that 
were more easily understood. There were no double-barrelled questions (two 
questions in one sentence) and ambiguity was avoided where possible. 
Wording was aimed to draw specific answers rather than general ones, and was 
not “loaded”. 
 
Ethics 
Ethical approval was gained from the University of Surrey Ethics Committee. 
Responders were emailed in their independent capacities as members of 
Gynaecological Societies. No resources or information directly related to the 
NHS were used and so ethical approval from the NHS was not required. 
  
Statistical analysis 
Simple descriptive statistics were used for response rate and demographic 
factors with means and standard deviations used where appropriate for 
continuous variables, and median and range used for skewed continuous, or 
discrete variables. To test for differences between proportions Pearson’s Chi-
square test was used and, where the groups were small, Fisher’s Exact test 
was employed. For testing differences in mean values between multiple groups 
an Anova was used. For testing differences in median values between multiple 
groups Kruskal-Wallis test was used. 
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Financing and insurance 
The only financial outlay for the study was the subscription for the Zoomerang 
survey system. This was $198 for 6 months use and was funded from a 
gynaecological endoscopy fund based at the Royal Surrey County Hospital. 
The author’s salary was 50% funded by the Minimal Access Therapy Training 
Unit with funds provided by Ethicon Endo-Surgery from October 2004 until April 
2008. 
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A Randomised Blinded Trial of Carbon Dioxide Laser 
Vaporisation versus Harmonic Scalpel Excision of rASRM 
Stage 1-3 Endometriosis in Women with Pelvic Pain. 
 
Participants 
Patients were recruited from General Practitioner NHS referrals to the Royal 
Surrey County Hospital (RSCH) and private referrals to a Surrey based private 
practice. The sample was therefore not self-selected. RSCH is a UK District 
General Hospital that has a history of performing tertiary referral-type 
gynaecological laparoscopy. The other site, The Guildford Nuffield Hospital, is a 
small private institution attached to the RSCH. Although consultation and 
surgery took place in more than one hospital, it was under the care of only one 
Consultant. From these, patients with pelvic pain who were booked for a 
laparoscopy for known or suspected endometriosis were judged against the 
inclusion-exclusion criteria and were then verbally invited to take part in the trial 
and given an information leaflet explaining the trial (appendix B). This was done 
either in the outpatient setting or on admission to the hospital prior to 
laparoscopy by one of the three surgeons taking part in the trial. The County of 
Surrey, in which the practice is based, has an “average” population with little 
evidence of poverty or other major public health problems, and is well 
connected by public transport.  
 
Eligibility 
Inclusion criteria 
 Patients in whom surgical treatment of the endometriosis is considered 
the treatment of choice. 
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 Patients consented to participate in the trial. 
 Patients who are 18 years old or older. 
 Patients who have no contraindications to either of the treatment 
modalities proposed. 
 Endometriosis stage I-III according to the revised American Society for 
Reproductive Medicine scoring system (rASRM) found on visual 
inspection at laparoscopy (Appendix H). 
 
Exclusion criteria 
 Patients who do not wish to participate or have not signed the informed 
consent form. 
 Pregnancy or breastfeeding. 
 Patients who are unable or unwilling to discontinue hormonal treatment 
for six months post-operatively. 
 Patients who have received additional treatment for their endometriosis 
within three months of surgery.  
 Patients with other known conditions causing pelvic pain other than 
endometriosis. For example, conditions of the gastrointestinal or genito-
urinary system. 
 
If patients agreed to participate they signed consent forms for admission to the 
trial (appendix C). All pre-op questionnaires were completed in hospital on the 
day of surgery and kept in an individual trial folder for each patient. The trial 
folder contained their personal details, consent forms, questionnaire replies, 
rASRM score sheet and any correspondence generated during the trial. The 
Senior Research Sister held all files secured in a filing cabinet in the team 
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office. Patients returned at 3, 6, and 12 months for follow-up appointments and 
were seen by the research Sister, or a deputising clinic, to fill in their post-op 
questionnaires. The research Sister also oversaw the administration of the 
private patients questionnaires. Patients who did not attend were contacted by 
mail or telephone and requested to return a postal questionnaire.  
 
Interventions 
The diagnosis and treatment intervention in this trial was laparoscopy on an 
intention to treat basis. These were carried out in either the Day Surgery Unit or 
Main Theatres at the RSCH or Guildford Nuffield Hospital. Three surgeons were 
involved in the interventions; one Consultant, and two experienced senior 
gynaecological laparoscopic surgery Fellows, who were trained in the operative 
technique by the same Consultant mentioned above. All cases were undertaken 
with the intention of being day cases.  
 
Laparoscopic entry was by the recognised Middlesbrough technique (1999). At 
laparoscopy patients were visually assessed for the presence of endometriosis 
by diagnostic laparoscopy. An assistant by the bedside completed the rASRM 
scoring sheet (Appendix H) with information supplied by the operating surgeon. 
All types of endometriosis were included including red, vesicular, blue, black 
and white lesions.  The score was added up, the stage derived, and reported 
back to the surgeon. Disease was judged to be deep if subjectively on palpation 
it appeared to infiltrate >5mm below the peritoneal surface. Women who were 
found to have stage 1-3 endometriosis, according to the rASRM score were 
then randomised to complete destruction of all visible endometriotic lesions 
either by vaporisation or excision (see randomisation paragraph).  
 53 
Sharplan carbon dioxide laser at 300mm focal length, 30w power with a 2.5mm 
Swiftlase spot, down a Stortz 10mm operating endoscope until the entire lesion 
was destroyed and normal underlying tissue was visible, carried out 
vaporisation. Excision was by Ethicon Endo-Surgery LCS-C5 or ACE Harmonic 
Scalpel staying in normal tissue at the edges to ensure total removal of lesions. 
Histology was not routinely collected from the beginning of the trial. This was 
changed and routine collection began in June 2005 with case number 46 when 
it was recognised that was desirable. On completion of the treatment the 
procedure was concluded by our standard closure technique.  
 
The rASRM scoring sheet was reassessed post-operatively for depth score 
since actual excision or vaporisation of the lesion gives a more accurate 
subjective view of depth compared with the original assessment by palpation. 
This did not result in any score adjustments leading to trial exclusion. The 
procedures were carried out or directly supervised by the three surgeons in the 
trial. Patients were generally discharged home the same day in most cases. 
Patients were unable to tell from the appearance of wounds after surgery which 
treatment they had received and were effectively blinded.   
 
Objectives 
The hypothesis of this trial was that there is no difference between excision and 
vaporisation in the treatment of rASRM stage 1-3 minimal to moderate 
endometriosis using the CO2 laser for vaporisation and Harmonic Scalpel for 
excision where pain is the primary outcome measure. 
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Outcomes 
Primary outcome measure 
The primary outcome measure with respect to improvement in endometriosis 
was pain as recorded by Endometriosis Health Profile-30 Core Pain domain 
(Jones et al., 2001). This gave a score between 0-100 where 0 is the best 
possible state and 100 the worst (Appendix E).  
 
Secondary outcome measures 
Pain 
 Visual Analogue Scales (VAS) 
10 cm ungraded line for dysmenorrhoea, dyspareunia, chronic pelvic 
pain (CPP, pain not associated with menstruation persisting for greater 
than 6 months), and dyschezia. Patients marked off a point on the line, 
which was measured and recorded as a score out of 10 to one decimal 
place (Appendix D). 
 
Health-related quality of life (HRQoL) 
 Endometriosis Health Profile Questionnaire (EHP-30)  
Core domains for control and powerlessness, emotional wellbeing, social 
support, self-image, and the intercourse module each resulting in a score 
out of 100 for each, where 0 is the best and 100 is the worst possible 
case (Appendix E). 
 Hospital Anxiety & Depression Scale (HADS) (Appendix F).  
Separate scores are derived for Anxiety and Depression with a maximum 
of 21 where 0 is the best state and 21 the worst. Scores are then 
classified into 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.  
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Demographic 
At 12 months a demographic questionnaire was given to all patients to collect 
data on whether or not they went onto hormonal treatment for endometriosis or 
had subsequent surgery or became pregnant in the 12 month follow up period 
(Appendix G). 
 
Rationale for choosing outcome measures 
A single VAS pain score may be subject to significant large day-to-day variation 
and so a more sensitive, responsive measure of pain incorporating the quality 
of life concerns of patients would be a more powerful tool. This resulted in the 
choice of EHP30 Core pain domain as the primary outcome measure. Mr 
Barton-Smith spent a day with the author of the Endometriosis Health Profile to 
learn its strengths and limitations to be sure that we applied it effectively. Also 
permission was granted to use EHP-30.  EHP-30 is likely to be a more sensitive 
means of measuring endometriosis pain than a VAS because it has a validated 
bell shaped probability distribution, showing good construct validity, enabling a 
moderate shift in mean score to be easily detected with two moderately sized 
treatment groups. The pain domain was developed to “evaluate the outcomes 
of conservative surgical treatment for women with endometriosis” and has the 
following attributes (Jones et al., 2001):  
  
1. Good construct validity against SF36 with a bell shaped probability 
distribution, showing good construct validity, enabling a moderate shift in 
mean score to be easily detected with two moderately sized treatment 
groups 
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2. Good internal reliability reflected by high alpha co-efficient values of 
>0.7 as required in standardised tools based upon established 
psychometric test theory (Nunnally 78). 
3. Good test-test reliability with intra class correlations exceeding 0.8. 
4. Good content validity as items are generated from the concerns of 
patients rather than medical signs and symptoms and give a more 
powerful indicator of patient benefit. 
5. Good responsiveness showing that the test is sensitive to subtle 
changes. It shows greater responsiveness than the SF36 bodily pain 
scale. 
 
The 11 questions in the EHP-30 Core pain domain give a total score of 44. The 
subjects’ score is calculated by dividing their score into 44 and multiplying by 
100 to give a score where 0 is the best health state and 100 is the worst. Any 
missing variable results in the whole score for that subject being discounted. 
Therefore there is a risk in choosing EHP-30 Core pain domain as the primary 
outcome, as it could have resulted in a large number of missing data. 
Consequently, the VAS scores were included for two reasons: 
 
1. As a back up for the risk of losing large amounts of EHP-30 
Core pain score data. 
2. As a means of being able to directly compare with previous 
trials that used VAS scores (see sample size below). 
 
In addition to pain data, it was considered important to collect HRQoL 
information that was relevant to patients’ ability to function on a day-to-day 
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basis. The remainder of EHP-30 Core questions and the sexual intercourse 
module fulfilled this criteria. HADS was added in order to evaluate levels of 
anxiety and depression in patients, as endometriosis is known to have a 
significant psychological effect in sufferers (Jones et al., 2004b). The HADS 
shows internal consistency of 0.93 and 0.90 for the subscales of anxiety and 
depression, as well as good face, concurrent and construct validity (Zigmond, 
1983). It is short, acceptable, easy to administer and also splits subjects into 
definable clinical groups.  
 
Outcome collection during the trial  
The following data was collected at the indicated time points during the trial. 
The primary time point of interest was 12 months. 
 
 Pre-operative 
Age 
EHP-30 Core and Intercourse Module 
 VAS scores for Dysmenorrhoea, Dyspareunia, CPP, and Dyschezia 
HADS 
 
 Intra-operative 
rASRM score and stage 
Depth and location of disease  
Surgeon 
Instrument 
Histology from case 46 onwards 
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 3, 6 and 12 months post-operative 
EHP-30 Core and Intercourse Module 
VAS scores for Dysmenorrhoea, Dyspareunia, CPP, and Dyschezia 
HADS 
 
 12 months post-operative 
Pregnancy data 
Adjuvant medical therapy 
Subsequent surgical intervention 
 
Sample size 
The power calculation for this trial was based upon two requirements: 
 
1. To compare against previous trials. 
2. To use a validated primary outcome measure for pain that is most 
pertinent to patients’ quality of life. 
 
To calculate a sample size against previous trials, there was only one RCT to 
use at the time in 2002. In the 1994 landmark Sutton vaporisation study (Sutton 
et al., 1994), 62.5% of patients showed an improvement in pain symptoms at 6 
months, based on a visual analogue scale of 0-10 asking patients to score 
according to their worst symptom, which was dysmenorrhoea in all cases. Of 
the case studies that existed for excision of endometriosis, David Redwine’s 
report of 400 consecutive women who had excision, showed a 75% complete 
relief, and 20% improvement in pain (Redwine, 1996). This suggested a 
potential difference of up to 32.5% in pain outcome. However, it was decided to 
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be more conservative with the difference, especially as the hypothesis was that 
there would be no difference. Being more conservative would result in an 
increase in the numbers required for the trial, but being able to show up to a 
20% difference gave a sample size that was manageable for a single centre as 
shown below.   
 
The hypothesis of this study was that there is no difference between excision 
and vaporisation, and so the power calculation to show that neither treatment 
was worse than the other was as follows. The Food and Drug Administration 
80/20 rule for bioequivalence was used to calculate the sample size required to 
achieve 80% power. Thus =0.20, =0.2 (as equivalence trial), 1-=0.8. This 
will need to be a 2-sided test as it is possible the harmonic scalpel is better than 
the laser. If we are assuming equivalence, then 1=2=0.625 (original study was 
62.5%). On this basis we would require 53 patients in each arm if we were to 
have an 80% chance of showing a 20% difference in treatment outcomes 
(Statistical procedures for bioequivalence using a standard two treatment cross 
over design. US Dept of Health and Human Services, Public Health Service. 
Food and Drug Administration 1992).  
 
As it turned out, the subsequent 2004 Abbott excision RCT (Abbott et al., 2004)  
used a 0-100 “no change in pain to complete relief of pain” visual analogue 
scale as the primary outcome measure, showing an improvement in 80% of 
patients at 6 months, and also VAS scores for all four pain modalities. This 
suggested a potential difference between excision and vaporisation in the order 
of around 20%, and endorsed the selection of 20% difference chosen for the 
power calculations.  
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The two primary outcome measures in the Sutton and Abbott RCTs are different 
and not easily directly comparable with each other. By using VAS scores in this 
study for dysmenorrhoea, dyspareunia, CPP and dyschezia, it will be possible 
to correlate the data directly to the dysmenorrhoea score in the Sutton trial and 
to all 4 modalities in the Abbott trial. There is no valid basis to combine the 
individual 4 pain modalities used for the VAS to create a global score, 
especially since some of the components are often not relevant to the patient 
(i.e. dyspareunia).  
 
The primary outcome measure in this study is EHP-30 Core pain score, derived 
and recorded on a continuous scale, and has a previously reported maximum 
SD for change in pain score of 26.0 (Jones et al., 2004a). In order to detect an 
underlying difference of 20 points out of 100, 28 subjects are needed in each 
treatment group (2-sided test with size = 5% and power = 80%). The number in 
the bioequivalence power calculation above comfortably satisfies this 
requirement. 
 
Randomisation 
Sequence generation 
Restricted randomisation was used to generate blocks of 10 random treatments 
where odd numbers 1,3,5,7,9 defined allocation to excision and even numbers 
2,4,6,8,10 defined allocation to vaporisation. This improved the chances of a 
balanced outcome at the cost of reducing the unpredictability of the sequence. 
The block size was not randomly varied. No stratification was used. 
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Allocation concealment 
Sealed opaque envelopes containing a number from 1-10, in blocks of ten, 
were then randomly sorted and added to the trial folders, one per folder. The 
sequence was therefore concealed until the intervention was assigned.  
  
Implementation  
The trial folders and envelopes containing the concealed treatment were 
produced by Mr Carpenter and Mr Barton-Smith and kept locked in a separate 
filing cupboard to the active and completed trial folders. The operating surgeons 
administered the pre-op questionnaires. Once in theatre, if the patient fulfilled 
the entry criteria by rASRM score, then the envelope was opened during the 
surgery. The surgeon was told the allocated treatment and carried this out 
immediately. Mr Carpenter and Mr Barton-Smith took part in both the generation 
and implementation of the random sequence of treatments. 
 
Blinding 
Both the patients and the research nurse who performed the post-operative 
assessments were blinded from the treatment received. The surgeons were 
blinded to the post-operative questionnaire replies. The success of the blinding 
was not evaluated to assess for performance or detection bias.  
 
Statistical Methods 
The study analysis was designed on an intention to treat basis. Descriptive 
analysis was generally presented as proportional numerator/denominator 
comparisons with percentages. Chi-square analyses were performed to analyse 
proportional differences. Primary and secondary outcome measures were 
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analysed, in terms of proportional improvements, with Chi-square tests. The 
extent of improvement for each technique at 12 months against baseline was 
analysed by paired t tests. Comparative analysis between treatment techniques 
of the extent of improvement was analysed with unpaired t tests. Standard 
deviations and 95% confidence intervals were quoted where appropriate. 
Pearson’s Correlation Test was used to examine association between 
continuous variables. The Mann-Whitney U Test was used to compare two 
groups for ordinal variable scores. Exploratory analysis of major findings, to 
identify demographic and other factors influencing results, was performed with 
backward stepwise linear regression. All statistical analysis was performed 
using SPSS v17 (SPSS inc Chicago IL, USA; 2008). 
  
Ethical approval 
Ethical approval for this trial was obtained from the Surrey Local Research 
Ethics Committee, and Research Governance was obtained from the Royal 
Surrey County Hospital Research and Development Committee. 
 
Cost of Study 
There were no additional costs over and above that entailed in current 
treatment schedules. The laser and harmonic scalpel are routinely used in the 
operating theatre. The author’s salary was 50% funded by the Minimal Access 
Therapy Training Unit with funds provided by Ethicon Endo-Surgery from 
October 2004 until April 2008. 
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Chapter 4 - Results  
Results of an International Survey of Surgical Techniques 
used in the Treatment of Endometriosis 
 
Introduction 
The survey was developed to gain a snapshot of what equipment and 
techniques gynaecological surgeons were using and why, as many devices and 
energy forms are available. From this a picture would hopefully emerge of the 
current views of gynaecological laparoscopists in relation to the evidence, or 
lack of it.  Implementing this trial was difficult in so far that obtaining agreement 
from the three societies proved to be very challenging. It took over a year to 
resolve data protection and distribution issues, and even then the plan for the 
AAGL was suboptimal, and the Australian Gynaecological Endoscopy Society 
had refused to participate. That being said, the survey was eventually sent out 
with optimism that it would achieve its aim. 
 
Pilot Study Results 
A Pilot Study of the Panorama based survey took place between 10 January 
and 8 February 2006. The survey was sent to 12 laparoscopic gynaecologists 
who act as Faculty members at the Minimal Access Therapy Training Unit at the 
University of Surrey. There were 7 completed responses received between 10-
31 January and one further response at the second attempt on 8 February 
2006. 
 
Total response after 2 emails was 8/12 (66.7%). The response rate was two 
thirds and so the length and feasibility of the survey seemed reasonable. 
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Certain changes were made to the questionnaire resulting from the pilot. Some 
of these were triggered from our own observations and some from the 
responders who had an extra question in their surveys asking about their views 
on the survey structure. The following adjustments were made: 
 
1. A question was added asking about whether responders try to treat 
their patients surgically at the time of laparoscopic diagnosis. 
2. A question about 2 stage procedures for endometriomas was included. 
3. More text boxes after possibly ambiguous questions were added to 
allow greater ability for responders to explain their practice. 
4. Minor wording changes were made to avoid ambiguity in some 
questions. 
 
Main Survey Results 
 
The main survey was initiated on 18 April 2008 and the last response before the 
survey was closed was recorded on 23 September 2008. 
 
Data cleaning 
The database was checked for errors by carrying out simple descriptive 
statistics and looking for potentially erroneous outliers. 17 responders were 
excluded because they failed to answer any questions once they had passed 
beyond the introduction page. 13 responders at question 4 said that they did not 
treat endometriosis surgically and so were automatically taken to the end of the 
survey and excluded from the analysis. 18 responders partially completed the 
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survey but were kept in the dataset. Therefore a total of 30 cases were 
excluded leaving a data set of 339 of which 321 were correctly completed and 
18 were partially completed. There were a number of correct partial responses 
with 5 who did not treat endometriomas, and 134 not treating recto-vaginal 
nodules, which meant that they were automatically filtered to the end of the 
survey at questions 15 and 21 respectively. Zoomerang had electronically 
coded some answers as “no” after partial responders had ceased to answer 
further questions. These were recoded as missing data. 
 
The wide variety of countries from which responses originated, coupled with the 
low response rate, meant that it was sensible to recode these as geographical 
regions of UK, mainland Europe, USA and the rest of the World. In addition to 
this, the free text responses were coded into either already existing codes or 
into new codes. New codes were created for the following: 
 
Q9: Argon beam coagulator, Bipolar-sealing systems. 
Q10: Argon beam coagulator. 
Q17: May observe endometriomas <3cm. 
Q22:  Intravenous Urogram 
 
 
 
 
 
 
Response Rate 
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Table 2. Survey response rates by specialist society. 
 No on database Successfully sent No of Replies (%) 
BSGE 489 390 92 (23.6) 
ESGE 1623 1481 175 (10.8) 
AAGL 3259 3007 102 (3.1) 
Overall 5371 4878 369 (7.5) 
  
There were 489 total visits to the survey, although as table 2 shows, 369 
actually started it which means that 120 people did not get beyond the 
introduction page. Once started, only 35 responders of those 369 (9.5%) failed 
to complete the questionnaire. 
 
General characteristics of responders 
General demographic data questions were asked for age, region of principal 
practice, number of years performing laparoscopic surgery independently, main 
form of training in laparoscopic surgery, years qualified as a doctor and whether 
they were a specialist or trainee.  
 
Specialist versus trainee 
267 (88%) responders were specialists whilst 37 (12%) were trainees with 35 
missing data. BSGE response was 23.6% of total membership but 194 (45%) 
are trainees and 237 (55%) specialists. When excluding trainee responses 
there were 54 responses from specialists, which is 54/237 = 22.8% of the 
consultant population. 
Region 
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The majority of responses came from mainland Europe and the UK as is seen 
in Fig 1 below.  
 
Fig 1. Distribution of responders by geographical region. 
 
 
 
Mainland Europe 49% 
UK   23.9% 
Rest of World 19.2% 
USA   7.7% 
 
 
 
 
Experience 
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As fig 2 below shows, the average age of responders is 46.9 years (+/-9.14). 
Although the age data are slightly skewed, the skewness is within acceptable 
limits and therefore parametric statistics could be used (skewness = 0.214, SE 
0.140).  
 
Fig 2. Age distribution of survey responders.    
 
 
 
 
As can be seen from fig 3 below, the time qualified as a doctor is normally 
distributed (skewness = -0.330 SE 0.140) with an average of 37.4 years (+/-
9.44) since qualification. 
 
 
Fig 3. Year survey responder qualified as a doctor. 
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The data for the number of years that responders have been performing 
independent laparoscopic surgery is skewed (skewness 0.584 SE 0.133) and 
shows a median value of 11 years (range 1-35). The skewness seen in fig 4 
below, illustrates more gynaecologists joining the specialty from about 20 years 
ago. As this skewness is minimal, it will be treated as normally distributed. This 
variable was used as the best indicator of experience in subsequent analysis. 
 
 
 
 
 
 
Fig 4. Number of years survey responder has performed independent laparoscopic surgery.   
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Training 
Fig 5. Pie chart of the distribution of training methods in survey responders.
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As seen in fig 5 above, 39% of responders had trained through a specific 
laparoscopic training programme or fellowship. This was more likely if you were 
less experienced in terms of number of years independently performing 
laparoscopic surgery. Responders who had had formal training had a mean of 
9.2 years experience versus 14.0 years for those who were self-taught, giving a 
mean difference of 4.6 years (p<0.0005, 95%CI 2.9 to 6.4). Those who had 
undergone a specific training program and fellowships also had a trend towards 
doing more complex surgery in terms of their likelihood to be doing surgery for 
recto-vaginal nodules (61% compared to 54%, although this difference was not 
statistically significantly different, p=0.251). 
 
Number of operations performed per month for endometriosis 
 
Table 3. Number of operations performed for endometriosis by survey responders per month. 
Operations <10 per month 10-20 per month >20 per month 
 n (%)  
Responders  202 (59.6) 102 (30.1) 35 (10.3) 
 
 
In table 3 above, the majority of responders are performing <10 procedures for 
endometriosis per month. A sub-analysis of these results showed that training 
method does not influence the number of procedures carried out per month is 
(p=0.227). However, gynaecologists with more experience in independent 
laparoscopic surgery undertook more surgical cases per month than those with 
less experience (Anova Test F=7.69, p=<0.001). This is well illustrated in fig 6 
below: 
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Fig 6. Means plot comparing the mean number of years performing laparoscopic surgery with 
the number of endometriosis operations performed per month. 
 
 
 
Types of endometriosis operated on 
 
Table 4. Percentages of survey responders that operate on various types of endometriosis. 
Type of endometriosis Responders n (%) 
Minimal to moderate 275 (81.1) 
Endometriomas 300 (88.5) 
Severe 176 (51.9) 
Recto vaginal nodules 141 (41.6) 
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Do responders treat at the time of laparoscopic diagnosis? 
 
Table 5. Proportion of surgeons who see and treat patients at the same time for endometriosis. 
Treat at Diagnosis  n (%) 
No 13 (3.8) 
Sometimes 44 (13.0) 
Yes, except severe 153 (45.1) 
Yes, always 129 (38.1) 
 
The data in table 5 above shows that the majority of patients are seen and 
treated at the same time. The means plot below in fig. 7 shows that more 
experienced surgeons treated patients at the same time as the diagnostic 
procedure, when compared to less experienced surgeons (Anova Test F=3.18, 
p = 0.024). 
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Fig 7. Means plot comparing the mean number of years performing independent laparoscopic 
surgery with “see and treat” management. 
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Changes in surgical instruments used to treat endometriosis 
Responders replied by ticking all instruments that they may currently use and 
have previously used to treat endometriosis as seen in table 6 below. 
 
Table 6. Previous and current use of surgical instruments for endometriosis. 
Type of instrument previous use current use P value 
 n (%)  
Cold scissors 207 (61.1) 198 (58.4)  *0.481 
Monopolar diathermy 231 (68.1) 193 (56.9) *0.006 
Bipolar diathermy 260 (76.7) 293 (86.4) *0.001 
Ultrasound technology 87 (25.8) 139 (41.1) *<0.001 
CO2/YAG/KTP laser 101 (29.8) 73 (21.5) *0.014 
Helica 24 (7.1) 19 (5.6) *0.431 
Argon beam coagulator 4 (1.2) 10 (2.9) **0.105 
Bipolar sealing devices 0 (0.0) 16 (4.7) NA 
* Pearson’s Chi-square Test  **Fisher’s Exact Test 
 
Electro-surgery is still the most frequently used energy source in the surgical 
treatment of endometriosis though the use of no energy with cold scissors only 
is still very common.  Bipolar and ultrasound energy use have significantly 
increased from 77% to 86% and from 26 to 41% respectively.  
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Management of minimal to moderate endometriosis 
 
Table 7. Number and percentages of responders who use various techniques as their main 
method for surgically treating minimal to moderate endometriosis. 
 Superficial n (%) Deep n (%) *P value 
Excision 90 (27.4) 158 (49.2) P<0.0005 
Vaporization 15 (4.6) 8 (2.5) P=0.137 
Combination 161 (48.9) 123 (38.3) P=0.002 
Coagulation 62 (18.8) 20 (6.2) P<0.0005 
*Pearson Chi-Square Test 
 
In table 7 above, there is a significantly larger proportion of surgeons using 
excision as the main technique for excising deep minimal to moderate 
endometriosis compared with superficial.  
  
There is a regional trend towards greater use of coagulation (22.7% v 11.7) and 
vaporisation (6.7% v 3.9%) in mainland Europe versus the UK (p=0.169).  This 
seems to be reflected in the instrument use in Europe where a significantly 
greater use of bipolar diathermy exists (p<0.001). Interestingly, experience in 
terms of number of years performing independent laparoscopic surgery does 
not affect choice of technique (Anova test p=0.496). 
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Why do responders choose their preferred technique for treating superficial and 
deep minimal to moderate endometriosis. 
Responders filled in a Likert scale question prompting them to reply to a set of 
statements as shown in the full survey (appendix M), along a spectrum where 
1= strongly disagree, 2= disagree, 3= neutral, 4= agree, 5= strongly agree. The 
results are shown in tables 8 and 9 below. 
 
Table 8. Reasons for choosing main technique for treating superficial minimal to moderate 
endometriosis.  
 Excision Vaporization 
 
Combination Coagulation  *P value 
  Median (IQR)   
Trained 4 (3-4) 4 (3-4.25) 4 (3-4) 4 (3-4) 0.299 
Self-taught 3 (2-4) 3.5 (2.75-4.25) 3 (2-4) 4 (3-4) 0.752 
Best way 4.5 (4-5) 4 (3-4.25) 4 (4-5) 4 (3-4) <0.0005 
Easier 3 (2-4) 3.5 (2.75-4)  3 (2-4) 4 (3-4) <0.0005 
Tried other 4 (3-4) 3.5 (3-4.25)  3 (2-4) 3 (2-4) 0.003 
No preference 2 (1-3) 2 (1-3.25) 2 (2-3.5) 3 (2-4) <0.0005 
Lack of equip 2 (1-4) 3 (2-4) 3 (1.5-4) 4 (3-5) <0.0005 
Lack of skill 2 (1-3) 2.5 (1.75-4) 3 (2-4) 4 (3-4) <0.0005 
Cost effective 3 (2.25-4) 3 (2.75-4.25) 3 (3-4) 4 (3-4) 0.194 
*Kruskal –Wallis Test 
 
As table 8 above illustrates, techniques for treating superficial endometriosis 
were used because the surgeon was trained in the particular procedure. 
Similarly, surgeons agreed that the technique they used was the best and 
disagreed that they had no preference over technique. 
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Table 9. Reasons for choosing main technique for treating deep minimal to moderate 
endometriosis. 
 Excision Vaporization 
 
Combination Coagulation  *P value 
  Median (IQR)   
Trained 4 (3-4) 4 (3-4) 4 (3-4) 4 (4-4) 0.782 
Self-taught 3 (2-4) 3 (2-4) 4 (3-4) 4 (3-4) 0.436 
Best way 5 (4-5) 3 (3-4) 4 (3-4.5) 3 (3-4) <0.0005 
Easier 2.5 (2-3) 3 (3-4) 3 (3-4) 4 (3-4) <0.0005 
Tried other 3 (2-4) 3 (3-4) 3 (2-4) 3 (2-4) 0.939 
No preference 2 (1-3) 3 (2-3) 3 (2-3) 3 (2-3) <0.0005 
Lack of equip 2 (1-4) 4 (3-4) 4 (2-4) 4 (3-4) <0.0005 
Lack of skill 2 (1-3) 3 (3-4) 4 (2-4) 4 (3-4) <0.0005 
Cost effective 3 (2-4) 4 (3-4) 3 (3-4) 4 (3-4) 0.210 
*Kruskal-Wallis Test 
 
In table 9 for deep disease, the users of all techniques agreed that they used 
their preferred technique because that is how they were trained or taught 
themselves to do it, though the feeling was stronger in favour of how they were 
trained and more coagulators appear to use their technique because they were 
self-taught. The feeling for all technique users was somewhere between neutral 
and agreement over concern over cost effectiveness. A further cross-tabulation 
of region against concern over cost effectiveness revealed no significant 
difference (p=0.292). 
 
The excisers agreed more strongly than other technique users that they used 
their technique because they thought it was the best and feel this more strongly 
when treating deep disease. They also seemed to have tried more techniques 
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than the others for treating superficial endometriosis. The coagulators felt more 
strongly that they used their technique because they thought it was easier. 
However they also felt that they lacked the skill or equipment to use another 
technique (there are however only 19 responders in the deep disease response 
group). Despite this they still believed that their technique was the best. The 
vaporizers and combined exciser/vaporizers seem to fall somewhere in the 
middle between the excisers and coagulators in their views. 
 
Management of Endometriomas 
98.4% of responders said that they surgically treated endometriomas. Initially 
they were asked to say whether or not they used a 2-stage technique of 
drainage, hormonal down regulation and subsequent definitive procedure. The 
results of this are shown in the pie chart in fig 8 below. 
 
Fig 8. Pie Chart showing the use of 2-stage procedures for endometriomas. 
 
Yes=26 (8%)  Sometimes=92 (29.9%)  No=190 (61.7%)  
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Table 10. Responders use of techniques for surgically treating endometriomas. 
 <3cm >3cm *P value 
Excision 206 (66.2) 223 (72.2) P=0.110 
Ablation 24 (7.7) 19 (6.1) P=0.580 
Combination 69 (22.2) 61 (19.7) P=0.455 
*Pearson Chi-square Test 
 
There is no significant difference in technique whether endometriomas are 
either less or greater than 3cm diameter however excision is clearly the 
commonest technique overall. 5 (1.5%) respondents commented that they 
observe endometriomas that are less than 3cm diameter and do not surgically 
treat them. 
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Why do responders choose their preferred technique for treating 
endometriomas of different size? 
The results for this are divided into the techniques used for endometriomas of 
<3cm and  >3cm diameter. 
 
Table 11. Reasons for choosing technique for treating endometriomas of <3cm diameter. 
 Excision Ablation 
 
Combination  *P value 
  Median (25-75%)  
Trained 4 (3-4) 4 (3-4) 4 (3-4) 0.862 
Self-taught 4 (3-4) 4 (3-4) 4 (3-4) 0.500 
Best 4 (4-5) 4 (3-4) 4 (4-5) <0.0005 
Easier 3 (2-4) 3 (3-4) 3 (3-4) 0.002 
Tried other 3 (2-4) 4 (2-4) 3 (2-4) 0.939 
No preference 2 (2-3) 3 (2-4) 3 (2-4) 0.001 
Lack of equipment 2 (1-3) 4 (2-5) 3 (2-4) <0.0005 
Lack of skill 2 (1-3) 4 (2-5) 3 (2-4) 0.001 
Cost effective 3 (3-4) 3 (3-4) 3 (3-4) 0.945 
*Kruskal-Wallis Test 
 
In table 11 above, for <3cm diameter endometriomas the technique groups do 
not vary in their view in that they agree that they carry out their technique 
because they were either trained or taught to do it. They are all neutral in their 
concern over cost effectiveness and whether they have tried other techniques 
or not. The excisers do not feel like they lack equipment or skill where as the 
ablators seem to, and the combined group are neutral on the issue. 
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Table 12. Reasons for choosing technique for treating endometriomas of >3cm 
diameter. 
 Excision Ablation 
 
Combination  *P value 
  Median (25-75%)  
Trained 4 (3-4) 4 (3.25-4) 4 (3-4) 0.351 
Self-taught 4 (3-4) 3 (2.25-4) 4 (3-4) 0.078 
Best 4 (4-5) 3.5 (3-4) 4 (4-5) <0.0005 
Easier 3 (2-3) 3 (3-3.75) 3 (2-4) 0.021 
Tried other 3 (2-4) 3 (2-4) 3.5 (2.75-4) 0.352 
No preference 2 (1-3) 3 (2.25-3) 3 (2-4) <0.0005 
Lack of equip 2 (1-3) 4 (3-4) 3 (2-4) <0.0005 
Lack of skill 2 (1-3) 3.5 (3-4) 3 (2-4) <0.0005 
Cost effective 3 (3-4) 4 (3-4) 3 (2-4) 0.245 
*Kruskal-Wallis Test 
 
In table 12 above, similar trends are apparent in the reasons for choosing 
treatment technique for >3cm endometriomas, suggesting that the approach to 
endometriomas does not seem to differ much no matter what the size. 
 
Management of recto-vaginal nodules 
175 responders said that they surgically treat recto-vaginal nodules. 
Responders were more likely to do this if they were more experienced in terms 
of number of years performing independent laparoscopic surgery (mean of 13.9 
v 10.1 years p<0.0005, mean diff 3.848, 95%CI 1.976-5.721). 78.6% of 
responders surgically treat recto-vaginal nodules more often by laparoscopy 
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compared with 10.7% who more often use laparotomy. A further 10.7% use 
laparoscopy and laparotomy equally. 
 
Preoperative investigations 
As table 13 below illustrates, trans-vaginal ultrasound scan (TVS) is the most 
common pre operative test for recto vaginal nodules followed by MRI.  
 
Table 13. Use of pre-operative tests for recto-vaginal nodules.  
 n (%) 
TVS 142 (81.1) 
TRS 55 (31.4) 
CT 15 (8.6) 
MRI 105 (60) 
Colon/sig 80 (45.7) 
Ba enema 25 (14.3) 
IVU 7 (4.0) 
None 4 (2.3) 
 
 
Operating with a colorectal surgeon 
 
Table 14. Number of responders who operate on recto-vaginal nodules with a colorectal 
surgeon. 
 n (%) 
Never 9 (5.4) 
Rarely 66 (39.3) 
Mostly 62 (36.9) 
Always 31 (18.5) 
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In table 14 above, only 5.4% of responders never operate with a colorectal 
surgeon and 18.5% always operate with a colorectal surgeon. The remaining 
responders are split between rarely or mostly. There are no significant 
differences when comparing training method (p=0.512) or experience (p=0.360) 
against likelihood of operating with a colorectal surgeon. 
 
Surgical technique for removing recto-vaginal nodules 
Table 15 below, shows surgeons’ surgical technique for removing recto-vaginal 
nodules in terms of whether an attempt is made to initially shave recto-vaginal 
nodules off the bowel to avoid opening it, those who try to use disc resection 
rather than segmental resection if shaving fails, those who are ever prepared to 
do a segmental resection, and those who always aim to do a segmental 
resection for all cases. 
 
Table 15. Surgical technique for treating recto-vaginal nodules.  
 Shave Disc  Ever segment  Always segment 
  n (%)  
No 22 (13.2) 57 (33.7) 48 (28.7) 124 (73.8) 
Yes, by myself 56 (33.5) 28 (16.6) 4 (2.4) 3 (1.8) 
Yes, with surgeon 27 (16.2) 56 (33.1) 103 (61.7) 32 (19.0) 
Yes, either/or 61 (36.5) 27 (16.0) 12 (7.2) 9 (5.4) 
  
 
144 (86.2%) responders were in favour of attempting an approach that tried to 
avoid opening the bowel in the first instance. 111 (65.7%) responders were 
prepared to carry out disc resections to avoid segmental resection if shaving 
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failed. 119 (71.3%) responders were prepared to use segmental resections. 44 
(26.2%) responders will always aim to carry out a segmental resection.  
 
Discussion 
 
The validity of the data is immediately called into question by the low response 
rate achieved, despite efforts to follow recognised methods of questionnaire 
construction in the methodology (Nakash R, 2006, Boynton, 2004).  
 
In an attempt to explain this, one can consider the strengths and limitations of 
the methodology. This study had certain strengths when considering survey 
administration. The questionnaire was salient to its population and should have 
generated an interest. An efficient means of completing the questionnaire was 
provided with an electronic link directly to it. A clear covering invitation letter 
confirming confidentiality was given. An incentive was provided in the form of a 
prize for one responder. A reminder was included, a researcher was available 
by email to answer questions, and a pilot study was performed.  
 
However, there were some limitations in administration also. There is a 
possibility that some of the responders in mainland Europe or non-English 
speaking countries may have been put off from completing the questionnaire in 
English. There was no pre-notification of the survey to the population. It would 
have been nice to have an advert in each society a month or so before sending 
out the survey to warn people that it was coming and generate some interest. 
However, bearing in mind the complexities involved in getting societies to agree 
to even sending out the survey, this would likely have been difficult. In addition, 
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the incentive was probably not strong enough. However this was developed 
within the economic restraints of the study. The lack of personal invitation email 
to AAGL members, and the refusal to send a reminder, undoubtedly limited the 
response from the AAGL. Many AAGL members would have missed the 
invitation in the newsletter or perhaps never read the newsletter at all. There 
also remains the possibility of over exposure in the population and a feeling of 
“oh no….not another questionnaire!”.  
 
From the questionnaire design perspective, the study was strong in that it did 
produce a clear design and layout that was visually appealing. At 34 questions 
long it was short according to Nakash’s meta-analysis, which defined shorter 
questionnaires as 7 to 47 questions (Nakash R, 2006). As has been described 
in the methodology section, a significant amount of effort went into question 
form, wording and ordering, that was refined following the pilot study. The main 
failure appeared to be getting people to start the survey as 90.5% did complete 
it if they went beyond the invitation page.  
 
Despite the low response rate, the characteristics of those returning the 
questionnaire appear to reflect those expected in the general population of 
laparoscopic gynaecologists. 
  
The age of responders is normally distributed and the number of years 
practising independently as a laparoscopic surgeon is only mildly negatively 
skewed. Assuming the historical growth of laparoscopic surgery over the last 20 
years, then it is not unreasonable to expect this skewness in the population, as 
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gynaecological laparoscopic surgeons join the sub-specialty each year in 
increasing numbers.  
 
Although only 10% of responders were trainees, they were analysed within the 
whole group together with qualified specialists. This was because they were 
considered as legitimate members of the specialist societies in their own right 
and there were not enough of them to excessively duplicate the answers of the 
specialist they worked with. 
 
The regional divide of responses was not equally representative as has been 
explained above by the poor response rate especially from the AAGL (3.1%). 
Consequently comparative regional analysis was not able to be carried out. 
 
41.6% of responders said that they operated on recto-vaginal endometriosis 
and this appears higher that one might expect. It seems unlikely that nearly half 
of gynaecological laparoscopic surgeons are genuinely tackling the most 
complex endometriosis. This suggests that, whilst we seem to be looking at a 
sample that is fairly normally distributed by age and experience, the sample 
population contains a greater proportion of surgeons undertaking complex 
endometriosis surgery than would be expected in the general population of 
gynaecological laparoscopic surgeons. It is perhaps not surprising that those 
who do tackle recto-vaginal endometriosis will have a greater vested interest in 
the disease, and therefore are more likely to respond to a survey such as this.  
 
Within the limits of the sample population described above, the analysis 
revealed that formal training appears to be frequent, and a surprisingly high 
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percentage (39%) of responders had undergone some form of specialist 
laparoscopic training. The finding that more experienced surgeons carried out a 
greater number of endometriosis cases per month, suggests that they are 
becoming more specialised with a greater proportion of endometriosis cases in 
their referrals. It is also possible that they are operating more quickly and 
efficiently.  
 
It is interesting that 19% of responders do not operate on minimal to moderate 
endometriosis. 78% of these 19% however do operate on endometriomas. 
Therefore, it is likely that this group consists mainly of infertility specialists who 
may be only dealing with endometriomas prior to IVF, and not dealing with any 
coexisting disease despite it existing in pretty much all cases (Banerjee et al., 
2008). Also 31% of the 19% stated that they do operate on recto-vaginal 
disease, and so this may represent a super specialised group who are dealing 
with only more complex cases.  
 
It is recommended that if a laparoscopy is performed and endometriosis 
diagnosed, then a see and treat approach be taken provided that adequate 
consent has been obtained (Kennedy et al., 2005). It is reassuring to see that 
the majority of surgeons take this approach. It perhaps is not surprising that if a 
patient sees a more experienced surgeon then they are more likely to get a see 
and treat approach. 
 
In terms of instruments used to treat endometriosis, a substantial number of 
surgeons will avoid energy use altogether, and just use cold scissors for 
removing presumably more straightforward lesions in the peritoneum that may 
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lie over sensitive structures like the ureters. This reduces the risk of thermal 
damage to these structures and the amount of bleeding from the peritoneum 
whilst using cold scissors is small, negating the need for a haemostatic 
instrument.  
 
When energy is used, electro-surgery remains the most frequently used energy 
source for treating endometriosis. This probably reflects its great flexibility as 
either an excision or vaporative tool in monopolar form, despite which 
surprisingly monopolar use has fallen significantly. The increase in bipolar use 
is potentially concerning as coagulating lesions not only fails to remove all 
disease and has been shown to result in a worse outcome for endometriomas 
(Hart et al., 2008), but also fails to allow full assessment and treatment of the 
full depth of lesions. However some bipolar use may be for haemostasis 
following excision by cold scissors or another energy source.  
 
Ultrasound devices have significantly increased in popularity possibly as a 
result of successful marketing claiming advantages of increased safety and user 
friendliness. Despite laser technology being supported by the RCT evidence for 
surgically treating endometriosis behind it (Sutton et al., 1994), its use seems to 
have significantly fallen away which may be due to the specific training or 
substantial initial financial outlay required.  
 
Minimal to moderate endometriosis 
In terms of technique used for minimal to moderate endometriosis, the 
significant increase in excision use for deep versus superficial disease is logical. 
In deep disease, excision alone is more popular than a combined approach of 
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excision/vaporization, which was the most popular approach for superficial 
disease. That the “excisers only” are a group who “strongly agreed” in their 
approach over others, was not a surprise. At conference, the excisers appear to 
defend their technique with more fervour than others. The majority view that a 
combination of true vaporization, resulting in the same visual effect as excision, 
or excision alone for superficial endometriosis is reassuringly correlative with 
existing randomized data (Jacobson et al., 2009, Wright et al., 2005). 
 
Coagulation by itself is a minority option compared with excision, vaporization or 
a combined excision/vaporization approach. This again seems to fit the 
hypothesis that ablation/coagulation is suboptimal in assessment and 
treatment. As argued above, the data may be biased in favour of experts as 
shown by the high percentage of responders that treat recto-vaginal 
endometriosis. This may mean that there is possibly an even higher percentage 
in the true population who use a superficial coagulation/ablation technique who 
lack the skills or instruments to carry out full excision or vaporization. This 
statement is supported by the fact that surgeons who are self-taught or feel they 
lack skills and equipment, were more likely to use coagulation. Despite 
admitting to a lack of equipment and skill, the coagulators had a tendency to 
agree that their technique was still the best, which may be influenced by a 
difficulty to admit that what you are doing is not the best option for the patient.    
 
Endometriomas 
The treatment of endometriomas is currently done by excision by the majority of 
responders whether or not they are > or < 3cm diameter. It is currently 
recommended in ESHRE guidelines that excision is the preferred technique in 
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endometriomas of >3cm to obtain the cyst wall for histology to exclude 
malignancy. If this fails then a two-stage procedure, with hormonal down 
regulation between operations, may be tried to improve the chances of ablation 
being successful at the second procedure. Only 30% of the responders in this 
study said that they sometimes use this technique, suggesting that they feel 
they are, more often than not, successful with a one-stage procedure, most 
likely using excision for this. It may also imply that the concern over potential 
ovarian damage from excision (Loh 99) is generally less important than the 
perceived improved pain, fertility and recurrence outcomes shown in several 
studies of endometrioma treatment (Beretta et al., 1998, Alborzi et al., 2004b). 
There is no randomised evidence commenting on the best treatment for 
endometriomas measuring <3cm diameter.  
 
Recto-vaginal endometriosis 
Laparoscopy is the predominant method to tackle recto-vaginal endometriosis 
amongst the responders. However, the finding that 10.7% mainly took a 
laparotomy approach may be erroneously low when considering the whole 
gynaecological surgical population. The question here remains whether or not 
women are being referred to this expert group for laparoscopic treatment and 
potentially fertility sparing surgery, or whether “non-experts” are still operating 
on a significant number with laparotomy and pelvic clearance.  
 
For advocates of a “conservative” approach to surgically removing recto-vaginal 
endometriosis, the ideal aim of preoperative testing would be to accurately 
predict that a lesion could be shaved off or removed by disc resection of the 
bowel without segmental resection. This would require accurate measurement 
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of the depth of invasion into the bowel wall and being able to correlate this 
information to correctly identify the surgical procedure required to remove the 
disease. However, the accuracy of such a pre-operative test remains unproven. 
For those surgeons who advocate segmental resection in all cases of bowel 
involvement, the logic of this approach relates to the finding of macroscopic and 
microscopic satellite lesions of endometriosis in the rectum and sigmoid colon in 
68% of cases (Keckstein, 1999). Thereby, removing the segment of bowel may 
reduce the risk of recurrence. This is however at the expense of significant 
chronic bowel morbidity in young patients (Dubernard et al., 2006).  
 
Preoperative tests like TVS, MRI and TRS have been effective at predicting 
bowel involvement in recto-vaginal endometriosis (Dessole et al., 2003, Hudelist 
et al., 2009, Fedele et al., 1998, Chapron et al., 2004, Bazot et al., 2009) and so 
their common use in modern practice seen in the survey results is 
understandable if only to alert the surgeon to potential bowel involvement and 
consequently to be able to adequately inform and consent the patient prior to 
surgery. In Hudelist’s report, involvement of the serosal and smooth muscle 
layers of the bowel was positively predicted in 98% of cases, and the PPV for 
mucosal involvement was 53%. These results are perhaps not immediately or 
easily reproducible in most units.  
 
Barium enema or sigmoidoscopy/colonoscopy are still used as adjuncts to the 
more effective imaging modalities outlined above. Double contrast barium 
enema alone has been shown in two recent studies to have close to 90% 
sensitivity, and specificity ranging from 54 to 88% (Ribeiro et al., 2008, Faccioli 
et al., 2008).  
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In modern practice where litigation is becoming increasingly predominant it is 
not surprising to find that only 5.4% of gynaecological laparoscopists never 
operate with a colorectal surgeon for recto-vaginal endometriosis.  
The argument of whether to shave, disc resect or segmental resect for recto-
vaginal endometriosis is one that has been a main focus in conferences over 
the last few years with surgeons offering their strong opposing opinions based 
on large case series (see table 1). There is no high quality evidence to support 
one procedure over the other and due to the methodological difficulties of 
designing an RCT, it is unlikely that evidence will emerge in the near future. 
Prior to this survey little was known about the extent to which opinion is divided 
in this contentious area. The majority of responders (86.2%) in the survey are in 
favour of a conservative shaving approach if possible in the first instance, with 
no significant regional variation in this opinion (p=0.291). Whilst 144 surgeons 
stated that they would attempt a shave first, there are only 111 and 119 in 
favour of ever performing discs resections or segmental resections respectively. 
This suggests a group of responders who either believe that one should avoid 
opening the bowel at all costs, or will refer the patient onto someone who can. 
 
At the other end of the spectrum lie the 26.2% of responders who will always 
aim to do a segmental resection. Nevertheless, the results show that the 
majority of responders take a pragmatic conservative approach to the problem 
of opening the bowel or performing segmental resections where they have to. 
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Conclusion  
  
Taking into account the poor response rate, though seemingly fairly 
representative sample nevertheless, this study reveals for the first time the 
attitudes and practice of gynaecological laparoscopists dealing with 
endometriosis who belong to specialist societies. In the main the findings 
support previous study results, but we must be guarded in this statement as the 
responders may well be a biased group of experts, and these results represent 
practice within the specialist societies, not what is likely to be happening 
amongst the general population of gynaecologists. 
 
It is reassuring to see that formal training is becoming commonplace especially 
as responders generally agreed that they carried out particular procedures 
because that is “how they had been taught to do it” implying that training is a 
major influence on practice. Practice was not dictated generally by concerns 
over cost, but some felt they lacked the skill or equipment to perform their 
optimal technique and this is something that is likely to improve over time. It is 
encouraging that the majority of responders favour a see and treat approach. 
 
For minimal to moderate endometriosis treatment, the majority of laparoscopic 
gynaecologists are electro-surgery users with a tendency to excise, or take a 
combined excision/vaporization approach, in line with current evidence, with a 
greater tendency to excise deep disease. Questions remain over endometrioma 
treatment where laparoscopic gynaecologists are generally excisers for all sizes 
of cyst, and possibly influenced by the current evidence, believing that on 
balance they are doing more good than harm. By and large, laparoscopic 
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gynaecologists are taking a conservative approach to recto-vaginal disease 
where possible, to avoid the potential complications of bowel surgery. However, 
when required, the study shows an acceptance of a multi-disciplinary approach 
involving colorectal colleagues in the surgical management.  
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Chapter 5 - Results 
Results of a randomised blinded trial of carbon dioxide laser 
vaporisation versus harmonic scalpel excision of rASRM 
stage 1-3 endometriosis in women with pelvic pain 
 
 
Participant Flow 
 
Fig 9. Flow diagram of participants through the trial. 
 
 
 
 527 eligble participants  
 133 randomly allocated 
66 allocated to 
Excision  
66 received allocated 
intervention  
 Followed up at 
3 months n=62 
6 month n=58 
12 months n=49 
48 in Analysis at 12 months  
1 missing baseline score,16 
lost to follow up, 1 excluded 
for pain  score zero at 
baseline 
67 allocated to 
Vaporisation 
67 received allocated 
intervention 
Followed up at 
3 months n=67 
6 months n=61 
12 months n=53 
47 in Analysis at 12 months 
1 missing baseline score, 17 
lost to follow up, 1 excluded 
for pain score zero at 
baseline,1 excluded for 
histology showing foreign 
body reaction  
394 excluded 
 (Due to current or recent 
hormonal treatment, not 
wishing to participate or no 
endometriosis at 
laparoscopy)  
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The study analysis was designed on an “intention to treat basis” but in the 
event, all of the patients received the surgical procedure that they were 
allocated to. Data for the reasons why eligible patients were excluded from 
entering the trial prior to surgery was not collected. However, subjectively, the 
majority of patients were not eligible because they had either received hormonal 
therapy in the previous 3 months, or were currently receiving it for pain control 
or contraception.  Additional, though less common reasons, were because they 
did not wish to participate or because they were found to not have 
endometriosis on visual inspection at laparoscopy.  
 
Interim analysis of recruiting and follow up 
Protocol deviations were identified in April 2006 when it was discovered that 
some patients were not actively being followed up because they had become 
pregnant. An interim analysis of recruiting and follow-up was therefore 
undertaken to analyse the effect of this. Dr Haider Jan independently reviewed 
the patient folders so that none of the researchers were unblinded. The 
completeness of the data and the reasons for failure to follow-up were 
reviewed. The findings were as follows: 
 
Overall Result 
79 women were in the database, 70 women were at 6 months or more 
post treatment. 56 of those women had completed 0,3 and 6 months 
questionnaires. Of the 14 who had not completed all questionnaires, 6 
had not done so because they had become pregnant and 8 had not done 
so because they had failed to attend follow-up appointments. 
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Drop out rate 
This reflected an overall drop out rate of 14/70 = 20%. Drop out rate due 
to reasons other than pregnancy was 8/70 = 11%. This was generally 
due to women not coming to appointments that had been sent to them 
through the post. 
 
Trial state 
106 women were required in total from the original power calculation. At 
the audit point, the trial was 56/106 = 53% complete.  
 
9 women had not completed all questionnaires. Given the drop out rate 
of 20%, then 7 of those should complete the trial.  
 
Therefore the current estimated number of trial completions was 63/106 
(56+7) or was 59% complete.  
 
Therefore 106-63 more women were needed = 43. Accounting for the 
estimated 20% projected drop out seen so far, then 9 patients out of 43 
would be expected to drop out.  
 
Therefore the total number required to complete the trial was 52 (43+ 9) 
in April 2006. With 79 already recruited, this implied that the total sample 
would now need to be 131 (79+52). 
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Recommendations of interim analysis: 
1. The follow-up protocol needed to be enhanced to improve the drop out 
rate of patients (see clarification letter at Appendix). 
2. Complete questionnaires for all those that missed their follow-up at 6 
or 12 months for a snapshot of how they are now, no matter the time 
post procedure. This should be attempted by telephone if other means 
fail as described in the clarification letter. 
3. Begin to transfer data from paper questionnaires onto an SPSS 
database so an electronic copy is formed.  
4. Repeat mail-shot to GPs to improve recruitment. 
5. OASIS training for the Nurse Researcher to improve her ability to 
independently contact women by telephone or mail. 
6. Adjustment of the originally intended sample size to compensate for 
the drop out rate from 106 to 132.   
7. Re-audit in 9 months.  
    
Final Audit of Database 
A 10% audit check of the entire SPSS database was carried out on 17/4/09 to 
confirm its accuracy. Incorrect data was found in the HADS 3 month and VAS 6 
month files. Instead they contained EHP-30 intercourse module data. Therefore 
a previously backed up version of the files was recovered and re-entered into 
HADS 3 month and VAS 6 month fields. Following this 10% of cases were 
randomly selected by random number generation for assessment on 6/5/09. 
The SPSS data for each case was completely checked against the original 
paper questionnaires.  
The selected cases were 11,17,33,37,48,53,64,67,77,88,102,121,127.  
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The following errors were discovered: 
Case 11 – 1 error in HADS 3, 3 missing boxes in EHP-30 12 month. 
Case 17 – 1 error EHP-30 6 month, 2 errors HADS 6 month.  
Case 102 – 1 error in EHP-30 intercourse module 12 month. 
 
The total number of data boxes per case is 220: (EHP-30=120, Intercourse=20, 
VAS=44, HADS=56). Therefore the total number of data boxes in the SPSS 
database is 220x133 patients = 29260. The total number of data box errors in 
the audit was 8 in 10% of the total dataset. Therefore 80 data box errors were 
estimated overall. As a percentage, the overall estimated data box error was 
80/29260 = 0.27%. This was judged to be acceptable.  
 
The final SPSS database was then analysed simply to look for outlying results 
suggestive of possible data entry errors. Two errors were found from this: Case 
62 had missing data for 3, 6, and 12 month EHP-30 Core questions as she had 
failed to attend follow up due to pregnancy. This had been entered erroneously 
as -9 (not relevant) instead of 99 (missing). A similar problem was found for 
case 85 who had missing data that had been entered erroneously as -9 instead 
of 99. 
 
Numbers analysed 
 
Recruitment 
133 Patients were recruited into the trial between 15 November 2002 and 30 
May 2008. Case number 59 was excluded from the trial at the end of her follow-
up period because her histology showed a foreign body reaction (she had had a 
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previous laparoscopy in 1990), suggesting that she did not have endometriosis. 
The follow-up period was completed in June 2009. The recruitment rate over 
66.5 months was 2.03 patients per month.  
 
Patients who did not attend for follow up 
The patients who did not attend for follow-up at each time point were analysed 
to ensure that they were not a common subgroup that could bias the results of 
the overall study. There were 4 patients who did not attend follow-up at 3 
months (2.3%), 14 at 6 months (10.5%) and 31 at 12 months (23.3%). 
Therefore 102 (76.7%) were followed up at 12 months.  
 
However, to establish whether there was a bias created by missing variables as 
a whole, the total number of missing scores for EHP-30 Core pain domain was 
calculated for each time point. This included those with a missing or zero pain 
score at baseline, as well as those who completely failure to attend follow-up. 
This is displayed in table 16 below: 
 
Table 16. Number of participants missing from EHP-30 Core pain score analysis. 
Technique Pre-op 
n/n  
3 months 
n/n  
6 months 
n/n  
12 months 
n/n (%) 
Missed >/= 1 
follow up 
Excision 2/66  5/66 11/66 18/66 (27.3) 19/66 
Vaporisation 3/67 8/67 13/67 20/67 (29.9) 24/67 
 
At 12 months there is no difference, in terms of group balance, between the 
18/66 (27.3%) for excision and the 20/67 (29.9%) for vaporisation (p=0.742, chi-
squared test). Therefore the number of patients in the main analysis for the 
primary outcome was well balanced between the two groups with 95 patients 
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analysed: 48 in the excision arm and 47 in the vaporisation arm. The 
characteristics of the 38 patients who had missing or excluded scores at 12 
months were analysed to see if they were not representative of the whole 
population in any way. As seen in fig 17 below, there were no findings 
suggestive that the group of missing or excluded results for EHP-30 Core pain 
domain were greatly different from the analysed results. 
 
Table 17. Comparison of baseline variables between patients included in the main analysis, and 
missing or excluded patients. 
  
Characteristic    Analysed  Missing/Excluded 
     (n=95)   (n=38)___________                      
Mean age +/- SD   33.69+/-7.57  31.18+/-7.90   
Median rASRM score (IQ Range) 6 (4-11)   5 (3-8)   
Positive Histology n/n (%)  44/55 (80%)  10/12 (83.3%)   
Deep disease n/n (%)   52/93 (55.9%)  20/37 (54.1%) 
____________________________________________________________________ 
 
Other factors that were considered when deciding on numbers analysed 
 
1. Pregnancy, adjuvant hormonal therapy and subsequent surgery. 
2. Patients who scored zero for the variable at outset. 
 
1. Pregnancy, adjuvant hormonal therapy and subsequent surgery.   
There were 22 pregnancies in 19 patients (3 patients had 2 pregnancies each), 
5 patients who underwent further surgery (including one hysterectomy and 
bilateral salpingo-oophorectomy, and four laparoscopies), and 16 patients who 
had adjuvant hormonal therapy at some point during the 12 month follow-up 
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period. These can be considered to be protocol deviations during the follow-up 
period. None of these patients were excluded from the main analysis in order to 
produce a result reflecting the natural evolution of the disease following surgery 
on an intention to treat basis. However, a “per protocol” sub-analysis of the 
main group without these patients was also carried out. 
 
2. Zero scores for outcome modalities pre-op 
Some patients had scores of zero for pain or QOL outcomes at the pre-op visit 
showing that they did not suffer from that particular symptom as a result of their 
endometriosis. These were excluded from the analysis of improvement for that 
particular modality as it was felt that they were unable to improve and only able 
to stay the same or get worse. The stay the same or get worse patients for each 
modality were subsequently analysed separately to ensure that we were not 
missing an effect of treatment causing symptoms to deteriorate. Similarly the 
same was applied to this group in that the patients who had the worst possible 
score at baseline were excluded as they were unable to get any worse. 
 
Summary of numbers analysed at each time point 
For the primary outcome measure EHP-30 Core pain score, the follow-up rates 
at 3, 6, and 12 months were 129/133 (97.0%), 119/133 (89.5%) and 102/133 
(76.7%). Taking further into account missing data and exclusions, the analysis 
rates were 122/133 (91.7%), 111/133 (83.5%) and 96/133 (72.2%). Table 18 
below summarises the numbers analysed for each outcome measure at the 
main analysis points in the trial: 
    
 
 104 
Table 18. Numbers analysed at each point of the trial for each outcome measure. 
 
Analysis point: 0 months 3 months 6 months 12 months  
Technique: Exc Vap Exc Vap Exc Vap Exc Vap 
Outcome   n=66 n=67 n=66 n=67 n=66 n=67 n=66 n=67                                                                                                                                        
EHP30 
Pain    65 65 62 60 56 55 48 48 
Control & powerlessness 64 64 62 61 57 55 47 48 
Emotional wellbeing  66 64 62 61 57 56 50 48 
Social support   64 65 62 60 56 56 49 49 
Self image   66 65 62 62 57 56 50 50 
Intercourse   61 54 57 51 53 47 45 44 
VAS 
Dysmenorrhoea  61 64 62 56 56 51 40 47 
Dyspareunia   59 59 57 47 52 45 40 44 
CPP    60 58 62 58 55 51 44 45 
Dyschezia   62 60 56 57 56 47 45 45 
HADS 
Anxiety    66 65 62 61 48 50 48 50 
Depression   66 63 60 60 49 50 49 50 
___________________________________________________________________________ 
 
Baseline Data 
Baseline data for the 132 patients included in the analysis was calculated for 
Age, rASRM score and stage, histology, location and depth of disease. 
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Overall baseline statistics for continuous variables 
 
Age 
As fig 10 below shows, the mean age of patients was 32.9 years (+/-7.7 
range 19-50) and was normally distributed. 
 
 
Fig 10. Age distribution of participants.  
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rASRM Score 
In fig 11 below, the distribution has a long tail showing that patients in the 
study are more frequently found in the lower stages of the disease and 
confirms the finding that endometriosis is not normally distributed 
according to rASRM score. Therefore, the descriptive analysis for rASRM 
score was calculated by median and interquartile range. Median rASRM 
score was 6 (interquartile range 3-10).  
 
 
Fig 11. Distribution of participants by rASRM score. 
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Overall baseline statistics for discrete variables 
 
rASRM Stage 
Fig 12 below shows that 87.9% patients are equally distributed between 
rASRM Stages 1 and 2. The remaining 12.1% fall into stage 3. This 
reflects the natural distribution of the disease between stages (Redwine, 
1990a, 1994). 
 
 
Fig 12. Distribution of participants by rASRM stage.  
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Histology 
Histology was taken in 65 of 133 cases (48.9%), 49 from the excision 
group and 16 from the vaporisation group. It was not always possible to 
get histology from the vaporisation group as biopsy may have resulted in 
excision of all or most of some lesions. Taking histology was not started 
till case 46 in June 2005. Overall 54 of the 65 cases had histology 
positive for endometriosis, showing a successful correlation between 
visual inspection and histological analysis in 83.1% of cases.   
 
Predominance of left sided disease 
The number of times that left sided and right sided disease was recorded 
in any location was analysed. There were three possible locations on 
each side of the pelvis where disease could be recorded for the rASRM 
score; ovary, side-wall and uterosacral ligament. It was found that there 
was more left sided disease overall in the trial population in that there 
were 175 areas of left sided disease v 125 areas of right sided disease 
(p=0.0005 paired t-test) as one would expect from previous observers 
(Vercellini et al., 2004). 
 
Did the patients with deep disease have a higher starting score 
The baseline statistics were analysed to see whether or not deep 
disease had a higher mean baseline score (table 19 below), suggesting 
they suffer from greater levels of pain compared with superficial disease: 
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Table 19. Comparison of mean starting scores for pain outcomes for superficial and deep 
disease. 
  
Outcome   Superficial   Deep   *p value 
Mean +/-SD   (n=66)   (n=66)__________ ___________                     
 
EHP30 pain   40.47+/-33.49  41.10 +/-22.28   p=0.899  
Dysmenorrhoea  6.53 +/-2.69  6.65 +/- 2.71  p=0.809 
Dyspareunia   4.15 +/-3.35  4.71 +/-3.20  p=0.36 
CPP    4.77 +/-3.31  4.93 +/-3.17   p=0.785 
Dyschezia   2.88 +/-3.44  3.29 +/-3.22   p=0.500 
________________________________________________________________________ 
*unpaired t test 
 
Comparative baseline statistics for patient characteristics 
Table 20 below summarises the comparative statistics between the two 
treatment groups for general baseline characteristics: 
 
Table 20. Comparison of mean baseline variables for excision and vaporisation. 
 
Characteristic    Excision   Vaporisation 
     (n=66)   (n=66)______                      
Mean age +/- SD   33.05+/-6.69  32.74+/-8.65 
Median rASRM score (IQ Range) 6(4-10)    6(3-9) 
Positive Histology n/n (%)  41/49 (83.7)  13/17 (76.5%) 
Deep disease n (%)   44 (66.7%)  28 (43.8%) 
________________________________________________________________ 
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The CONSORT Statement warns against using statistical tests to adjust for 
baseline variable differences as this can bias the estimated treatment effect 
(Altman et al., 2001). Deep disease has been claimed to show a greater extent 
of improvement after surgical treatment than superficial disease (Banerjee et 
al., 2008) and so imbalanced groups for depth of disease may bias the results. 
By chance there were 44 (66.7%) deep cases in the excision group compared 
with 28 (43.8%) in the vaporisation group (p=0.009, Chi-sq test).  
 
However, no attempt was made to adjust for this difference in depth as this may 
have resulted in a bias in the estimated treatment effect. It has already been 
shown above that women with deep disease do not start on a significantly 
higher baseline pain score (table 20) and therefore uneven distribution in 
disease depth between the groups does not affect the baseline primary 
outcome measure of pain. To decide whether imbalanced depth of disease 
between the groups has biased outcomes, depth was sub analysed later in this 
chapter. 
 
Comparative baseline statistics for outcome measures 
Firstly, the data were analysed to see whether a higher baseline pain score 
resulted in a greater probability of a larger fall in score for the primary outcome 
measure EHP-30 Core pain domain if the patient improved. The implication of 
this is that if the groups are not balanced in baseline scores then the one with 
the significantly higher score has a greater chance of showing more 
improvement.  There is a highly significant positive correlation between baseline 
pain score and amount of improvement in pain for EHP30 Core pain score 
(Pearson’s Correlation test r=+0.535, p<0.0005). However in the table 21 
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below, the groups are well balanced for mean starting scores so this effect is 
not likely to affect the results in this study: 
 
Table 21. Comparison of mean baseline outcome scores for excision and vaporisation. 
 
Outcome     Excision   Vaporisation 
Mean +/-SD     (n=66)   (n=66)______                      
EHP30 
Pain      42.3 +/-21.6  43.3 +/-21.7 
Control & powerlessness   51.0 +/-27.3  53.9 +/-21.3 
Emotional wellbeing    48.6 +/-21.4  47.3 +/-19.6 
Social support     40.4 +/-30.9  41.4 +/-24.8 
Self image     33.7 +/-28.2  38.1 +/-26.8 
Intercourse     48.9 +/-29.2  55.7 +/-28.6 
VAS 
Dysmenorrhoea    6.8 +/-2.8  6.5 +/-2.6 
Dyspareunia     4.2 +/-3.3  4.8 +/-3.3  
CPP      4.8 +/-3.3  4.9 +/-3.1 
Dyschezia     3.4 +/-3.5  2.8 +/-3.1 
HADS 
Anxiety      9.6 +/-4.2  9.6 +/-4.0 
Depression     4.1 +/-3.3  4.5 +/-3.7 
_______________________________________________________________________ 
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Outcomes and Estimation 
 
Primary outcome measure: EHP30 Core Pain 
In the whole study group 76 (80%) patients improved and 19 (20%) patients 
stayed the same or got worse at 12 months. 
 
Comparative pain was analysed using two outcomes: 
1. The proportion of patients who improved or “stayed the same or got 
worse”, to see if one technique was managing to improve a greater 
number of people. 
2. The extent of improvement for each technique to see if one technique 
gave a greater amount of improvement. 
 
Proportional improvement in primary outcome measure 
Table 22 below shows the proportion of patients showing improvement for the 
primary outcome variable EHP-30 Core pain score at all the analysis time 
points:  
 
Table 22. Proportion of patients showing improvement for EHP-30 Core pain score. 
Analysis point  Excision Vaporisation Difference p value* 
   n/N (%)  n/N (%)  %  ________________________ 
Improved 
3 months   46/62 (74.2) 44/60 (73.3) 0.9   0.954 
6 months   41/56 (73.2) 40/55 (72.7) 0.5   0.954 
12 months  41/48 (85.4) 35/48 (72.9) 12.5   0.132 
____________________________________________________________________________ 
*Chi-square test 
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Both forms of surgical treatment are effective in reducing endometriosis-
associated pain to any degree at 12 months (85.4% for excision against 72.9% 
for vaporisation). Comparing the two treatment arms against each other does 
not produce statistical significance (p=0.132) showing that both treatment 
modalities result in improvement in line with that found by previous observers 
(Sutton et al., 1994, Abbott et al., 2004).  
 
Extent of improvement in primary outcome measure 
Table 23 below shows that both treatment modalities alone result in significant 
improvement in absolute pain score at 12 months compared with baseline:  
 
Table 23. Extent of improvement in EHP-30 Core pain score against baseline for excision and 
vaporisation alone at 12 months. 
 
   Mean change 0 v 12 months +/- SD  *p value (95%CI)__________ 
Excision  -23.9 +/-26.2    p<0.0005 (-31.5 to -16.3) 
Vaporisation  -10.7 +/-20.8    p=0.001 (-16.7 to -4.7) 
____________________________________________________________________________ 
*paired t test 
 
Comparative extent of score improvement in primary outcome measure 
Table 24 below summarises the changes in EHP-30 Core pain score (score at x 
months – score at baseline) for each of the analysis points. Since a higher 
score on the EHP-30 Core pain scale represents a higher level of pain, a 
negative change indicates an improvement (nb: this rule applies to score results 
for all questionnaires in the analysis): 
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Table 24. Comparative extent of improvement in EHP-30 Core pain score against baseline for 
excision and vaporisation at all follow-up points.  
 
Analysis point  Excision Vaporisation  Difference         p value* 
   mean score improvement +/-SD  mean (95% CI)____________ 
3 months   -15.8 +/-21.1 -11.0 +/-15.8  -4.7(-11.5 to 2.0) 0.168 
6 months   -14.4 +/-23.3 -12.0 +/-17.9  -2.4(-10.3 to 5.5) 0.544 
12 months  -23.9 +/-26.2 -10.7 +/-20.8  -13.2 (-22.8 to -3.5) 0.008 
____________________________________________________________________________ 
*unpaired t test 
 
Excision exhibits a greater improvement in pain score than vaporisation at 3, 6 
and 12 months and reaches statistical significance at 12 months with a greater 
improvement by -13.2 points (p=0.008, 95%CI -22.8 to -3.5, unpaired t-test).  
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As can be seen in the graph in fig 13 below, over time the two treatment 
modalities appear to be fairly equal up to 6 months. The significant difference 
between excision and vaporisation appears to develop between 6 and 12 
months. 
 
Fig 13. Graph of mean improvement in EHP-30 Core pain score against time for excision and 
vaporisation. 
 
 
Overall 14.6% of the excision group and 27.2% of the vaporisation group were 
“the same or worse” at 12 months, however there is not a statistically significant 
difference between the two groups (p=0.132, Chi-square test).  
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Secondary outcome measures 
 
Extent of score improvement in VAS 
VAS pain scores were analysed independently for each of the 4 symptoms of 
dysmenorrhoea, dyspareunia, CPP and dyschezia. As both treatment arms, and 
superficial and deep disease, started with similar pre-op scores, the results are 
given as absolute changes in pain score out of 10.  
 
Individual improvement in VAS pain modalities, by treatment arm, comparing 
baseline against 12 month follow up results (score at 12 months – score at 
baseline), are shown in tables 25 and 26 below. 
 
Excision 
Table 25. Mean improvement in VAS symptom scores for excision at 12 months against 
baseline.      
   Mean change 0 v 12 months +/- SD  *p value (95%CI)___________ 
Dysmenorrhoea -2.94 +/-3.65     <0.0005 (-4.22 to -1.67) 
Dyspareunia  -1.98 +/-3.34    0.006 (-3.33 to -0.63) 
CPP   -3.50 +/-3.62    <0.0005 (-4.91 to -2.10) 
Dyschezia  -2.73 +/-4.18    0.007 (-4.64 to -0.83) 
____________________________________________________________________________ 
*paired t test 
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Vaporisation  
Table 26. Mean improvement in VAS symptom scores for vaporisation at 12 months against 
baseline.        
   Mean change 0 v 12 months +/- SD  *p value (95%CI)___________ 
Dysmenorrhoea -1.50 +/-2.82    0.001 (-2.40 to -0.61)  
Dyspareunia  -1.27 +/-3.42    0.040 (-2.49 to -0.06)  
CPP   -0.93 +/-2.78    0.060 (-1.90 to 0.04)  
Dyschezia  -1.11 +/-3.42    0.143 (-2.62 to 0.41) 
*paired t test  
 
There are statistically significant improvements in all VAS pain score symptoms 
in the excision arm at 12 months compared with baseline. For vaporisation, 
there are statistically significant improvements in dysmenorrhoea and 
dyspareunia.   
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Comparative improvement for VAS pain modalities 
Table 27 below summarises the extent of comparative improvement by 
treatment arm in VAS for dysmenorrhoea, dyspareunia, CPP and dyschezia for 
each of the trial follow up points: 
 
Table 27. Extent of comparative improvement for VAS symptom scores for excision and 
vaporisation at all follow up points. 
Analysis point  Excision Vaporisation Difference       p value* 
  mean score improvement +/-SD mean (95%CI)_______________________ 
Dysmenorrhoea 
3 months  -1.26 +/-2.85 -1.33 +/-2.68 0.07(-1.02 to 1.15) 0.904 
6 months  -1.48 +/-2.80 -1.60 +/-3.01 0.12(-1.08 to 1.32) 0.841 
12 months  -2.94 +/-3.65 -1.50 +/-2.82 -1.44(-2.93 to 0.05) 0.059 
CPP 
3 months  -1.64 +/-3.05 -1.31 +/-2.83 -0.33(-1.61 to 0.95) 0.612 
6 months  -2.38 +/-3.10 -0.99 +/-2.37 -1.38(-2.67 to -0.10) 0.035 
12 months  -3.50 +/-3.62 -0.93 +/-2.78 -2.57(-4.20 to -0.95) 0.002 
Dyspareunia 
3 months  -2.42 +/-3.29 -1.97 +/-3.53 -0.45(-2.00 to 1.10) 0.564 
6 months  -1.91 +/-3.07 -2.36 +/-3.64 0.44(-1.17 to 2.05) 0.584 
12 months  -1.98 +/-3.34 -1.27 +/-3.42 -0.71(-2.49 to 1.07) 0.429 
Dyschezia 
3 months  -1.58 +/-3.09 -2.32 +/-3.54 0.73(-0.96 to 2.43) 0.391 
6 months  -1.87 +/-2.99 -1.74 +/-3.10 -0.14(-1.78 to 1.50) 0.866 
12 months  -2.73 +/-4.18 -1.11 +/-3.42 -1.62(-3.97 to 0.72) 0.170 
*unpaired t test 
 
In terms of the extent of score improvement, there was no significant difference 
between excision and vaporisation for dyspareunia and dyschezia. For 
dysmenorrhoea, there was an indication of excision being better than 
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vaporisation at 12 months but this did not reach statistical significance 
(p=0.059). However, there was a significantly greater improvement in CPP in 
the excision group at 6 and 12 months compared with vaporisation (p=0.035 
and p=0.002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 120 
Proportion of improvers for VAS pain scores 
Table 28 below shows the comparative proportion between treatment arms of 
patients showing improvement for the 4 modalities of pain measured by VAS at 
all the analysis time points:  
 
Table 28. Comparative proportion of improvement for VAS symptom scores for excision and 
vaporisation at all follow up points. 
  
Analysis point  Excision Vaporisation Difference p value* 
   n/n (%)  n/n (%)  %  _______________________ 
Dysmenorrhoea 
3 months  31/52(59.6) 32/51(62.7) -2.9  0.745 
6 months  27/47(57.4) 27/46(58.7) -1.3  0.903 
12 months  26/34(76.5) 26/41(63.4) 13.1  0.222 
Dyspareunia 
3 months  27/39(69.2) 25/38(65.8) 3.4  0.747 
6 months  24/34(70.6) 23/36(63.9) 6.7  0.551 
12 months  18/26(69.2) 19/33(57.6) 11.6  0.358 
CPP 
3 months  27/43(62.8) 26/41(63.4) -0.6  0.953 
6 months  27/38(71.1) 18/35(51.4) 19.7  0.085 
12 months  22/28(78.6) 20/34(58.8) 19.8  0.098 
Dyschezia 
3 months  22/32(68.8) 23/29(79.3) -10.5  0.349 
6 months  21/31(67.7) 19/25(76.0) -8.3  0.496 
12 months  14/21(66.7) 14/22(63.6) 3.1  0.835 
____________________________________________________________________________ 
*Chi-square test 
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There was no significant difference between excision and vaporisation in terms 
of the proportion of patients who improved at each follow up point. 
 
Individual extent of score improvement in EHP-30 HRQoL measures 
EHP-30 HRQoL scores were analysed independently for each of the domains. 
As both treatment arms, and superficial and deep disease, started with similar 
pre-op scores, the results are given as absolute changes in score out of 100. 
 
Individual improvement in EHP-30 HRQoL domains, by treatment arm, 
comparing baseline against 12 month follow up results (score at 12 months – 
score at baseline), are shown in tables 29 and 30 below. 
 
Excision 
Table 29. Extent of improvement in EHP-30 HRQoL outcome measures for excision alone at 
baseline against 12 months. 
      
   Mean change 0 v 12 months +/- SD  *p value (95%CI)___________ 
Control & Powerlessness -30.56 +/-29.56   <0.0005 (-39.77 to -21.34) 
Emotional wellbeing  -24.74 +/-20.65   <0.0005 (-30.68 to -18.81) 
Social support   -31.25 +/-30.12   <0.0005 (-41.29 to -21.21) 
Self image   -21.37 +/-25.13   <0.0005 (-29.51 to -13.22) 
Intercourse   -21.11 +/-32.86   <0.0005 (-31.91 to -10.31) 
____________________________________________________________________________ 
*paired t test 
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Vaporisation 
Table 30. Extent of improvement in EHP-30 HRQoL outcome measures for vaporisation alone 
at baseline against 12 months. 
     
   Mean change 0 v 12 months +/- SD  *p value (95%CI)___________ 
Control & Powerlessness -12.86 +/-28.74   0.004 (-21.40 to -4.33) 
Emotional wellbeing  -13.95 +/-23.82   <0.0005 (-21.02 to -6.88) 
Social support   -12.35 +/-28.91   0.008 (-21.36 to -3.34) 
Self image   -5.75 +/-28.24   0.194 (-14.56 to 3.05) 
Intercourse   -22.42 +/-30.18   <0.0005 (-32.07 to -12.76) 
____________________________________________________________________________ 
*paired t test 
 
There were highly significant improvements in all domains at 12 months 
compared with baseline for excision patients. This was also the case with 
vaporisation other than for self-image. 
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Comparative extent of score improvement in EHP-30 HRQoL measures 
Table 31 below summarises the extent of comparative improvement by 
treatment arm in EHP-30 HRQoL domains for each of the trial follow up points: 
 
Table 31. Comparative extent of score improvement in EHP-30 HRQoL outcome measures for 
excision and vaporisation at all follow up points. 
Analysis point  Excision Vaporisation  Difference               p value* 
   mean score improvement (+/-SD)  mean(95%CI)_______ 
Control & powerlessness 
3 months  -22.73(+/-23.87)-11.94(+/-23.55) -10.80(-19.52 to -2.08)  0.0166 
6 months  -18.75(+/-25.86)-11.48(+/-28.82) -7.27(-17.88 to 3.33)       0.177 
12 months  -30.56(+/-29.56)-12.86(+/-28.74) -17.69(-30.05 to -5.33)    0.006 
Emotional wellbeing 
3 months  -16.53(+/-22.13)-9.04(+/-20.03)  -7.49(-15.13 to 0.15)       0.055 
6 months  -17.19(+/-20.58)-10.11(+/-22.91) -7.08(-15.31 to 1.15)       0.091 
12 months  -24.74(+/-20.65)-13.95(+/-23.82) -10.80(-19.86 to -1.73)  0.020 
Social support 
3 months  -16.41(+/-28.90) -2.55 (+/-24.75) -13.86(-24.40 to -3.32)    0.010 
6 months  -16.62 (+/-31.87) -2.17(+/-29.77) -14.45(-27.15 to -1.75)    0.026 
12 months  -31.25(+/-30.12)-12.35(+/-28.91) -18.90(-32.13 to -5.66)    0.006 
Self image 
3 months  -4.83(+/-28.08)  -4.17(+/-25.07)  -0.67(-11.00 to 9.67)  0.898 
6 months  -9.63(+/-29.46)  -5.27(+/-29.94)  -4.36(-16.12 to 7.40)  0.464 
12 months  -21.37(+/-25.13) -5.75(+/-28.24)  -15.61(-27.47 to -3.75)  0.011 
Intercourse 
3 months  -20.44(+/-27.48) -14.33(+/-29.83) -6.11(-17.79 to 5.56) 0.301 
6 months  -15.77(+/-26.52) -14.41(+/-27.09) -1.36(-12.72 to 10.01) 0.813 
12 months  -21.11(+/-32.86) -22.42(+/-30.18) 1.31(-12.91 to 15.53) 0.855 
*Unpaired t test 
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At 12 months excision was statistically significantly better than vaporisation at 
improving scores in all of the EHP-30 HRQoL domains other than for sexual 
intercourse where no difference was found. 
 
Change in Anxiety & Depression Categories between baseline and 12 months 
Fig 14 below shows the number of patients falling into the different categories of 
normal (0-7 points), mild (8-10 points), moderate (11-14 points) or severe (15-
21 points) for anxiety and depression at baseline compared with 12 months for 
all patients not differentiating by treatment arm. 
 
Fig 14. Distribution of participants for different grades of anxiety at baseline and 12 months.  
 
  
In the anxiety graphs comparing baseline and 12 months for anxiety, visually 
there appears to be a shift of patients to the left, or more normal side of the 
graph at 12 months.  
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Fig 15. Distribution of participants for different grades of depression at baseline and 12 months. 
 
 
This shift is not apparent in the depression graph as the majority of people were 
not depressed at the beginning and the two graphs remain very similar. 
 
Individual extent of score improvement in HADS for treatment arms 
HADS scores for anxiety and depression were analysed independently for 
changes. As both treatment arms, and superficial and deep disease, started 
with similar pre-op scores, the results are given as absolute changes in score 
out of 21. 
 
Individual improvement in EHP-30 HRQoL domains, by treatment arm, 
comparing baseline against 12 month follow up results (score at 12 months – 
score at baseline), are shown in tables 32 and 33 below. 
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Excision 
Table 32. Extent of improvement in anxiety and depression for excision alone at 12 months 
versus baseline.     
  Mean change 0 v 12 months +/- SD   *p value (95%CI)__________ 
Anxiety   -2.88 +/-4.84    <0.0005 (-4.28 to -1.47) 
Depression  -0.96 +/-3.46    0.068 (-1.99 to 0.07) 
____________________________________________________________________________ 
*paired t test 
 
Vaporisation 
Table 33. Extent of improvement in anxiety and depression for vaporisation alone at 12 months 
versus baseline.     
     
   Mean change 0 v 12 months +/- SD  *p value (95%CI)___________ 
Anxiety   -1.64 +/-3.27    0.001 (-2.57 to -0.71) 
Depression  -0.66 +/-3.21    0.165 (-1.60 to 0.28) 
____________________________________________________________________________ 
*paired t test 
 
There was a significant improvement in anxiety levels for both excision and 
vaporisation at 12 months compared with baseline, but not for depression.     
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Comparative extent of score improvement in HADS for treatment arms 
Table 34 below summarises the comparative extent of improvement for excision 
and vaporisation in scores for anxiety and depression: 
 
Table 34. Comparative extent of improvement in anxiety and depression for excision and 
vaporisation at all follow up points.  
 
Analysis point  Excision Vaporisation  Difference                 p value* 
   mean score improvement +/-SD  mean(95%CI)_____________ 
Anxiety  
3 months  -1.94(+/-3.68) -0.80(+/-3.35)  -1.13(-2.39 to 0.13) 0.077 
6 months  -2.96(+/-4.89) -1.64(+/-3.27)  -1.32(-2.98 to 0.34) 0.119 
12 months  -2.88(+/-4.84) -1.64(+/-3.27)  -1.24(-2.89 to 0.42) 0.141 
Depression 
3 months  -0.74(+/-3.46) -0.61(+/-3.07)  -0.13(-1.35 to 1.09) 0.833 
6 months  -1.02(+/-3.52) -0.66(+/-3.21)  -0.36(-1.75 to 1.02) 0.605 
12 months  -0.96(+/-3.46) -0.66(+/-3.21)  -0.30(-1.67 to 1.08) 0.669 
*unpaired t test  
 
Comparatively, there was no difference between excision and vaporisation for 
improvement of anxiety.  
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Exploratory Sub analysis 
 
Linear regression analysis to investigate possible predictors of improvement in 
primary outcome measure EHP-30 Core pain score  
Backward stepwise linear regression analysis was performed to investigate 
whether any of the demographic factors (technique, age, surgeon, rASRM 
score, depth of disease, location of disease) influence change in EHP-30 Core 
pain score at 12 months over baseline. Three statistically significant factors 
were identified as reducing improvement in pain (r squared for final model = 
0.154):  
 
1. Vaporisation (p=0.012)  
estimated loss of pain reduction = 12.24/100 (95%CI 2.81 to 21.67)  
2. Being operated on by Surgeon 1 (p=0.035)  
estimated loss of pain reduction = 10.19/100 (95%CI 0.76 to 19.62) 
3. Patient being older (p=0.035)  
estimated loss of pain reduction = 0.68/100 per year (95%CI 0.047 to 
1.306) 
 
Linear regression analysis to investigate possible predictors of CPP 
improvement 
CPP was found to have statistically significantly improved to a greater extent 
than excision in the main analysis (table 28). Therefore backward stepwise 
linear regression analysis was performed to investigate whether any of the 
demographic factors (technique, age, surgeon, rASRM score, depth of disease, 
location of disease) influence change in CPP at 12 months over baseline. There 
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were two statistically significant factors identified as influencing improvement in 
CPP (r squared for final model = 0.195): 
 
1. Vaporisation (p=0.014)  
estimated loss of pain reduction = 0.27/10 (95%CI 0.06 to 
0.48) 
2. Disease in uterovesical fold (p=0.027)  
estimated gain in pain reduction for superficial disease 
compared with no disease in uterovesical fold = -0.31/10  
(95%CI -0.58 to -0.04)  
estimated gain in pain reduction for deep disease compared 
with no disease in uterovesical fold = -0.62/10  (95%CI -1.16 to 
-0.08)  
 
Depth and rASRM Stage of disease 
 
Sub analysis of deep against superficial disease for each treatment modality at 
12 months for the primary outcome measure, EHP Core pain score, was 
performed. Excision results in significant improvement in pain score for both 
deep (mean point reduction of -23.86 out of 100, +/-26.59, p<0.0005, paired t 
test) and superficial disease (mean point reduction of -23.99, +/-26.36, p=0.001, 
paired t test). Whilst vaporisation shows significant pain score improvement for 
superficial disease (mean point reduction of -17.89 out of 100, +/-19.78, 
p<0.0005, paired t test), it fails to result in significant improvement for deep 
disease (mean point reduction of -4.44, +/-18.07, p=0.262, paired t test).  
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On direct comparison between the two treatment arms, as seen in table 35 
below, there is no significant difference in outcome for the treatment of 
superficial disease. However, excision performs equally well for deep disease 
as it does for superficial, whereas vaporisation performs significantly worse than 
excision for the treatment of deep disease.  
 
Table 35. Comparison of the extent of improvement in EHP-30 Core pain score for excision and 
vaporisation with deep and superficial disease at 12 months against baseline.  
    
  Excision Vaporisation  Difference          p value* 
   mean score improvement +/-SD  mean (95%CI)  ____________ 
Deep disease  -23.86+/-26.59 -4.44+/-18.07      -19.42(-32.61 to -6.23)  0.005 
Superficial disease -23.99+/-26.36 -17.89 +/-19.78       -6.10(-20.67 to 8.46) 0.402 
____________________________________________________________________________ 
*unpaired t test 
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Is deep disease or more severe disease (by rASRM stage) more likely to 
improve EHP-30 Core pain score at 12 months versus baseline? 
 
The results in tables 36 and 37 below show a trend towards a greater chance of 
improvement at 6 and 12 months if endometriosis at baseline was superficial 
rather than deep, and a statistically significant chance of greater improvement 
for patients with a lower rASRM stage. 
 
Table 36. Comparative proportional improvement of patients with deep disease against those 
with superficial disease at 6 and 12 months. 
  
  6 months  12 months   
   n/n (%)   n/n (%)   ___________ 
Excision 
Deep   25/38 (65.8)  25/30 (83.3)   
Superficial  16/18 (88.9)  16/18 (88.9) 
*p value  0.106   0.696 
Vaporisation 
Deep   19/27 (70.4)  15/23 (65.2) 
Superficial  20/26 (76.9)  19/23 (82.6) 
*p value  0.589   0.179 
Overall 
Deep   44/65 (67.7)  40/53 (75.5) 
Superficial  36/44 (81.8)  35/41 (85.4) 
*p value  0.102   0.236 
_______________________________________________________________________ 
*Chi-square test 
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Table 37. Comparative proportional improvement of patients with different rASRM stages at 6 
and 12 months. 
  6 months  12 months   
   n/n (%)   n/n (%)   ___________ 
Excision 
rASRM 1  19/25 (76)  20/22 (90.9)   
rASRM 2  18/25 (72)  18/21 (85.7) 
rASRM 3  4/6 (66.7)  3/5 (60) 
*p value  0.631   0.170 
Vaporisation 
rASRM 1  21/27 (77.8)  18/21 (85.7) 
rASRM 2  17/21 (81.0)  15/21 (71.4) 
rASRM 3  2/7 (28.6)  2/6 (33.3) 
*p value  0.114   0.024 
Overall 
rASRM 1  40/52 (76.9)  38/43 (88.4) 
rASRM 2  35/46 (76.1)  33/42 (78.6) 
rASRM 3  6/13 (46.2)  5/11 (45.5) 
*p value  0.137   0.008 
________________________________________________________________________ 
*Mann-Whitney U test 
 
Per protocol analysis for primary outcome measure EHP-30 Core pain score 
Analysis was carried out on the sub sample whose benefits appear to be solely 
related to surgery, excluding the patients who became pregnant during follow 
up, took hormonal medication for pain or contraception in the follow up period, 
or had subsequent surgery within the follow up period. There were still 35 
patients in each group at 12 months, and still a difference was found of -21.04 
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(+/-23.97) for excision against -9.42 (+/-19.36) for vaporisation (p=0.029, 95%CI 
-22.02 to -1.23). The results are shown in table 38 below. 
 
Table 38. Extent of improvement in EHP-30 Core pain score for “per protocol” patients for 
excision and vaporisation at all follow up points. 
 
Analysis point Excision Vaporisation  Difference  p value* 
  mean score improvement +/-SD  mean (95% CI)__________________ 
3 months  -14.64(+/-21.12)-10.96(+/-16.06) -3.68 (-10.64 to 3.28) 0.297 
6 months  -12.75(+/-22.20)-11.50(+/-17.41) -1.25 (-9.08 to 6.59) 0.753 
12 months -21.04(+/-23.97) -9.42(+/-19.36)  -11.62 (-22.02 to -1.23) 0.029 
____________________________________________________________________________ 
*unpaired t test 
 
Was there a placebo effect in the “same or got worse” subgroup 
Fig 16 below shows a graph for patients who at 12 months “stayed the same or 
got worse” for EHP-30 Core pain score over time. Interestingly these patients 
appear to improve initially at 3 months and recover to baseline at 6 months 
before then deteriorating. This may result from an initial placebo effect following 
treatment rather than a positive effect of the treatment itself. However, in this 
small sub group of patients (n=20), the only statistically significant difference 
was observed between 3 months and 12 months. In order to identify a 
statistically significant difference over the shorter time span of 3 months, from 0-
3 months and 3-6 months, given the level of variation shown by the confidence 
limit intervals in the graph below accompanying this small sub group sample 
size, the underlying improvement at 3 months would have had to be extremely 
dramatic. 
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Fig 16. Extent of improvement in EHP-30 Core pain score for “same or worse” pateints at 12 
months over time.  
 
 
 
 
Adverse events 
There were no major surgical complications reported in any of the trial patients 
in either group. 
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Discussion 
 
Synopsis of the key findings 
At the outset of this trial it was a firmly held belief that there would be no 
difference between excision and vaporisation for the treatment of minimal to 
moderate endometriosis. The major concern was that the sample size would be 
too small to show up the suspected small difference that might be found 
between the two treatment arms, and the bioequivalence power calculation 
allowed for this in that, with sufficient patients recruited, it would be possible to 
claim that one treatment was no worse than the other. The unexpected result, 
that excision performed better than vaporisation in this trial, was consequently a 
surprise that prompted an analysis that was often directed towards finding 
statistical evidence that the outcome was incorrect.   
 
Primary outcome measure – EHP-30 Core pain score   
For the primary outcome measure, EHP-30 Core pain score, there was a 
significant improvement in score at 12 months versus baseline whether excision 
or vaporisation was used as the treatment, where excision showed a mean -
23.9 drop (p<0.0005), and vaporisation a mean -10.7 drop on the 100 point 
scale (p=0.001). Also, there was no significant difference in the proportion of 
patients who improved in each treatment arm (85.4% for excision and 72.9% for 
vaporisation, p=0.132). However, at 12 months, the extent of score 
improvement above was statistically significantly greater in the excision versus 
the vaporisation group (p=0.008, 95%CI -22.8 to -3.5). In addition, the excision 
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group appear to be still improving at 12 months, whereas the vaporisation group 
improvement did not continue after 6 months. 
 
In terms of the treatment of deep and superficial disease, excision resulted in 
statistically significant improvement in pain score at 12 months versus baseline 
in both superficial (mean -23.99 +/-26.36, p<0.001) and deep disease (mean -
23.86 +/-26.59, p<0.0005). However, vaporisation only showed statistically 
significant improvement for superficial disease (mean -17.89 +/-19.78, 
p<0.0005) and not for deep (mean -4.44 +/-18.07, p=0.262).  Comparatively, 
there was no difference in the extent of improvement between excision and 
vaporisation for treating superficial disease (mean difference -6.10, p=0.402). 
However, the improvement in pain score for excision was highly statistically 
significantly better than vaporisation for the treatment of deep disease (mean 
difference -19.42, p=0.005). 
 
Of interest is that 14.6% of the excision group and 27.2% of the vaporisation 
group were either the same or worse at 12 months compared with baseline. The 
comparative difference between excision and vaporisation does not reach 
statistical significance (p=0.132). Those patients who stayed the same or got 
worse appear to initially improve possibly showing a placebo effect, though it is 
not statistically possible to show this in this study. 
 
VAS scores for Dysmenorrhoea, Dyspareunia, CPP and Dyschezia 
Excision resulted in a statistically significant score improvement in all four pain 
modalities at 12 months versus baseline scores. This was true for vaporisation 
for dysmenorrhoea (p=0.001) and dyspareunia (p=0.040), but not for CPP 
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(p=0.060) and dyschezia (0.143). However, the proportion of improvers was not 
statistically different for the treatment arms at any time point in the trial. The 
extent of improvement in CPP in the excision group versus vaporisation was 
statistically significant at 6 (p=0.035) and 12 months (p=0.002). As this trial 
included only stage 1-3 rASRM scores one would expect dyschezia to be a less 
significant symptom in this group of patients and even question whether it is an 
appropriate question to include. In support of this Table 21 shows that 
dyschezia is the lowest scored symptom at baseline and appears less of a 
problem than dysmenorrhoea (the most significant symptom), CPP and 
dyspareunia. However patients still scored dyschezia between 2.8-3.4 out of 10 
at baseline and it is interesting to note that excision still resulted in a statistically 
significant improvement in dyschezia in these stage 1-3 patients (p=0.007). The 
conclusion is that it was correct to include it as a symptom in the VAS pain 
scores. 
 
EHP-30 HRQoL outcomes 
Excision resulted in highly statistically significant improvements in all EHP-30 
HRQoL domains at 12 months versus baseline (all p values <0.0005). Results 
for vaporisation were also statistically significant other than for self-image 
(0.194). However, when considering the extent of improvement, excision 
resulted in statistically significantly greater improvement than vaporisation at 12 
months for all domains other than the intercourse module, for which there was 
no significant difference (p=0.855). For the social support domain, excision was 
significantly better at all follow up points in the trial. At no follow-up point, for any 
domain, was vaporisation significantly better than excision. 
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HADS Anxiety and Depression 
For the sample as a whole, patients did not generally appear to be depressed at 
baseline, with the majority of patients falling into the normal category. For 
anxiety though, there was a spread of patients throughout the categories with 
most falling into the normal to moderate categories. At 12 months less patients 
appear to be anxious, with a shift into the normal and less severe groups. The 
lack of depression remains similar. The extent of improvement in anxiety was 
statistically significant for both excision (p=<0.0005) and for vaporisation 
(p=0.001). However, there was no difference in the extent of change in anxiety 
(p=0.141) or depressive scores (p=0.669) comparing between excision and 
vaporisation. 
 
Summary  
Contrary to expectation, for the primary outcome, VAS scores and HRQoL 
outcomes, whilst both techniques resulted in significant improvement in scores 
at 12 months, excision outperformed vaporisation statistically at 12 months in 
the extent of improvement for all outcome measures, suggesting that it is the 
best technique for the surgical treatment of minimal to moderate endometriosis. 
However it should be noted that the absolute improvement was no better than a 
mean -23.9 point drop on the 100 point EHP-30 Core pain scale at 12 months 
(from a baseline mean of 42.3 to 18.4, or a 56.5% drop in pain score), and a 
concerning number of patients reported being either the same or worse.  
 
Possible mechanisms and explanations 
The primary outcome for this study was pain as measured by EHP-30 Core pain 
score. This was selected as it was judged to be the most sensitive measure and 
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the one that would relate most directly to the impact of pain on women’s quality 
of life.  Based on this outcome measure the data show that excision is better 
than vaporisation at reducing pain at 12 months post treatment. It has been 
argued that ablation/vaporisation does not remove all of the disease particularly 
with superficial ablation (Wright et al., 2005). Wright theorised in his randomised 
trial of excision versus ablation that ablative techniques have the potential 
disadvantage of leaving a greater area of necrotic tissue behind, with increased 
inflammatory action and a higher propensity to develop adhesive disease. 
 
In our study laser vaporisation was used to destroy all visible lesions down to 
normal tissue until it looked like an excision has been carried out. This can be 
done quickly and efficiently for widespread superficial disease and appears to 
be a useful technique. However our study shows that even this technique of 
vaporisation performs statistically significantly worse than excision. The reasons 
are not clear although several possible mechanisms can be suggested. 
 
The implication of the results is that in some way the operative field is not the 
same for each treatment at the end of the operation despite it visually appearing 
so. It may be that there is more residual disease in the vaporisation cases than 
the excision ones. There are several possible ways to explain this. It may be 
that by vaporising a lesion, margins may be left that are not easily visible and 
are missed by the surgeon. In contrast, excision aims to remain in the normal 
tissue margin from the beginning of the dissection and so may be better at 
clearing marginal disease. Alternatively, possibly the power of the laser beam is 
driving off active endometriotic tissue particles into adjacent areas that then 
implant and recur. Full vaporisation of deep lesions is technically more difficult 
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as an eschar tends to build up on the lesion surface that has to be washed 
away to continue the vaporisation of the lesion. It is easier to imagine 
incomplete vaporisation with these deep lesions.  
 
Our study also shows that excision is significantly better for treating deep 
disease than vaporisation. Vaporisation is not only significantly comparatively 
worse than excision, but also gave insignificant improvement in EHP-30 Core 
pain score at 12 months versus baseline for deep disease. This could have 
been explained by the fact that there were more deep cases in the excision 
group, if it had also been found that patients with deep disease had a higher 
mean starting score, and that a higher mean starting score resulted in a greater 
chance of having a larger score reduction. Both of these possibilities were 
tested for. It was indeed found that having a higher starting score resulted in a 
greater probability of a larger fall in score at 12 months for EHP-30 Core pain 
score (Pearson’s Correlation test r=+0.535, p=<0.0005). However, mean scores 
at baseline were the same for superficial and deep disease for EHP-30 Core 
pain score and VAS scores, and also for excision and vaporisation arms for all 
outcome measures at baseline. This also fits with the finding that the extent or 
depth of the disease does not correlate with pain (Crosignani et al., 1996, Garry 
et al., 2000) Therefore the possible bias resulting from unbalanced baseline 
scores did not occur in favour of the excision group. Furthermore, the superficial 
group had an advantage by having less deep disease for two reasons. Firstly it 
performed significantly worse for deep disease and secondly, superficial 
disease was more likely to improve overall in our study.  
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Backward stepwise linear regression analysis was also carried out on the EHP-
30 Core pain score results to see whether technique, age, surgeon, rASRM 
score and depth or location of disease influenced the change in EHP-30 Core 
pain score at 12 months over baseline. This confirmed the finding of 
vaporisation as a significant factor in reducing pain improvement (p=0.012, 
95%CI 2.81 to 21.67). It has already been shown above that a sample with a 
lower mean baseline score has less capacity to improve. Mean baseline scores 
for instrument and technique use were similar and so the finding that 
vaporisation is genuinely performing worse was reinforced.  
 
However, it was hypothesised that a significantly lower mean baseline score for 
the less successful surgeon and older patients could explain the finding that 
they appear to have resulted in a significantly lower improvement. Indeed, this 
was found to be the probable cause, as the surgeon identified had less capacity 
for his patients to improve. His 68 cases had a significantly lower mean baseline 
score of 34.79 (+/-31.47). This is compared with the mean baseline score for 
the other surgeons of 46.84 (+/-21.23) (difference of 12.05, p=0.012, unpaired t-
test). At 12 months his patients mean improvement in score was -12.64 against 
the other surgeons mean improvement of -21.78 (difference of -9.14, p=0.066, 
unpaired t-test). Neither did the surgeon have significantly more vaporisation 
cases than the other surgeons, which would have biased his performance in 
favour of less improvement (he performed 34 cases with each technique). Older 
patients also had less capacity to improve, as there was a statistically significant 
negative correlation between age and pre-op pain score (Pearson’s correlation 
test: r=-0.320, p<0.0005). 
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VAS scores for dysmenorrhoea, dyspareunia, CPP and dyschezia mirrored the 
findings in EHP-30 Core pain score in that there was no difference in the 
proportion of patients who improved at any follow-up point for excision and 
vaporisation. Vaporisation analysed alone did not result in a statistically 
significant improvement at 12 months versus baseline for CPP and dyschezia, 
though significance was almost reached for CPP. There seems to be no 
obvious explanation for this other than the general trend in this study that 
vaporisation performs less well at 12 months. Comparative scores of the extent 
of improvement show up a significant difference for excision performing better 
than vaporisation in reducing CPP at 6 and 12 months. Significance is almost 
reached for dysmenorrhoea too, and the remaining two symptoms of 
dyspareunia and dyschezia show a trend towards excision performing better.  
 
Thus, as with EHP-30 Core pain score, the results illustrate that the proportion 
of patients improving after surgery is similar for vaporisation and excision, but 
the extent to which they improve is greater for excision compared with 
vaporisation. It may be that the failure to show significance in all symptoms is 
related to limitations in the performance of visual analogue scales as Abbott 
found and commented on in his trial (Abbott et al., 2004). Alternatively, it may 
be that women are able to relate better to some questions than others. Perhaps 
the notion of CPP is more meaningful than the notion of dyschezia. There 
appears to be no clear trend of one symptom improving to a greater extent than 
another from the results.  
 
The backward stepwise linear regression analysis that was performed to see if 
any factors influenced the change in CPP score at 12 months versus baseline 
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again confirmed that vaporisation was predictive of a lesser improvement in the 
EHP-30 Core pain score, although this was only by 0.27 points on the 10 point 
scale. The finding that disease in the uterovesical fold results in a greater 
likelihood of score improvement cannot be explained, and is more likely to be 
due to chance. 
 
The trend of excision outperforming vaporisation continued into the EHP-30 
HRQoL parameters. Alone, though generally resulting in improvement, 
vaporisation did not produce results that were as significant. In comparative 
terms, the significantly better improvement in quality of life domains for excision, 
mirroring the reduction in pain, presumably reflects the profound effect that 
chronic pain has on quality of life. It stands to reason that, as the quality of life 
questions in EHP-30 are ones specifically identified by endometriosis sufferers, 
then they will improve if the treatment is effective. Again, there appeared to be 
no trend of any one domain improving more than any other, and it is not clear 
why sexual intercourse was the only domain that did not show up a 
comparatively statistically significant difference between excision and 
vaporisation. It is possible that women don’t like responding to questions about 
sexual intercourse and are therefore less likely to provide responses that reflect 
reality. It is also possible that a considerable proportion of women feel that 
sexual intercourse is not such a prominent aspect of their lives as being able to 
go to work or socialise for example.   
 
Study reports of medical therapy for endometriosis have commented that 
starting scores for HRQoL scores are less than population norms and do not 
return to normal levels following treatment (Miller, 2000, Zhao et al., 1999, 
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Bergqvist and Theorell, 2001), and only recently have HRQoL measures like 
SF-12 and EQ-5D been used in surgical studies (Garry et al., 2000, Abbott et 
al., 2003, Abbott et al., 2004). However, it is not possible to comment on 
whether scores started below or returned to that found in general population 
norms in our study, as EHP-30 is a disease specific measure and there are no 
data relating to the general population. Nonetheless, the EHP-30 has been 
externally validated against SF-36 and been shown to be more sensitive to 
changes (Jones et al., 2004a).   
 
 The HADS questionnaire attempts to find anxiety and depression in subjects, 
not in the sense of the extent of their predisposition to these stresses, but in the 
transient amount of stress they actually have. In contrast to the EHP-30 HRQoL 
domains, it does not deal with factors that moderate the impact of these 
stresses like coping or social support. The results show that depression is not a 
component of psychological stress in patients with minimal to moderate 
endometriosis. Most probably, those that lie outside of the normal range are 
depressed for reasons other than their endometriosis. Anxiety ratings did 
improve significantly for both treatments between baseline and 12 months. As a 
result, it appears to compare with the EHP-30 Core pain, HRQoL and VAS 
score outcomes. Contrary to the EHP-30 data, the HADS anxiety scale is 
judged against general population norms, suggesting that anxiety returns to 
normal levels in many cases.  
   
Comparison with other studies 
In the report of the trial by Sutton et al (Sutton et al., 1994), it is not clear in the 
original paper whether the linear analogue scale for pain as a primary outcome 
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measure related to overall pain, or for each of the symptoms of dysmenorrhoea, 
dyspareunia or pelvic pain. In their follow up paper in 1997, they comment that: 
 
“in the original study, no attempt was made to separately assess the 
symptoms….in all cases, the most severe symptom was dysmenorrhoea, 
which was therefore the symptom assessed when the patients were 
asked to quantify their worst symptom by visual analogue score…” 
(Sutton et al., 1997b).  
In the original study by Sutton and colleagues (2004) there was a 62.5% 
improvement in pain for laser vaporisation at 6 months. Our trial shows a 72.7% 
improvement in EHP-30 Core pain, and a 58.7% improvement in 
dysmenorrhoea at 6 months, and consequently appears to have a similar 
outcome at 6 months, particularly when comparing dysmenorrhoea.  
 
The Sutton trial reported a greater proportion of pain improvement of 73.7% for 
the mild and moderate patients analysed alone compared with the overall 
improvement of 62.5%, suggesting that more severe disease results in a 
greater chance of improvement. The statistical robustness of this finding is open 
to criticism as the data were broken down into stage 1-3 versus stage 2-3, and 
this kind of sub-analysis is likely to create bias in treatment outcomes. However, 
a view appears to have developed since this paper was published that 
superficial disease is more difficult to treat than deep disease. In contrast, in our 
study we found a definite trend that patients were more likely to have improved 
EHP-30 Core pain scores if they had superficial disease at baseline, and a 
statistically higher chance of improvement for patients with lower rASRM stage 
at baseline. Also this study did not support the finding by Banerjee that better 
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relief of pain was found in women who had deep disease rather than superficial 
(Banerjee et al., 2008). Their study had a poor follow-up rate of near 50% and it 
may be that the non-responders were those patients with deep disease who did 
not improve. Also their study includes those with stage 4 disease that are a sub-
group not included in our study.  
 
In our study we showed that having a higher baseline score results in a greater 
likelihood of a greater drop in pain score. It may be that these other studies had 
higher baseline scores in their more severe and deep disease biasing the 
outcome. In our study the baseline scores were not significantly different 
between superficial and deep disease, and it seems logical that less severe 
disease should be easier to treat and clear. Abbott’s findings support this to the 
extent that the higher the stage of disease, the greater likelihood of requiring re-
operation (Abbott et al., 2003).   
 
The Abbott trial reports an 80% improvement for the immediate surgery group 
that underwent excision at 6 months, though it is not clear how the change in 
the overall level of pain was calculated (Abbott et al., 2004). Baseline 
demographic parameters could not be compared, as they are not detailed in the 
Abbott paper. In our study, the proportion of improvers for excision by EHP-30 
Core pain score at 6 months was 73.2 %. This again appears comparable, 
although as previously mentioned, the sample in the Abbott trial differs in that it 
included severe disease, and had a median rASRM score of 16 in the group 
that underwent immediate excision, compared with a median score of 6 in our 
study. For HRQoL outcomes, our trial is unable to shed light on Abbott’s finding 
of a return to statistically insignificant differences compared with population 
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norms, found in contrast to their previous investigations (Garry et al., 2000, 
Abbott et al., 2003).  
 
In the Abbott 2003 prospective observational cohort study of excision treatment, 
there appears to be an improvement in pain sustained out to 2-5 years for 67% 
of patients. Our study confirms that there is no drop off in effect at 12 months for 
improvers who underwent excision, and in fact, for EHP-30 Core pain score, 
both the proportion and extent of improvement still appears to be increasing at 
12 months post surgery for excision and not for vaporisation, in keeping with a 
trend that adds some weight to Abbott’s 2-5 year findings.  
 
In contrast, Sutton et al followed up on their 1994 trial and reported that 90% of 
those patients who had shown pain improvement at 6 months had reported 
continued benefit at 12 months, suggesting a small drop off in the effect of 
vaporisation, though this was no longer part of the blinded trial (Sutton et al., 
1997b). In this study, the proportion of patients with improved dysmenorrhoea 
score (the best direct comparison with the Sutton results) increased from 58.7 
at 6 months to 63.4% at 12 months, but stayed the same for EHP-30 Core pain 
score (72.7% versus 72.9%). This does not confirm this possible drop off effect. 
However, whilst the extent of score improvement in EHP-30 and 
dysmenorrhoea continued to improve in the excision group from 6 months to 12 
months, this did not occur in the vaporisation group, again suggesting that 
vaporisation is struggling to maintain its effect at 12 months compared with 
excision.    
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In our study it is not the proportion of patients showing any improvement that 
shows the difference between excision and vaporisation, but the extent of 
improvement at 12 months. In Sutton’s trial the median VAS score for 
vaporisation dropped by 2.85/10 points from a baseline median score of 8.5 
(based mainly on dysmenorrhoea) between baseline and 6 months. This is 
comparable with the 30/100 (range 0-95 on a 100 point linear scale) noted for 
excision in Abbot’s trial for the immediate surgery group. In our study, VAS 
dysmenorrhoea score for vaporisation reduced by a more conservative 1.60/10, 
from a mean baseline score of 6.5, at 6 months. For excision this improved to 
2.94/10 at 12 months versus baseline. Alarmingly, what the data from all these 
results suggests is that at best on average, pain is improved by only 
somewhere between a quarter and a half.  
 
Added to this seemingly moderate improvement in pain scores, that are similar 
for EHP-30 HRQoL outcomes, is the concerning finding that 20% of patients in 
this study stayed the same or got worse. Abbott also found 20% of the patients 
in his study stayed the same or got worse (Abbott et al., 2004) all of whom had 
positive histology for endometriosis. It is probable in these cases that it is not 
the surgery per se that is causing symptoms to worsen. Recurrence of new, or 
progression of residual lesions are both possible culprits. However, Sutton 
found that only 2 of the 5 women with continued pain, who had laser treatment 
initially and then had a second look laparoscopy, were found to have visually 
confirmed endometriosis (Sutton et al., 1994). The other possibility is that pelvic 
pain in these women is not related to endometriosis at all, and is caused by 
other pathologies with very similar symptoms like adenomyosis, irritable bowel 
syndrome or interstitial cystitis. 
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If the range of improvement in pain scores was narrow then the moderate 
extent of pain improvement achieved would call into question whether 
subjecting patients to surgery is indeed worth it. However, the ranges of 
improvement are wide, with some patients showing extensive improvement and 
others showing very little, none, or becoming worse; this implies that we need to 
have better prognostic indicators to select out those who will truly benefit from 
surgical treatment of endometriosis. 
 
There remains one other possibility suggested by the findings of Abbott’s 
prospective cohort (Abbott et al., 2003)  looking at follow-up at 2-5 years after 
excision. It may be that the benefits of surgery are in fact much more gradual 
than we believe, as the level of pain improvement in this study measured by 
drop in median VAS pain score appears greater than that seen at 6-12 months 
(dysmenorrhoea 9 to 3, non-menstrual pain 8 to 3, dyspareunia 7 to 0, and 
dyschezia 7 to 2). However, at such follow-up periods, many confounding 
variables are likely to be introduced including recurrent surgery or 
hysterectomy, hormonal therapy and intervening pregnancies, all of which are 
present in these results.        
 
Limitations of the study 
 
Methodological limitations 
As with all surgical trials, there are many pitfalls that can cast doubts upon the 
validity of results. In this trial every attempt was made to be a rigorous as 
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possible over methodology. However, retrospectively it is always possible to 
find limitations, and that was no different with this trial. 
 
Patient selection 
One must first consider the type of patients that were entered into this trial. 
Surrey is a relatively wealthy area, with a significant proportion of educated, 
“middle class” patients that have a keen interest in their own health care. 
Therefore they may be, to some extent, a biased set of patients in comparison 
to the general population. However, they will of course be a similar set of 
patients to the Sutton trial that was performed in the same unit 10 years 
previously (Sutton et al., 1994). All geographical locations are likely to have 
their own climates, economics, physical geography, social and cultural 
peculiarities, all of which can affect a studies external validity. However, none of 
the factors in this trial area or population are so extreme that they are likely to 
be having a major influence on external validity. 
 
Eligibility criteria 
The other factors influencing the type of patients in the trial, and consequently 
the external validity, are the eligibility criteria. In this trial, as in the other major 
trials reported by Jacobson in his Cochrane review (Jacobson et al., 2009), we 
excluded patients aged under 18, pregnancy, pelvic inflammatory disease and 
inflammatory bowel conditions of the pelvis, and patients not willing to comply 
with the trial protocol. However, there were several other exclusions mentioned 
in these other trials that we did not use:  
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Sub-fertility patients were not excluded, as in this trial they all received 
treatment and so had the possible benefit of improved fertility as a result 
(Jacobson et al., 2004b). Those women who were included with sub-fertility 
were not assessed for normal ovulatory cycles, partner’s semen sample, recent 
infertility treatment or previous fertility surgery. Therefore, we were not able to 
assess whether or not surgical treatment for endometriosis resulted in an 
improvement in spontaneous conception. 
 
Suspected gynaecological malignancy was not stated as an exclusion in the 
protocol. No patients had suspected gynaecological malignancy, although one 
turned out to have a borderline tumour of the ovary following ovarian 
cystectomy, which was managed conservatively for fertility reasons. 
 
Urgent patients were not included in the exclusion criteria, but no emergency 
patients were included in the trial. All patients were admitted for elective 
surgery. 
 
Severe adhesions were not included in the list of exclusion criteria. If patients 
fell within the rASRM score for stages 1-3 then they were included in the trial no 
matter what the distribution of disease was. 
 
Previous abdominal surgery was not listed as a reason for exclusion. There is a 
possible limitation with this trial as a result of this. Some patients may have had 
multiple unsuccessful laparoscopies for pelvic pain previously, with perhaps 
little improvement. This may have biased the result against the positive effect of 
surgical treatment. Conversely it may have biased the result in favour of 
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treatment, where “expert patients” had received repeated benefit from previous 
surgeries. The other problem arising from previous surgery is that of creating 
lesions containing psammoma bodies that mimic endometriosis leading to false 
positive assessment of the pelvis (Martin and Vander Zwagg, 1987). In fact, the 
sole exclusion from this trial before analysis was due to this.  
 
This potential limitation of including patients who had undergone previous 
abdominal surgery could have been prevented by taking histology in all cases, 
and only including those with positive histology in the analysis as Abbott 
rigorously did in his studies (Abbott et al., 2003, Abbott et al., 2004). However, 
in those trials, excision was the only treatment modality, and so the problem of 
biopsying small lesions without excising them before vaporisation did not exist. 
Further to this, inflammation in lesions and traumatic biopsy can affect the 
architecture of endometrial glands and stroma, making histological examination 
difficult, resulting in false negative results (Shafik A, 2000), meaning that 
patients are erroneously excluded. As has already been described, in this study 
histology was taken in 65 of 133 cases (48.9%), partly because taking histology 
was not begun until case 46 and partly because it was not always possible to 
get a biopsy with vaporisation, as it may have resulted in excision of all or most 
of the lesion. Overall 54 of the 65 cases had histology positive for 
endometriosis, showing a successful correlation between visual inspection and 
histological analysis in 83.1% of cases. A similar correlation of 88% was found 
by Ballard between visual inspection and positive histology (Ballard et al., 
2009). 
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Randomisation 
Proper randomisation should be able to eliminate selection bias from a sample 
and is very important to achieve a high quality result (Altman, 1991). In this trial 
the generation of the randomisation sequence was not computer generated. 
However, the generated sequence was truly random in blocks of ten and there 
was no way of telling which treatment was contained in the sealed opaque 
envelope in each unallocated folder. There is a potential argument that, as the 
generation of the sequence was done by two of the surgeons, this could have 
affected the randomisation concealment at allocation at the time of surgery. 
However, neither surgeon felt that this was a problem in this trial, especially as 
the recruitment rate was about 2 patients per month, and each block of ten 
folders took, on average, 5 months to allocate. This meant that mentally 
keeping track of randomisation generation and allocations was unfeasible. 
 
Recruitment 
The slow recruitment rate of two patients per month mainly arose from the 
exclusion of potentially eligible patients because they were on hormonal 
medication for contraception rather than patients not wishing to participate. 
Those who were on hormonal therapy for symptomatic relief only were asked if 
they would stop it 3 months prior to surgery so as to fit the inclusion criteria. 
However, by no means all patients agreed to do this. Additionally, there was 
also an increased risk that such patients may have been more likely to restart 
hormonal medication within the follow up period. Recruitment and follow up 
management of patients in surgical trials is particularly difficult as strong 
eligibility criteria are required to reduce the risk of confounding variables, 
resulting in long recruitment periods that subsequently require long term follow-
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up. It is not surprising, therefore, that it took nearly 66 months to recruit for this 
trial, followed by another 1 year for the follow-up of the final patient, to complete 
the trial in a total of six and a half years, during which time the trial standards 
need to be maintained. 
 
Blinding 
Strict double blinding was not possible as this is a surgical trial and so there 
was no way of blinding the surgeon from the procedure he was performing. 
However, the surgeon was blinded from the outcomes, the patient was blinded 
from the procedure, and the evaluator was also blinded from the procedure. 
Although there was no evaluation carried out of the success of blinding, the 
importance of blinding was strongly appreciated, particularly as this trial had the 
subjective measure of pain as its primary outcome measure. An additional 
question in the 12 month demographic questionnaire asking whether patients 
were able to guess the treatment they received would have been useful. 
Theoretically, they should have been no more likely to guess correctly than 
chance. That being said, the fact that all patients were treated with what had 
been hypothesised as equally good treatments, and there was no placebo 
group, reduced the risk of performance bias also. There were no specific 
adverse effects from treatment that could lead the patient or evaluator to 
ascertain the treatment group. Equally, a positive outcome at evaluation did not 
suggest one treatment or other as both treatments were thought to be equally 
efficacious. 
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Protocol deviations   
The protocol deviations discovered in April 2006, whereby pregnant women 
were not being followed up, resulted in a mid term audit that proved to be very 
useful in assessing the recruitment and drop out rate into the trial as well as 
tightening any areas of the protocol that had become loose. This seems 
particularly important in trials that take a long time to recruit. 
 
Lack of control group  
Both Sutton and Abbott reported placebo effects at 3 months (Sutton et al., 
1994, Abbott et al., 2004), and possibly up to 6 months in Abbott’s trial. The 
follow up in this study was continued up to 12 months for this reason. Since 
there is no control group, there was potential placebo interference that would 
result in criticism of 6 months results. It seems more likely that the placebo 
effect has worn off at 12 months and the results show the benefits of surgical 
treatment.  
 
Outcome limitations 
  
Follow up rates and missing data 
The loss of 27.8% of patients at 12 months for the analysis of the primary 
outcome measure is a potential limitation of this trial. However, the lost sub 
group was analysed in two ways to see if their absence from the main analysis 
may have had a significant effect on the result. Firstly, it was determined 
whether or not this had created imbalanced groups. This was not found to be 
the case as the excision arm lost 27.3% of cases and the vaporisation arm lost 
29.9% (p=0.742). Secondly, the lost sub group was analysed against the 
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remaining patients in the main analysis to see whether they differed in age, 
median rASRM score, histology finding and depth of disease. No difference was 
found here either; suggesting that the lost sub group did not differ significantly 
from the main analysis group, and consequently had not biased the result.    
 
Balanced arms in the main analysis group 
From the descriptive statistics, that otherwise showed well balanced groups for 
age, rASRM score and positive histology, there was a potential limitation found 
in that there were more deep cases in the excision group (44/66, 66.7%) 
compared with the vaporisation group (28/66, 43.8%). As the results show that 
vaporisation performed significantly less well for deep disease, both 
independently and in comparison with excision, then less deep cases in the 
vaporisation group gave it an advantage. Consequently, vaporisation appeared 
to be performing better than it would have done had the number of deep cases 
been evenly distributed. The comparative advantages of excision over 
vaporisation may well be underestimated by this study as a result.  
 
A further limitation relating to depth of disease exists here, as its assessment 
was by palpation the visual appearance of the lesions, and so was a subjective 
decision by the surgeon that it appeared to be infiltrating >5mm below the 
surface of the peritoneum. This may have resulted in assignment errors to the 
wrong depth classification, casting doubt on the results relating to depth of 
disease. However, all the surgeons were experienced at diagnosing 
endometriosis and the depth adjusted on the rASRM score sheet at the end of 
the case once a better assessment of depth was available following treatment 
of the lesions. If any bias resulted, it is likely that there would have been an over 
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diagnosis of deep disease, rather than an under diagnosis. This would have 
diluted the deep category with more superficial cases, again allowing the 
vaporisation group an advantage.       
 
Protocol deviations and “per protocol” analysis 
The patients with protocol deviations during the follow up period were included 
in the main analysis and result in a possible trial limitation. There were 19 
patients who became pregnant, 5 who underwent further surgery, and 16 who 
had some form of adjuvant hormonal therapy. A “per protocol” analysis for the 
primary outcome measure EHP-30 Core pain was carried out on those patients 
who had not deviated from the protocol. The improvements found in these 
patients are more likely to be related to surgical treatment. There were still 35 
patients in each arm at 12 months (more than the 28 patients required in the 
power calculation for EHP-30 Core pain to have an 80% chance of showing a 
20% difference). Excision (-21.04 +/- 23.97) still outperformed vaporisation (-
9.42 +/-19.36) at 12 months (p=0.029, 95%CI -22.02 to -1.23).    
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Chapter 6 - Conclusions 
 
This thesis set out to improve our understanding of the surgical treatment of 
endometriosis. Much of the early evidence in the literature was related to fertility 
outcomes rather than pelvic pain and clinical practice thus emphasised this 
component of the problem. Larger case series and randomised trials have 
subsequently begun to focus on the more subjective issue of pelvic pain. Two 
clear technique categories developed, vaporisation/ablation and excision, both 
with randomised data supporting their use. However, there has been no clear 
data about who is really using which techniques, and whether any one is really 
any better than the other. In addition, the hypothesis of this thesis was that 
there would be no difference between the two techniques in terms of pain 
outcome if the lesions were truly vaporised by CO2 laser down to normal tissue. 
 
The lack of information regarding the extent to which gynaecological 
laparoscopic surgeons are using varying techniques for treating pelvic 
endometriosis of all types, was investigated with an international web-based 
survey to address this. This survey has some definite limitations in terms of its 
sample size, however it does suggest that surgeons who belong to the 
specialist laparoscopic societies appear to be aware of the evidence currently 
available and are trying to practise in an evidence-based manner. Some 
surgeons would change their practice if they had the access to training and 
equipment to allow them to do so. In general, there exists a view that 
endometriomas should be excised and that bowel resection should be avoided 
if possible for recto-vaginal disease. For minimal to moderate disease, 
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superficial disease can be treated with a combination of excision or vaporisation 
depending on the case, but that deep disease should be excised. 
 
This very question for minimal to moderate disease was addressed in the 
randomised blinded trial reported in this thesis. It was clearly found that, 
contrary to expectation, although the proportion of patients who improve is no 
different for either vaporisation or excision, the extent of improvement in both 
pain and quality of life is significantly better for excision than vaporisation at 12 
months post operation. In addition to this, for deep disease vaporisation does 
not convey significant improvement at 12 months. The statistical analysis very 
much set out to try and disprove this finding as it was contrary to the hypothesis 
at the outset. However, it became apparent that the finding was genuine and 
the limitations were sufficiently small to accept the result. Since diagnosing 
deep endometriosis is essentially an intra-operative one, and since excision will 
give the best results in all forms of minimal to moderate disease, it makes 
logical sense to approach treatment intending to excise in every case in the 
light of these findings. 
 
The implications of this view must be considered in the context of clinical 
practice. There is little doubt that training doctors to laparoscopically excise 
endometriosis is not a straightforward one. A sound knowledge of the anatomy 
of the pelvic side-wall and the skill to avoid damage in this location is integral. 
Not all gynaecologists are likely to be able to achieve the skills required or have 
the training opportunity to achieve this safely, in order to stop the culture of not 
surgically excising at the time of diagnosis or dusting the surface with bipolar 
diathermy. The implication of this is that most patients with endometriosis may 
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need referral to a specialist gynaecologist, which is probably currently 
unattainable. This does however seem to present more evidence that we 
should be moving towards a culture of greater subspecialisation, and away from 
the old fashioned “jack of all trades” Obstetrician and Gynaecologist. 
 
Furthermore it must be added that a significant proportion of patients will 
deteriorate even with surgery and that the extent of improvement is 
disappointing on average and widely variable in practice. To this end, much 
more work is required to ascertain the symptoms or signs that will allow us to 
direct our surgical treatment towards those patients who are most likely to 
benefit, and avoid operating unnecessarily on those who will not.  
 
The current randomised data only tells of improvement for a year, which brings 
into question the cost-benefit of endometriosis surgery, especially when there is 
at least a third risk of recurrent surgery within five years. The extent of 
improvement resulting from excision beyond 12 months still remains unclear as 
no randomised data exists, and is likely to be confounded by other variables 
introduced over time following the index surgery. 
 
The use of EHP-30 as a validated tool to evaluate pain and quality of life in 
endometriosis appears to have been successful in this study as it attempts to 
address issues directly related to the patient and their quality of life. The data 
gained here will be pooled with existing data to further improve its use as a tool 
for endometriosis, though ideally population norm data is required for EHP-30. 
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In conclusion, whilst it is recognised that all studies have their limitations, and 
that is no different in this case, it appears that for the surgical treatment of 
endometriosis, excision is the way forward and that training and referral 
strategies need to be put in place to ensure that women have access to the 
optimal treatment.         
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Appendix B – Endometriosis Trial Patient Information 
Leaflet 
 
Patient information 
 
A study comparing: 
Laser surgery with the harmonic scalpel 
In the treatment of pelvic pain due to endometriosis. 
 
THANK YOU FOR READING THIS. 
 
Introduction 
 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends, 
relatives and your GP if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to take part. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘ Medical 
Research and You ‘. This leaflet gives more information about medical research and 
looks at some questions you may want to ask. A copy may be obtained from CERES, 
PO Box 1365, London N16 OBW. 
 
Purpose of Study 
 
Endometriosis is a common and debilitating disorder that diminishes the quality of 
women’s lives in their reproductive years. It is associated with pelvic pain, infertility 
and menstrual disorders. It remains a difficult condition to treat. Drugs are ineffective in 
the long term and have unacceptable side effects. However, laparoscopic (key hole) 
surgery has been shown to be an effective form of treatment. 
 
Keyhole laser surgery was first performed in this country at St. Luke's Hospital in 
Guildford in l982, so we have 20 years experience of this technique and an excellent 
safety record on more than 4,500 patients. We conducted the world’s first scientific 
study of laser surgery, which clearly showed that laser treatment is an effective 
treatment in the majority of patients and has considerable advantages over medical 
therapy with anti-endometriosis drugs. 
 
It is now our normal practice is to use a carbon dioxide laser to vaporise the 
endometriotic deposits.  
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Recently, the UltraCision Harmonic Scalpel has been developed. It was introduced 
commercially in 1993, and since then it has been increasingly used in surgery.  We 
would like to lead the way in developing the use of the UltraCision Harmonic Scalpel in 
the treatment of endometriosis.  
 
The UltraCision Harmonic Scalpel converts electrical energy, to mechanical motion at 
the instrument’s titanium tip, which vibrates at a speed of 55,500 cycles per second. 
This mechanical energy allows both cutting of tissue and coagulation  (the prevention of 
bleeding) at the precise point of impact. For this reason, we feel that the UltraCision 
Harmonic Scalpel offers a safe alternative to the carbon dioxide laser. Further more, 
keyhole laser surgery is not widely available in this country. The UltraCision Harmonic 
Scalpel is easier to use than a laser, and considerable cheaper to purchase. It is 
potentially much more widely available in other hospitals, and it also has multiple 
applications in gynaecological surgery, whereas the lasers have much more limited 
range of uses. 
 
 
Why have I been chosen? 
Patients with pelvic pain and a known or possible diagnosis of endometriosis are being 
asked to take part in the study. We plan to recruit around 100 patients over the space of 
one year.  
 
 
Do I have to take part? 
 
It is up you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. This will not affect the standard of care you receive. If you do not wish to take 
part in the study, then you will receive keyhole laser surgery as per our usual practice. 
 
What will happen to me if I take part? 
 
Your symptoms will be recorded before surgery in the usual way. Standard 
questionnaires will be used to assess the effect your symptoms have on the quality of 
your life and on your psychological state. 
 
The comparison of laser and the UltraCision Harmonic Scalpel has never been 
subjected to a scientific study. Because we do not know which way of treating patients 
is best, we need to make such a comparison. People will be put into two groups. The 
groups will be selected by a computer, which has no information about the individual 
(i.e. by chance). Patients in each group will then have a different treatment and these 
treatments are then compared. Because this is a double blind trial neither you nor the 
research nurse who will follow you up in the clinic will know in which treatment group 
you are (although, if your doctor needs to find out he / she can do so). 
The operation (keyhole surgery) is performed under general anaesthesia through a 
telescope called a laparoscope, which is introduced inside the abdomen via a tiny cut 
within the umbilicus. You will also have 2 or 3 small cuts just above the hairline for 
additional instruments to be inserted into your abdomen. The remaining endometriotic 
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deposits will then be destroyed by means of the UltraCision Harmonic Scalpel or the 
laser.  
 
The research nurse will also record any changes in your symptoms at 3, and 6 months 
following surgery. The need for any medical therapy or further surgical treatment for 
pelvic pain will also be recorded.  
 
 
What do I have to do? 
You will not have to restrict or change your life style in any way. This study will not 
affect your fertility intentions at all. Those women who want to get pregnant will be 
encouraged to do so. Those women who do not will be asked to use a barrier 
contraceptive (cap, condom or coil) or be sterilised as they wish. We will ask you to 
avoid using an oral or an injectable hormonal contraceptive for the 6 months following 
surgery. This is because hormonal contraceptives affect the degree of pain and the 
amount of bleeding during a period. 
 
 
What are the additional risks of taking part? 
  
There are no additional risks beyond that of routine laparoscopic (keyhole) surgery. The 
risks include injury to the bowel, bladder, or blood vessels, which occurs in about 1 in 
1000 cases and may need a laparotomy (a surgical procedure to open the abdomen and 
repair the injuries).  These issues are routinely discussed with the patients at the time of 
informed consent. 
 
What are the possible benefits of taking part? 
 
We hope that both the treatments will help you. However, this cannot be guaranteed. 
The information we get from this study may help us to treat future patients 
endometriosis better. 
 
What if new information becomes available? 
 
If new information about the treatment being studied becomes available during the 
course of a research project, you will be told about it. If this happens, your research 
doctor will discuss with you whether you want to continue in the study. If you decide to 
withdraw your research doctor will make arrangements for your care to continue. If you 
decide to continue in the study you will be asked to sign an updated consent form. 
 
What if something goes wrong? 
 
If taking part in this research project harms you, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have 
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grounds for legal action. Regardless of this, if you wish to complain about any aspect of 
the way you have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you. 
 
Will my taking part in this study be kept confidential? 
 
All information that is collected about you during the course of the research will be kept 
strictly confidential. Any information about you that leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. Your GP or the 
doctor who referred you to Mr Kent for treatment will be kept informed of your 
treatment and your participation in the study by hospital discharge summary in the usual 
way. 
 
What will happen to the results of the study? 
 
After your 6 months follow up appointment the research doctor will tell you which arm 
of the study you were in. The results of this study will be published in a medical 
journal, and they will be presented to other doctors at scientific meetings. You will not 
be identified in any report or publication. 
 
Who is organising and funding the research? 
 
The project is being organised by Mr Peter Barton-Smith and Mr Andrew Kent. We do 
not receive any specific funding for this project at the present time. Ethicon-endo 
Surgery, who make the UltraCision Harmonic Scalpel do however contribute to the 
research budget of the department.  
 
Who has reviewed the study?  
 
The South West Surrey LREC has reviewed and approved this study. 
 
Contact for further information  
  
The persons to contact in the event of an unexpected reaction or incident will be           
Mr Peter Barton-Smith, 01483 571122 page 4210 or Mrs Pat Haines 01483 571122 ext 
4569. 
Please keep this information sheet for your own records, together with the copy of 
the consent form. 
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Appendix C – Endometriosis Trial Consent Form 
 
 
Study Number: 
Patient Identification Number for this trial 
 
CONSENT FORM 
 
 
Title of Project: Carbon dioxide-laser versus UltraCision Harmonic Scalpel in the 
treatment of pelvic pain due to endometriosis. 
 
Name of Researcher: Mr Peter Barton-Smith, Clinical Research Fellow in 
Gynaecological Endoscopy. 
 
 
 
 
1. I confirm that I have read and understand the information sheet dated 
…………………. (Version) for the above study and have had the opportunity to 
ask questions 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected 
3. I agree to take part in the study 
 
 
 
 
 
 
 
Name of Patient   Date   Signature 
 
 
 
 
Name of Person Taking Consent Date   Signature 
(If different from researcher) 
 
 
 
 
Researcher    Date   Signature 
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1 for patient; 1 for researcher; 1 to be kept in hospital notes 
 
 
Appendix D – Endometriosis Trial Visual Analogue Scale 
 
Visual Analogue Score for Pelvic Pain due to Endometriosis 
 
 
Hospital No: 
 
 
Dysmenorrhoea  Yes / No / Not Sure 
(painful periods) 
 
 
 
No pain _______________________________________________  Worst pain 
 
 
 
Chronic Pelvic Pain  Yes / No / Not Sure 
(pain not linked to periods going on for >6 months) 
 
 
 
No pain _______________________________________________  Worst pain 
 
 
 
Dyspareunia   Yes / No / Not Sure 
(painful sexual intercourse) 
 
 
 
No pain _______________________________________________  Worst pain 
 
 
 
Dyschezia    Yes / No / Not Sure 
(pain on bowel opening) 
 
 
 
No pain _______________________________________________  Worst pain 
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Additional information: 
 
Appendix E – Endometriosis Trial EHP 30 Questionnaire 
 
 
 
                                                      
 
 
                                                 
 
 
 
 
                                                    University of Oxford      National Endometriosis Society 
 
The Endometriosis Health Profile Questionnaire (EHP 30)  
 
 2001 Nuffield Department of Obstetrics & Gynaecology & Health Services Research 
Unit 
University of Oxford 
 
In collaboration with The National Endometriosis Society U.K. 
___________________________________________________________________________ 
 
 This questionnaire has been developed to measure the effect endometriosis has upon 
a woman's quality of life  
 
 To complete the questionnaire please would you answer;  
 
Part 1: All 30 questions 
 
Part 2: All sections that apply to you 
 
 We are aware that you may have had endometriosis for a long time. We also 
understand that how you feel now may be different to how you have felt in the past. 
However, please would you answer the questions only in relation to the effect that 
endometriosis has had on your life during the last 4 weeks 
  
 There are no right or wrong answers, so please tick the answers which best 
represent your feelings and experiences. 
 
 Due to the personal nature of some of the questions please understand that you do 
not have to answer any questions if you would prefer not to. 
 
 The information and answers you give will be treated with the utmost 
confidentiality. 
 
 If you have any problems or would like any help or assistance with the completion 
of this questionnaire please contact Pat Haines on 01483 406797  who will be 
happy to help you. 
 
 Once you have completed the questionnaire please could you return it in the pre-
paid envelope provided. 
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 We would like to thank you very much in anticipation for taking the time to help us 
with this important research and we look forward to receiving your answers. 
 
 This research was funded with an educational grant from Pharmacia Corporation, 
USA 
 
_________________________________________________________ 
PART 1: CORE QUESTIONNAIRE 
 
DURING THE LAST 4 WEEKS, HOW OFTEN 
BECAUSE OF YOUR ENDOMETRIOSIS HAVE YOU….. 
 
    Never       Rarely         Sometimes       Often         Always 
______________________________________________________________________________________________ 
 
1. Been unable to go to social events                
because of the pain? 
 
_____________________________________________________________________________ 
 
2. Been unable to do jobs around the             
home because of the pain? 
 
_____________________________________________________________________________ 
3. Found it difficult to stand because              
of the pain?             
 
_____________________________________________________________________________ 
 
4. Found it difficult to sit because of              
the pain?       
_____________________________________________________________________________ 
 
5. Found it difficult to walk because              
of the pain?    
_____________________________________________________________________________ 
 
6. Found it difficult to exercise or do the             
leisure activities you would like to do  
because of the pain? 
 
_____________________________________________________________________________ 
 
7. Lost your appetite and/or been unable            
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to eat because of the pain?  
  
_____________________________________________________________________________ 
 
Please check that you have ticked one box for each question  
before moving onto the next page 
 
 
 
DURING THE LAST 4 WEEKS, HOW OFTEN 
BECAUSE OF YOUR ENDOMETRIOSIS HAVE YOU….. 
 
    Never       Rarely         Sometimes       Often         Always 
_____________________________________________________________________________ 
 
8. Been unable to sleep properly because             
of the pain?    
 
_____________________________________________________________________________ 
 
9. Had to go to bed/lie down because of             
the pain? 
  
_____________________________________________________________________________ 
 
10. Been unable to do the things you want            
to do because of the pain?  
 
______________________________________________________________________________________________ 
   
11. Felt unable to cope with the pain?            
   
_____________________________________________________________________________ 
 
12. Generally felt unwell?              
      
_____________________________________________________________________________ 
 
13. Felt frustrated because your symptoms            
are not getting better? 
   
_____________________________________________________________________________ 
 
14. Felt frustrated because you are not             
able to control your symptoms?   
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_____________________________________________________________________________ 
 
Please check that you have ticked one box for each question 
before moving onto the next page 
 
 
 
 
 
DURING THE LAST 4 WEEKS, HOW OFTEN 
BECAUSE OF YOUR ENDOMETRIOSIS HAVE YOU….. 
 
    Never       Rarely         Sometimes       Often         Always 
_____________________________________________________________________________ 
 
15. Felt unable to forget your symptoms?             
   
_____________________________________________________________________________ 
 
16. Felt as though your symptoms are             
ruling your life? 
_____________________________________________________________________________ 
 
17. Felt your symptoms are taking away             
your life?    
 
______________________________________________________________________________________________ 
 
18. Felt depressed?               
      
_____________________________________________________________________________ 
 
19. Felt weepy/tearful?                
          
_____________________________________________________________________________ 
 
20. Felt miserable?               
       
_____________________________________________________________________________ 
 
21. Had mood swings?               
        
_____________________________________________________________________________ 
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22. Felt bad tempered or short tempered?            
   
_____________________________________________________________________________ 
 
Please check that you have ticked one box for each question  
before moving onto the next page 
 
 
 
 
DURING THE LAST 4 WEEKS, HOW OFTEN 
BECAUSE OF YOUR ENDOMETRIOSIS HAVE YOU….. 
 
    Never       Rarely         Sometimes       Often         Always 
_____________________________________________________________________________ 
 
23. Felt violent or aggressive?              
       
_____________________________________________________________________________ 
 
24. Felt unable to tell people how you feel?           
     
_____________________________________________________________________________ 
 
25. Felt others do not understand what you             
are going through?  
  
_____________________________________________________________________________ 
 
26. Felt as though others think you are              
moaning?    
_____________________________________________________________________________ 
 
27. Felt alone?                
            
_____________________________________________________________________________ 
 
28. Felt frustrated as you cannot always              
wear the clothes you would choose? 
 
_____________________________________________________________________________ 
 
29. Felt your appearance has been affected?            
       
_____________________________________________________________________________ 
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30. Lacked confidence?              
  
_____________________________________________________________________________ 
  
Please check that you have ticked one box for each question 
before moving onto Part 2 
 
 
Part 2: Modular Questionnaire 
 
Section C: These questions concern the effect endometriosis has had on your sexual 
relationships during the last 4 weeks 
 
 
How often during the last 4 weeks 
BECAUSE OF YOUR ENDOMETRIOSIS HAVE YOU….. 
      
Never       Rarely         Sometimes       Often         Always 
_____________________________________________________________________________ 
      
1. Experienced pain during or after             
intercourse?  
If not relevant please tick here    
 
2. Felt worried about having intercourse             
because of the pain?  
If not relevant please tick here   
 
3. Avoided intercourse because of the              
pain?     
If not relevant please tick here         
 
4. Felt guilty about not wanting to have            
 intercourse?    
If not relevant please tick here    
      
5. Felt frustrated because you cannot              
enjoy intercourse? 
If not relevant please tick here    
    
_____________________________________________________________________________ 
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Appendix F – Endometriosis Trial HADS Questionnaire 
Hospital Anxiety and Depression Scale (HADS) 
Patients are asked to choose one response from the four given for each 
interview.   They should give an immediate response and be dissuaded 
from thinking too long about their answers.  The questions relating to 
anxiety are marked "A", and to depression "D".  The score for each 
answer is given in the right column.  Instruct the patient to answer how it 
currently describes their feelings. 
  
A I feel tense or 'wound up':   
  Most of the time 3 
  A lot of the time 2 
  
From time to time, 
occasionally 
1 
  Not at all 0 
  
D 
I still enjoy the things I used 
to enjoy: 
  
  Definitely as much 0 
  Not quite so much 1 
  Only a little 2 
  Hardly at all 3 
  
A 
I get a sort of frightened 
feeling as if something awful 
is about to happen: 
  
  
Very definitely and quite 
badly 
3 
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  Yes, but not too badly 2 
  
A little, but it doesn't worry 
me 
1 
  Not at all 0 
 
D 
I can laugh and see the 
funny side of things: 
  
  As much as I always could 0 
  Not quite so much now 1 
  Definitely not so much now 2 
  Not at all 3 
  
A 
Worrying thoughts go 
through my mind: 
  
  A great deal of the time 3 
  A lot of the time 2 
  
From time to time, but not 
too often 
1 
  Only occasionally 0 
  
D I feel cheerful:   
  Not at all 3 
  Not often 2 
  Sometimes 1 
  Most of the time 0 
  
A 
I can sit at ease and feel 
relaxed: 
  
  Definitely 0 
  Usually 1 
  Not Often 2 
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  Not at all 3 
 
 
  
D 
I feel as if I am slowed 
down: 
  
  Nearly all the time 3 
  Very often 2 
  Sometimes 1 
  Not at all 0 
  
A 
I get a sort of frightened 
feeling like 'butterflies' in 
the stomach: 
  
  Not at all 0 
  Occasionally 1 
  Quite Often 2 
  Very Often 3 
  
D 
I have lost interest in my 
appearance: 
  
  Definitely 3 
  
I don't take as much care as I 
should 
2 
  
I may not take quite as much 
care 
1 
  
I take just as much care as 
ever 
0 
  
A I feel restless as I have to be   
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on the move: 
  Very much indeed 3 
  Quite a lot 2 
  Not very much 1 
  Not at all 0 
  
D 
I look forward with 
enjoyment to things: 
  
  As much as I ever did 0 
  Rather less than I used to 1 
  Definitely less than I used to 2 
  Hardly at all 3 
  
A 
I get sudden feelings of 
panic: 
  
  Very often indeed 3 
  Quite often 2 
  Not very often 1 
  Not at all 0 
  
D 
I can enjoy a good book or 
radio or TV program: 
  
  Often 0 
  Sometimes 1 
  Not often 2 
  Very seldom 3 
 
  
Scoring (add the As = 
Anxiety.  Add the Ds = 
Depression).  The norms 
below will give you an idea of 
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the level of Anxiety and 
Depression. 
  0-7 = Normal   
  8-10 = Borderline abnormal   
  11-21 = Abnormal   
      
Reference: Zigmond and Snaith (1983) 
Appendix G – Endometriosis Trial 12 month Demographic 
Questionnaire 
 
Endometriosis Trial Demographic Questionnaire 12 months 
 
 
…………Months since initial operation 
 
You were recruited into our trial comparing the surgical treatment of endometriosis by 
vaporisation with a carbon dioxide laser or excision with harmonic scalpel on: 
 
 
……………………….... 
 
 
We would now like to ask you to answer these questions about what has happened to 
you since your operation. 
 
  
Further surgery 
 
 
Have you undergone any of the following procedures since your initial operation? 
 
 
1. Repeat laparoscopy and treatment of endometriosis WITHOUT removal of the uterus 
or ovaries 
 
YES  NO 
 
2. Hysterectomy 
 
YES  NO 
 
3. Removal of one or both ovaries  
 
YES  NO 
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Details 
 
 
………………………………………………………………………………………….. 
 
 
………………………………………………………………………………………….. 
 
 
Medical treatment for endometriosis 
 
Have you received any of the following treatments FOR ENDOMETRIOSIS since 
your initial operation? 
 
 
Combined oral contraceptive pill   YES   NO 
 
 
Progesterone pill     YES   NO 
 
 
Mirena coil      YES   NO 
 
 
GnRH analogues     YES   NO 
 
 
Other………………..............    YES   NO 
 
 
 
Details (e.g.: how soon after operation/dates/ongoing?): 
 
 
………………………………………………………………………………………….. 
 
 
………………………………………………………………………………………….. 
 
 
………………………………………………………………………………………….. 
 
 
………………………………………………………………………………………….. 
 
 
………………………………………………………………………………………….. 
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………………………………………………………………………………………….. 
 
 
………………………………………………………………………………………….. 
 
 
………………………………………………………………………………………….. 
 
 
………………………………………………………………………………………….. 
 
Fertility 
 
 
1. How many times had you been pregnant BEFORE your initial operation? 
 
………………times 
 
 
Details of dates and outcome (live births/top/miscarriage/IVF etc)….………………… 
 
 
………………………………………………………………………………………… 
 
 
2. Were you actively trying to become pregnant BEFORE your initial operation? 
 
YES  NO 
 
 
 If YES, how long had you been actively trying for? 
 
……………..Months 
 
 
3. Have you had difficulty in becoming pregnant AFTER your initial operation? 
 
YES  NO 
 
 
If YES, how long have you been actively trying for? 
 
………………Months 
 
 
4. How many times have you been pregnant AFTER you had your initial 
operation? 
 
……………..times 
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Details of dates and outcome (live births/TOP/miscarriage etc)….…………………… 
 
 
………………………………………………………………………………………… 
 
 
………………………………………………………………………………………… 
 
 
 
 
5. Have you had infertility treatment since your initial operation? 
 
YES  NO   
 
 
If YES, give details (IVF/IUI, outcome etc) 
 
 
 
………………………………………………………………………………………….. 
 
 
………………………………………………………………………………………….. 
 
 
………………………………………………………………………………………….. 
 
 
………………………………………………………………………………………….. 
 
 
 
Overall 
 
If you had pain from your endometriosis, the pain has changed in the following 
way: 
 
 
Pain free         much improved         improved         same         worse         much worse  
 
 
 Overall my operation resulted in my quality of life being: 
 
 
much improved         improved         same         worse         much worse 
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Appendix H – rASRM Scoring Sheet 
 
Harmonic / Laser Study 
                                                                 Randomisation No:     
Hospital ID no: 
Laparoscopic staging of endometriosis 
Revised American Fertility Society Classification 
Endometriosis < 1 cm 1 – 3 cm >3 cm 
Pelvic Superficial 1 2 4 
Peritoneum Deep 2 4 6 
Right Superficial 1 2 4 
Ovary Deep 4 16 20 
Left Superficial 1 2 4 
Ovary Deep 4 16 20 
Posterior cul-de-sac Partial Complete 
obliteration 4 40 
Adhesions < 1/3 1/3 – 2/3 > 2/3 
Right Flimsy 1 2 4 
Ovary Dense 4 8 16 
Left Flimsy 1 2 4 
Ovary Dense 4 8 16 
Right Flimsy 1 2 4 
Tube Dense 4* 8* 16 
Left Flimsy 1 2 4 
Tube Dense 4* 8* 16 
 
*If the fimbrial end of the fallopian tube is completely enclosed, change the point to 16 
 
Additional 
endometriosis…………………………………………………………………….............. 
…………………………………………………………………………………………… 
 
 
 
 
 197 
 
  
 
 
 
 
 
 
 
 
Stage 1: 1 - 5            Stage II : 6 - 15             Stage III : 16 - 40                Stage IV : > 40 
 
Appendix I  – Trial Follow up Clarification letter 
 
Clarification on follow-up protocol for women taking part in the 
carbon dioxide laser vs. harmonic scalpel endometriosis study. 
March 2006 
 
 
1. ALL women who are entered into the study must be followed up according to 
the protocol at 3, 6 and 12 months post-surgical treatment. This includes women 
who have become pregnant and women who have started on other treatments for 
endometriosis since being entered into the trial. These women may form 
interesting subgroups at later analysis.  
2. Should the woman be unavailable at exactly 3,6,or 12 months then every attempt 
should be made to ensure that the questionnaires are completed as close to the 
correct time as possible. 
3. Every attempt within reason should be made to locate women for follow up if 
they do not attend for their follow up appointment. Normally this would entail a 
polite telephone call to the patient if they have not responded to contact by letter.  
4. They must complete ALL of the questionnaires as normal. 
5. In cases where the woman is not menstruating due to pregnancy, or medical 
treatment inducing a “pseudo menopausal” or “pseudo pregnancy” state, then 
they should be directed by the person conducting the questionnaires to omit 
answering questions relating to menstruation. The person conducting the 
questionnaires should record the reason why these answers have been omitted. 
This will include what medication is taken, why, its duration and who started it. 
In the case of pregnancy, the LMP and EDD must be recorded. These subgroups 
will be analysed at the end of the trial. 
6. Initially, ALL women should be invited to the hospital to fill in the 
questionnaires to ensure that as many as possible are completed in the same 
environment. This will reduce the risk of bias especially in the anxiety 
questionnaire, as patients are less likely to be anxious in their home 
environments. If they are unwilling and this is not possible, then responses by 
telephone or postal questionnaire may be carried out and the method used must 
be recorded.  This must be first discussed with the research fellow, or if he is 
unavailable then AK. 
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7. Once the patient has completed the questionnaires then the responses should be 
also entered onto the SPSS database as soon as possible so that an electronic 
record is also held. At present there is only one copy of the results and a 
duplicate is required in case of loss of data for any reason. This database is 
currently being produced. 
 
 
 
 
Mr Andrew Kent   Mr Peter Barton-Smith 
Investigator   Investigator 
 
   13 March 2006
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Appendix J  – Invitation email for Pilot Survey 
 
                                  
 
 
 
An International Survey of Surgical Techniques in the 
Treatment of Endometriosis – Pilot Study 
 
Compiled by the Minimal Access Therapy Training unit, Guildford, UK. 
Approved by the British Society of Gynaecological Endoscopy. 
 
         
Dear MATTU Faculty, 
 
We are conducting a web survey of the surgical techniques used worldwide by 
laparoscopists in the treatment of endometriosis. We would like to invite you to take 
part in the pilot study of this survey. It should only take between 5 and 10 minute to fill 
in!  
 
The results of this pilot study will be used to improve the survey for general release in 
2006. We hope to collate UK data first and then expand the survey to other countries 
including the USA, European countries and Australia.  
 
Please now click on the following link to start the survey or come back to this email 
later when you have a few moments free to fill it in: 
 
http://surveys.som.surrey.ac.uk/survey?code=32425470 
 
Many thanks for sparing a few minutes to help out 
 
 
 
 
 
Peter Barton-Smith  Andrew Kent   Karen Ballard 
Research Fellow  Gynaecology Director  Lecturer 
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Appendix K – Invitation email for Main Web Survey 
 
 
 
An International Survey of Surgical Techniques in the Treatment of Endometriosis 
Compiled by the Minimal Access Therapy Training unit, Guildford, UK. 
In Affiliation with the 
 American Association of Gynecologic Laparoscopists  
European Society of Gynaecological Endoscopy  
British Society of Gynaecological Endoscopy 
Dear Colleague, 
  
We are conducting a web-survey of the surgical techniques used worldwide by laparoscopists 
in the treatment of endometriosis. This email has been sent to members of gynaecological 
endoscopy societies around the world. We are interested in how you trained in laparoscopic 
surgery, how you treat endometriosis and which instruments you use.  
  
We would like to invite you to take part in this survey. It consists of 34 mainly multiple 
choice type questions. It should only take between 5 and 10 minutes to fill in! 
  
Clicking on the link to the survey below will constitute your consent to participate in the 
study. However you may withdraw at any time by contacting us (p.barton-
smith@surrey.ac.uk). Your responses will then be removed from the database if you so wish. 
The anonymous responses you give are confidential and held on a secure database.  
If you complete the survey and enter your email address (for prize draw purpose 
only) then you will be automatically entered into a prize draw and one lucky 
respondent will win an Apple iPod nano! 
 
YOU MAY RECEIVE THIS EMAIL MORE THAN ONCE BY VIRTUE OF BEING ON THE MAILING 
LIST OF MORE THAN ONE SOCIETY. HOWEVER PLEASE ONLY COMPLETE IT ONCE.  
 
Many thanks for sparing a few minutes to help out.  
Peter Barton-Smith  Andrew Kent    Karen Ballard      
Research Fellow    Director of Gynaecological Surgery    Senior Lecturer 
Please now click on the following link to start the survey or come back to this email later 
when you have a few moments free to fill it in. 
 
http://www.zoomerang.com/survey.zgi?p=WEB227E6KPU7AD  
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Appendix L – Pilot Web Survey 
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Appendix M – Main Web Survey 
 
